The cost-effectiveness of a home-based exercise programme for the treatment of knee pain in the community by Thomas, Kim Suzanne
Thomas, Kim Suzanne (2001) The cost-effectiveness of 
a home-based exercise programme for the treatment of 
knee pain in the community. PhD thesis, University of 
Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/11621/1/367107.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
MEDICAL liBRARY 
" CJJEets MEIJICAl CENTAI i 
'tJDT-(t N ~ - ~ ~ ~ ~ ~ ~ , 
The cost-effectiveness of a home-based exercise programme for the 
treatment of knee pain in the community 
by 
K.S. Thomas, BSc 
April 2001 
Table of contents 
ABSTRACT .......................................................................................................................... XI'''' 
SUMMARY ........................................................................................................................... XXI 
1 INTRODUCTION ............................................................................................................ 1 
1.1 OSTEOARTHRITIS ........................................................................................................... 1 
1.1.1 What is osteoarthritis? ........................................................................................ 1 
1.1.2 Aetiology of osteoarthritis ................................................................................... 2 
1.1.3 Radiographic assessment of osteoarthritis .......................................................... 4 
1.1.4 Prevalence of osteoarthritis ........................................ ......................................... 6 
1.2 KNEE OSTEOARTHRITIS ............................................................................................... 11 
1.2.1 Defining knee osteoarthritis ........................... .................................................... 11 
1.2.1.1 Radiographic definitions of knee osteoarthritis ......................................................... 11 
1.2.1.2 Clinical definitions of knee osteoarthritis .................................................................. 13 
1.2.2 Aetiology of knee osteoarthritis ......................................................................... 18 
1.2.3 Prevalence of knee osteoarthritis .. ..................................................................... 21 
1.2.4 Prevalence of symptomatic osteoarthritis ........................................ .................. 22 
1.3 KNEE PAIN AND OSTEOARTHRITIS ................................................................................ 25 
1.3.1 The importance of knee pain .................................................. ............................ 25 
1.3.2 Aetiology of knee pain ....................................................................................... :=5 
1.3.2.1 Muscle weakness ..................................................................................................... 26 
1.3.2.2 Psychological well-being ........................................................................................... 28 
1.3.3 Knee pain and disability .................................................................................... 32 
IA TREATMENT OF KNEE OSTEOARTHRITIS ....................................................................... 35 
1.-1-.1 Physical therapy ................. ............................................................................... 37 
1.4.:= Telephone support ............................................................................................. ..f..f 
1.5 E C O N ( ) ~ 1 1 IC E\' ALUATION OF OSTEOARTHRITIS ... ... ....... ....................................... ....... -+ 7 
.. 
11 
1.5.1 Economic evaluation techniques ....................................................................... 47 
1.5.1.1 Cost-effectiveness analysis ........................................................................................ 48 
1.5.1.2 Cost-utility analysis .................................................................................................. -1.9 
1.5.2 Presentation of cost data ................................................................................... 51 
1.5.2.1 Cost-effectiveness plane ............................................................................................ 51 
1.5.2.2 Cost-effectiveness acceptability curves ..................................................................... 52 
1.5.2.3 Sensitivity analysis .................................................................................................... 53 
1.5.3 Cost analysis within rheumatology ............................................................ · ...... · 55 
1.5.4 Economic impact of osteoarthritis ..................................................................... 58 
1.5.5 Intangible costs associated with osteoarthritis ............................................... · .. 60 
1.5.6 Cost of knee osteoarthritis ................................................................ · .. · ...... · ...... 61 
1.5.7 Economic evaluation of treatment provision ..................................................... 62 
1.6 SUMMARY .................................................................................................................... 67 
1.7 CONTRIBUTION OF CURRENT STUDy ............................................................................ 68 
1.7.1 Study design ................ ....................................................................................... 68 
1.7.2 Pragmatic nature of the trial ............................................................................. 69 
1.7.3 Case criteria ......................................................... ............................................. 70 
1.7.4 Concurrent economic evaluation ....................................................................... 70 
1.8 SUMMARY OF STUDY DESIGN ...................................................................................... 71 
2 INTERVENTION STUDY ............................................................................................ 72 
2.1 AIMS AND OBJECTIVES ................................................................................................. 72 
2.2 METHOD ...................................................................................................................... 73 
2.2.1 Ethics ................................................................................................................. 73 
2.2.2 Study population ................................................................................................ 73 
2.2.3 Sal11ple size ........................................................................................................ 75 
2.2.4 Questiollnaire .................................................................................................... 75 
2.2.5 Distributioll of questiollnaires ........................................................................... 75 
2.2.6 /lltervelltiOll study desigll ................................................................................... 76 
111 
2.2.7 Subjects .............................................................................................................. 78 
2.2.8 Materials and Procedures ................................................................................. 79 
2.2.8.1 Subject Recruitment. .................................................................................................. 79 
2.2.8.2 Assessment procedure ............................................................................................... 79 
2.2.8.3 Muscle strength assessment ....................................................................................... 81 
2.2.8.4 Radiographic assessment ........................................................................................... 82 
2.2.9 Randomisation and blinding .............................................................................. 83 
2.2.10 Exercise intervention ................................................ · ............................... · ........ 84 
2.2.10.1 Assessment of exercise adherence ............................................................................... 88 
2.2.11 Telephone support ............................................................................................. 89 
2.2.12 Placebo illtervention .................................................... ·· ..... · .. ·· .. · .. ..................... 90 
2.2.13 No intervention control group ........................................................................... 91 
2.2.14 Scoring of health outcomes ........ ........................................................................ 91 
2.2.15 Outconze nzeasures .................................................... ······ .................... ............... 93 
2.2.15.1 Primary outcome measure .......................................................... · ........ · .................. · .. 93 
2.2.15.2 Secondary outcome measures .................................................................................... 93 
2.3 DATA MANAGEMENT .................................................................................................... 94 
2.3.1 General data management ................................................................................. 94 
2.3.2 Handling of missing values ...................................................................... · ...... · .. 94 
2.3.3 Intent-to-treat analysis .... ................................................................................... 94 
2.3.4 Number needed to treat ..................................................................................... 95 
2.4 STATISTICAL ANALySIS ................................................................................................ 95 
2.4.1 Primary outcome ............................................................................................... 96 
2.4.2 Secondary outcomes .......................................................................................... 97 
2.4.3 Exploratory analysis .......................................................................................... 98 
2.5 RESULTS ................................................................................................................. 100 
2.5.1 Postal questiollnaire ........................................................................................ 100 
2.5.2 Recruitment for intenJention study ......................... .......................................... 100 
2.5.2.1 Comparison of recruited and non-recruited subjects ................................................ 102 
IV 
2.5.2.2 Baseline characteristics of subjects entering the trial ............................................... 102 
2.5.3 Primary outcome - self-reported knee pain at 24 months ................................ 107 
2.5.3.1 Analysis by treatment group .................................................................................... 107 
2.5.3.2 Number needed to treat ............................................................................................ 110 
2.5.3.3 Analysis by factor .................................................................................................... 112 
Interaction of factors ................................................................. ··· ..... ······················· 113 
Handling of missing values ......................................................... '" .......................... 11..J. 
2.5.3.4 
2.5.3.5 
2.5.4 Secondary outcomes ................................................................. · ........ · .... · ........ 115 
2.5.4.1 Knee specific stiffness and physical function (WOMAC) ....................................... 115 
2.5.4.2 Muscle strength ........................................................................................................ 117 
2.5.4.3 Exercise adherence .................................................................................................. 120 
2.5.4.4 SF-36 ....................................................................................................................... 123 
2.5.4.5 Anxiety and depression ............................................................................................ 124 
2.5.4.6 Patient satisfaction ................................................................................................... 125 
2.5.5 Multivariate analysis ....................................................................................... 127 
2.6 DISCUSSION ........................................................................................................... 130 
2.6.1 Mainfindings ................................................................................................... 130 
2.6.2 Secondary outcomes ........................................................................................ 132 
2.6.3 Comparison with other studies ........................................................................ 133 
2.6.4 Caveats ............................................................................................................ 136 
3 COST OF KNEE PAIN ............................................................................................... 139 
3.1 AIMS AND OBJECTIVES ............................................................................................... 139 
3.2 METHOD .................................................................................................................... 140 
3.2.1 Study perspective ............................................................................................. 140 
3.2.2 Subjects ............................................................................................................ 140 
3.2.3 Clarification of terminology ............................................................................ 141 
3.2.4 Costs included in the cost analvsis .................................................................. 1-/.2 
3.2.5 Definition of costs ............................................................................................ 142 
3.2.5.1 Medical costs ............................. .. \..J.2 
\. 
3.2.5.2 Personal medical costs ............................................................................................. 1.+6 
3.2.5.3 Costs not included in the economic analysis ........................................................... 1.+8 
3.2.6 Unit costs ......................................................................................................... 149 
3.2.7 Data manipulation .............................................. ............................................. 149 
3.2.7.1 General data management. ....................................................................................... 1.+9 
3.2.7.2 Key assumptions ...................................................................................................... 151 
3.2.7.3 Regression analysis .................................................................................................. 152 
3.3 RESULTS .................................................................................................................... 15.+ 
3.3.1 Subject characteristics ..................................................................................... 154 
3.3.2 Medical costs ................................................................................................... 155 
3.3.2.1 Total medical costs .................................................................................................. 155 
3.3.2.2 GP costs ................................................................................................................... 156 
3.3.2.3 GP prescribed drugs ................................................................................................. 159 
3.3.2.4 Hospital costs ........................................................................................................... 160 
3.3.3 Other medical costs ......................................................................................... 161 
3.3.4 Personal costs ................................................... ............................................... 161 
3.3.4.1 Prescription charges ................................................................................................. 162 
3.3.4.2 Travel costs .............................................................................................................. 162 
3.3.4.3 OTC drug costs ........................................................................................................ 163 
3.3.5 Other costs ....................................................................................................... 163 
3.3.6 Indirect costs .......... .......................................................................................... 164 
3.3.7 Summary of total costs ..................................................................................... 166 
3.3.8 Sensitivity analysis ...................................................................... ..................... 167 
3.3.9 Regression analysis ......................................................................................... 172 
3.3.9.1 Logistic regression ................................................................................................... 173 
3.3.9.2 Linear regression ..................................................................................................... 17.+ 
3 . .+ DISCUSSION ............................................................................................................... 176 
3.-+.1 Alain findings ................................................................................................... 176 
3.4.1. I Regression analysis ................................................................................................. 178 
3. -+.2 Comparison H'ith other studies ........................ ............................................... 179 
\' 1 
3.4.3 Strengths and weaknesses of the study .................... ......................................... 184 
4 ECONOMIC EVALUATION OF TRIAL INTERVENTIONS .............................. 187 
4.1 AIMS AND OBJECTIVES ............................................................................................... 187 
4.2 METHOD .................................................................................................................... 188 
4.2.1 Study perspective ............................................................................................. 188 
4.2.2 Subjects ............................................................................................................ 188 
4.2.3 Materials ............................................. ............................................................. 188 
4.2.4 Costs included in the cost analysis .................................................................. 191 
4.2.5 Definition of costs ............................................................................................ 192 
4.2.5.1 Direct cost of treatment provision ............................................................................ 192 
4.2.5.2 Personal costs of treatment provision ...................................................................... 194 
4.2.5.3 Medical costs ........................................................................................................... 194 
4.2.5.4 Personal medical costs ............................................................................................. 194 
4.2.5.5 Indirect Costs ........................................................................................................... 194 
4.2.6 Unit costs ......................................................................................................... 195 
4.2.7 Data lnanagement ............................................................................................ 195 
4.2.7.1 General data management. ....................................................................................... 195 
4.2.7.2 Total costs versus change in costs ........................................................................... 196 
4.2.7.3 Handling of missing values ...................................................................................... 196 
4.2.7.4 Handling of uncertainty ........................................................................................... 197 
4.2.8 Statistical analysis ........................................................................................... 197 
4.2.8.1 Power ....................................................................................................................... 198 
4.2.8.2 Incremental cost-effectiveness analysis ................................................................... 199 
4.2.8.3 Interpretation of ICERs ............................................................................................ 200 
4.3 RESULTS .................................................................................................................... 203 
4.3.1 Cost of treatment provision ............................................... ............................... ::03 
4.3.1.1 Direct treatment costs .............................................................................................. 203 
4.3.1.2 Personal costs ...................................................................................................... 203 
4.3 . .:? i\ledical costs ................................................................................................... .:?05 
.. 
\' 11 
4.3.2.1 Baseline medical costs ............................................................................................ 205 
4.3.2.2 Medical and personal costs incurred during the trial .............................................. 207 
4.3.2.3 Impact of study interventions on medical costs .................................... . . ........ 20S 
4.3.3 Indirect costs ............................................................................. ....................... ] 1] 
4.3.4 Incremental cost-effectiveness analysis .. ......................................................... :? 13 
4.3.5 Acceptability curve .......................................................................................... 215 
4.3.6 Sensitivity analysis .................................................................................. ......... 217 
4.3.6.1 Sensitivity analysis - costs .................................................................................... '" 217 
4.3.6.2 Sensitivity analysis - benefits ................................................................................... 218 
4.3.7 Cost-utility analysis ......................................................................................... 221 
4.4 DISCUSSION ............................................................................................................... 223 
4.4.1 Main findings ................................................................................................... 223 
4.4.2 Comparison with other studies ........................................................................ 226 
4.4.3 Strengths and weaknesses of the study ............................................................. 230 
5 SUMMARY AND CONCLUSION ............................................................................. 233 
5.1 MAIN FINDINGS .......................................................................................................... 233 
5.2 INTERPRETATION ....................................................................................................... 236 
5.3 RECOMMENDATIONS FOR THE FUTURE ....................................................................... 236 
REFERENCES ...................................................................................................................... 238 
APPENDICES ........................................................................................................................ 270 
ApPENDIX 1: CONSENT FORMS ............................................................................................ 270 
ApPENDIX 2: RECRUITMENT QUESTIONNAIRE ...................................................................... 271 
ApPENDIX 3: ASSESSMENT QUESTIONNAIRE ........................................................................ 272 
ApPENDIX -i: INFORMATION LEAFLET AND GENERAL ADVICE .............................................. 273 
ApPENDIX 5: SATISFACTION QUESTIONNAIRE ...................................................................... ~ 7 4 4
ApPENDIX 6: EXERCISE DIARy ............................................................................................. 275 
:-\PPENDIX 7: STRENGTH OF EXERCISE BANDS UNDER LABORATORY CONDITIONS ............... 276 
... 
\' III 
ApPENDIX 8: ASSESSMENT OF ADHERENCE ....................................................................... 277 
APPENDIX 9: TELEPHONE SUPPORT CHECKLIST ................................................................... 278 
ApPENDIX 10: CASE NOTE ABSTRACTION FORMS ..................................................... · .. · ........ 279 
APPENDIX 11: PUBLICATIONS ARISING FROM THIS THESIS ................................................... 280 
\\ 
Index of tables 
TABLE 1 KELLGREN AND LAWRENCE GRADING SCHEME FOR OSTEOARTHRITIS ........................... 5 
TABLE 2 SUMMARY OF RECENT PREVALENCE STUDIES FOR KNEE ~ A A .......................................... 8 
TABLE 3 SUMMARY OF THE PAIN QUESTIONS USED IN EPIDEMIOLOGICAL STUDIES .................... 16 
TABLE 4 RISK FACTORS FOR RADIOGRAPHIC KNEE OA (ADAPTED FROM FELSON, 1990) ........... 19 
TABLE 5 PSYCHOLOGICAL FACTORS ASSOCIATED WITH KNEE PAIN AND DISABILITY ................. 29 
TABLE 6 SUMMARY OF QUESTIONS RELATING TO COPING STRATEGIES AS ASSESSED BY THE PAIN 
MANAGEMENT INVENTORY AND THE COPING STRATEGIES INVENTORy ........................... 32 
TABLE 7 SUMMARY OF RECENT EXERCISE STUDIES .................................................................... 39 
TABLE 8 FACTORS USED TO DISTINGUISH THE CHARACTERISTICS OF DIFFERENT HEALTH CARE 
EVALUATIONS (FROM DRUMMOND ET AL., 1997) ............................................................ .l7 
TABLE 9 SUMMARY OF THE GUIDELINES FOR ECONOMIC ANALYSIS ........................................... 57 
TABLE 10 ASSESSMENT PROCEDURE .......................................................................................... 80 
TABLE 11 TIMETABLE FOR THE EXERCISE INTERVENTION .......................................................... 85 
TABLE 12 SUMMARY OF EXERCISE BANDS USED ACCORDING TO MVC RECORDINGS ................ 87 
TABLE 13 CODING OF EXERCISE ADHERENCE IF DAILY EXERCISE DIARY WAS NOT COMPLETED. 89 
TABLE 14 SUMMARY OF OUTCOME MEASURES USED ................................................................. 92 
TABLE 15 BASELINE CHARACTERISTICS OF STUDY POPULATION .............................................. 103 
TABLE 16 RANDOMISATION TO TREATMENT GROUP (DEMOGRAPHIC DETAILS AND KEY OUTCOME 
MEASURES) ..................................................................................................................... 105 
TABLE 17 BASELINE AND CHANGE IN WOMAC PAIN SCORES AT 24 MONTHS BY TREATMENT 
GROUP (ITT ANALYSIS) .................................................................................................. 107 
TABLE 18 BASELINE AND CHANGE IN WOMAC PAIN SCORES AT 6 MONTHS BY TREAT\IENT 
GROUP (ITT ANALYSIS) .................................................................................................. 108 
TABLE 19 N l l ~ I B E R R NEEDED TO TREAT Ii\: ORDER TO ACHIEVE .. \ ~ ~ 50% REDUCTI()", Ii\: PAI:\ AT 2.l 
r-.IONTHS (ITT ANALYSIS) ................................................................................................ III 
TABLE 20 SUi\Ii\IARY OF WOi\lAC CHA:\C;ES IN PAIN SCORES BY TREAT\IEi\:T FACTOR AT 2.l 
i\10NTHS - ITT ANALYSIS ........................................................ . .................... 113 
TABLE 21 IMPACT OF THE INTERACTION OF FACTORS ON WOMAC PAIN SCORES (ITT 
ANALYSIS) ...................................................................................................................... 11.+ 
TABLE 22 ALTERNATIVE HANDLING OF MISSING DATA - WOMAC PAIN AT 2.+ MONTHS ......... 115 
TABLE 23 CHANGE IN WOMAC PHYSICAL FUNCTION AND STIFFNESS AT 2.+ MONTHS - (ITT 
ANALYSIS) ...................................................................................................................... 116 
TABLE 24 CHANGE IN MVC AT 24 AND 6 MONTHS - (ITT ANALYSIS - PRACTICE B ONLy) ..... 118 
TABLE 25 IMPACT OF CHANGE IN MVC SCORES ON WOMAC PAIN SCORES AT 2.+ MONTHS (ALL 
GROUPS - PRACTICE B) ................................................................................................... 119 
TABLE 26 SUMMARY OF REASONS FOR NON-COMPLETION OF THE EXERCISE PROGRAMME ...... 121 
TABLE 27 IMPACT OF EXERCISE ADHERENCE ON WOMAC PAIN SCORES AT 24 MONTHS ....... 122 
TABLE 28 IMPACT OF EXERCISE ADHERENCE ON CHANGE IN MUSCLE STRENGTH AT 24 MONTHS . 
....................................................................................................................................... 123 
TABLE 29 CHANGE IN SF-36 PHYSICAL FUNCTION AT 24 AND 6 MONTHS (ITT ANALySIS) ...... 123 
TABLE 30 MEAN BASELINE AND CHANGE IN ANXIETY SCORES BY FACTOR AT 24 MONTHS (ITT 
ANALYSIS) ...................................................................................................................... 124 
TABLE 31 MEAN BASELINE AND CHANGE IN DEPRESSION SCORES BY FACTOR AT 24 MONTHS 
(ITT ANALYSIS) .............................................................................................................. 125 
TABLE 32 SELF-REPORTED BENEFICIAL AND ADVERSE EVENTS RESULTING FROM PARTICIPATION 
IN THE STUDy .................................................................................................................. 126 
TABLE 33 RESULTS OF MULTIVARIATE ANALYSIS FOR CHANGE IN WOMAC SCORES 
THROUGHOUT THE 24-MONTH PERIOD (DEPENDENT VARIABLE: AREA UNDER THE CURVE) . 
....................................................................................................................................... 129 
TABLE 34 DEFINITION OF KEY TERMS USED IN THE CURRENT STUDY AND ALTERNATIVE 
DEFINITIONS USED BY OTHER AUTHORS (ADAPTED FROM PETmI, 1994) ....................... 1.+1 
TABLE 35 ARTHRITIS RELATED DRUGS ..................................................................................... 1.+.+ 
TABLE 36 SUMMARY OF QUANTITY AND PRICE OF OTC DRUGS ............................................. 1.+7 
TABLE 37 SUf\If\IARY OF BASELINE PATIENT CH,"'\RACTERISTICS ............................................... 15.+ 
TABLE 38 DIRECT \IEDICAL COSTS I:\ClIRRED DURI:\C; BASELI:\E 6 \10'., TH ............................. 1-:'7 
,\1 
TABLE 39 TOTAL DRUG COSTS IN RELATION TO PRESCRIPTION CHARGES PAID ........................ 160 
TABLE 40 NUMBER OF P AMs SESSIONS INSTIGATED THROUGH PRIMARY CARE ..................... 161 
TABLE 41 PERSONAL MEDICAL COSTS (EXCLUDING OTC COSTS) ............................................ 162 
TABLE 42 OTC DRUGS BOUGHT FOR KNEE-RELATED CARE ..................................................... 163 
TABLE 43 OTHER KNEE-SPECIFIC COSTS INCURRED OVER 12 MONTHS .................................... 16.+ 
TABLE 44 THE NEED FOR ASSISTANCE WITH ACTIVITIES OF DAILY LIVING .............................. 165 
TABLE 45 SUMMARY OF PRIMARY CARE COSTS, DIRECT MEDICAL COSTS AND SOCIETAL COST 
....................................................................................................................................... 166 
TABLE 46 SENSITIVITY ANALYSIS ........................................................................................... 171 
TABLE 47 RESULTS OF LOGISTIC REGRESSION - RISK FACTORS FOR INCURRING PRIMARY CARE 
COSTS .............................................................................................................................. 174 
TABLE 48 RESULTS OF LINEAR REGRESSION - PRIMARY CARE COSTS ...................................... 175 
TABLE 49 SUMMARY TABLE OF COST OF ILLNESS STUDIES ..................................................... 180 
TABLE 50 CALCULATION OF EQ-5D UTILITY SCORES ............................................................. 191 
TABLE 51 SUMMARY OF 2-YEAR TREATMENT COSTS BY TREATMENT TYPE ............................. 204 
TABLE 52 PERSONAL TIME COSTS INCURRED BY SUBJECTS IN THE EXERCISE PROGRAMME ...... 205 
TABLE 53 BASELINE MEDICAL COSTS BY TREATMENT GROUP .................................................. 206 
TABLE 54 SUMMARY OF MEDICAL AND SOCIETAL COSTS INCURRED DURING THE TRIAL PERIOD . 
....................................................................................................................................... 207 
TABLE 55 MEDICAL COSTS BY TREATMENT GROUP OVER 24 MONTHS ..................................... 208 
TABLE 56 FREQUENCY OF RESOURCE USE AND TOTAL MEDICAL COSTS OVER THE 24-MONTH 
STUDY PERIOD - EXERCISE VERSUS NON-EXERCISE ......................................................... 211 
TABLE 57 INCREMENTAL COST-EFFECTIVENESS RATIOS BASED ON WOMAC PAIN AND NNT 
SCORES AT ~ 4 4 MONTHS ................................................................................................... 213 
TABLE 58 SENSITIVITY ANALYSIS ............................................................................................ 220 
TABLE 59 CHANGE IN QAL Y AT 6 AND 2.+ MONTHS (EXERCISE VERSUS NON-EXERCISE) ........ 2 ~ ~ 1 
TABLE 60 EQ-5D DOMAINS AT 24 MONTHS - EXERCISE VERSUS NON-EXERCISE .................... 2 ~ 2 2
.. 
,\11 
Index of figures 
FIGURE 1 CURRENT MODEL OF THE AETIOPATHOGENESIS OF OA ................................................. 3 
FIGURE 2 GRAPH SHOWING THE PREVALENCE OFOA (GRADES 2-4) BY AGE (FROM CROFT. 
1990) .................................................................................................................................. 9 
FIGURE 3 SUMMARY OF THE ACR CRITERIA FOR THE CLINICAL CLASSIFICATION OF KNEE OA. 1-+ 
FIGURE 4 SUMMARY OF THE INTERACTION OF RISK FACTORS ASSOCIATED WITH RADIOGRAPHIC 
KNEE OA AND KNEE PAIN ................................................................................................. 26 
FIGURE 5 SUMMARY OF GUIDELINES FOR THE MEDICAL MANAGEMENT OF KNEE OA (FROM ACR 
SUBCOMMITTEE ON OA GUIDELINES, 2000) ..................................................................... 36 
FIGURE 6 THE COST-EFFECTIVENESS PLANE (TAKEN FROM BRIGGS & FENN, 1998) .................. 51 
FIGURE 7 EXAMPLE OF A TYPICAL ACCEPTABILITY CURVE ........................................................ 53 
FIGURE 8 SUMMARY OF TREATMENT ALLOCATION .................................................................... 77 
FIGURE 9 SUMMARY OF STUDY RECRUITMENT ......................................................................... 101 
FIGURE 10 PROGRESS OF VOLUNTEERS THROUGH THE TRIAL. .................................................. 106 
FIGURE 11 MEAN CHANGE IN WOMAC PAIN SCORES BY TREATMENT GROUP (ITT ANALYSIS) . 
....................................................................................................................................... 109 
FIGURE 12 MEAN CHANGE IN WOMAC PAIN - EXERCISE V NON-EXERCISE (ITT ANALYSIS). 112 
FIGURE l3 CHANGE IN MUSCLE STRENGTH: PER PROTOCOL DATA (PRACTICE B ONLY) ........... 117 
FIGURE 14 ADHERENCE WITH INTERVENTIONS AT 6 AND 24 MONTHS ...................................... 120 
FIGURE 15 TOTAL BASELINE COSTS TO THE HEALTH PROVIDER (6-MONTH PERIOD) ................. 155 
FIGURE 16 CONTRIBUTION OF DRUG TYPE TO TOTAL ARTHRITIS DRUG COSTS .......................... 159 
FIGURE 17 SUMMARY OF DATA COLLECTION ........................................................................... 189 
FIGURE 18 MEAN SOCIETAL COSTS BY TREATMENT TYPE ........................................................ 210 
FIGURE 19 COST-EFFECTIVENESS PLANE (SHOWING BOOTSTRAPPED leERs) .......................... 215 
FIGURE 20 ACCEPTABILITY CURVE (EXERCISE ONLY COMPARED WITH NO INTERVE:\TIO" 
CONTROL). BASED ON TOTAL SOCIETAL COSTS Ai\D CHANGE I" WOMAC PAl" ......... 216 
X1ll 
Index of equations 
EQUATION 1 EQUATION USED TO CALCULATE THE ALLOCATION OF EXERCISE BA:\OS BY ~ I U S C L E E
STRENGTH ......................................................................................................................... 88 
EQUATION 2 EFFECT SIZE CALCULATION ................................................................................... 96 
EQUATION 3 CALCULATION OF BODY MASS INDEX .................................................................... 97 
EQUATION 4 AREA UNDER THE CURVE CALCULATION FOR WOMAC PAIN SCORES ................... 98 
EQUATION 5 COST-EFFECTIVENESS FORMULAE FOR CHANGE IN WOMAC PAIN ..................... 200 
EQUATION 6 COST-EFFECTIVENESS FORMULAE FOR NNT ....................................................... 200 
\.\ \ 
Abstract 
Objectives: 
o To determine the prevalence of knee pain in the population aged ~ 4 5 5 years. 
o To determine the benefit or otherwise of regular home exercise and 
telephone contact in reducing the burden of knee pain in the community. 
o To determine the economic burden of knee pain from a societal perspective. 
o To determine the cost-effectiveness and cost-utility of the compared 
interventions. 
Design: An initial postal questionnaire regarding knee pain was sent to 9296 
individuals aged ~ 4 5 5 years registered with two large general practices in 
Nottingham. This was followed by a two-year, single-blind, randomised 
factorial trial. Treatment arms included: exercise therapy, telephone social 
support, a placebo health food product and no intervention. Economic data 
were collected prospectively alongside the trial. Analysis was conducted on an 
intent-to-treat basis. 
Primary outcome: Self-reported knee pain at 24 months. This was assessed 
using the Western Ontario MacMaster's Universities Osteoarthritis Index 
(WOMAC) - a knee specific questionnaire. 
Results: The postal questionnaire was returned by 650/0 of the study 
population. The prevalence of self-reported knee pain in the community in 
those aged :2:.+5 years was 320/0 (35% in fen1ales and 28% in males). Costs 
incurred during the 6-month period prior to randomisation showed medical 
costs for the treatment of knee pain to be 7% of total medical costs and 11 % of 
primary care costs. Annual societal costs were estimated to be £48 per person. 
The intervention study demonstrated that a simple, home-exercise programme 
could reduce self-reported knee pain, knee stiffness and knee related physical 
disability after 24 months (p=<0.001, 0.01 and <0.001 respectively). Effect 
sizes were modest, but improvements were incremental to nonnal care. The 
number needed to treat (NNT) in order to achieve a 2 50% reduction in pain at 
24 months for individuals allocated to the exercise programme was between 8 
and 13. Neither telephone contact nor the placebo dolomite tablet contributed 
significantly to the observed reduction in pain. 
The cost per person of delivering the two-year exercise programme was £ 113. 
Analysis of GP records revealed no change in medical costs during the trial. 
Cost-effectiveness analysis suggested that the cost per unit change on the 
WOMAC pain scale was £ 108. The cost-effectiveness of achieving a 2 50% 
reduction in pain in a single individual (based on NNT figures) was £1,012. 
Conclusion: Knee pain is common in the general UK population aged 245 
years and incurs an estimated cost of £218 to £350 million per annum 
(excluding indirect costs) in 1996 prices. The burden of knee pain could be 
reduced by the in1plementation of a cost-effective primary care-based c.\crcise 
progran1111e, although such improvements are likely to be modest. 
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Summary 
This thesis describes a set of inter-related studies that address the medical 
management of knee pain in the community. It is presented as a health services 
research project and is multidisciplinary in nature (including epidemiology, 
research methodology, clinical issues, economic evaluation and medical 
statistics). A community-based sample has been chosen as being most 
appropriate for study since the majority of patients receive their treatment 
within primary care. A pragmatic approach has been adopted in order to 
achieve broadly generalisable results. 
In chapter one, an introduction to the relevant issues and current debates 
surrounding the management of osteoarthritis and knee pain are outlined. 
Literature was searched from relevant electronic databases including 
MEDLINE, the Cochrane Database of Systematic Reviews, DARE (Database 
of Reviews of Effectiveness), the NHS Economic Evaluation database and the 
HTA web site. Further references were obtained by hand searching retrieved 
articles. Whilst this was not intended to be an exhaustive systematic review of 
the literature, published reviews by other authors were identified in the 
literature wherever possible. No specific timeframe was adopted for the search. 
Nevertheless, more recent studies tended to be better executed and designed in 
the light of existing knowledge. As a result, emphasis has been placed on these 
findings. The advantage of such an approach over a full systematic review is 
that it is able to provide a broad introduction to the field within the time and 
word lin1its available to the thesis. Clearly, further interrogation of additional 
XXI 
databases, using more structured search terms, would undoubtedly reveal 
further relevant literature. 
Chapter two describes the intervention study and includes results of the initial 
postal survey and the subsequent randomised controlled trial (RCT). For the 
RCT a factorial design has been employed in which exercise therapy is 
compared with telephone support, a placebo health food product and a no 
intervention control group. The primary outcome is self-reported knee pain at 
24 months and has been assessed using a knee-specific instrument (WOMAC). 
Other secondary outcomes include knee specific stiffness and physical 
function, quadriceps muscle strength, anxiety and depression (HADs) and more 
general indicators of quality-of-life (SF-36 physical function and EuroQol EQ-
SD). Regression analysis has been used in order to identify possible predictors 
of response that may be useful in directing future research activity. 
Chapter three presents cost-of-illness data relating to the treatment of knee 
pain. It describes patient-specific cost data collected for volunteers during the 
6-month period prior to participation in the RCT. Whilst a societal perspective 
has been adopted, the primary focus is on costs to the health provider and to the 
patient. Total costs have been collected in addition to knee-specific costs since 
patients with osteoarthritis are reported to incur higher costs than their non-
arthritic controls for a range of medical conditions. Regression analysis has 
been used in order to identify factors associated with high primary care costs. 
Finally. chapter 4 describes the economic evaluation of the study interventions. 
This included cost-effectiveness and cost-utility analyses. 
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1 Introduction 
1.1 Osteoarthritis 
1.1.1 What is osteoarthritis? 
Osteoarthritis (OA) is a chronic locomotor condition, most commonly 
associated with the elderly. Pathologically it involves the loss of articular 
cartilage in synovial joints and changes in the underlying bone at joint margins 
(Doherty et al. 1997). Clinically, OA may result in joint pain and tenderness, 
limited range of movement, crepitus, mild effusion and deformity. Most 
commonly affected sites include the knees, hips, hands and spine (Lawrence et 
al. 1966). It is associated with considerable morbidity, particularly in relation 
to locomotor difficulties and limitations in activities of daily living (Davis et al. 
1991). 
OA is not a recent condition, nor is it confined solely to man. Evidence of 
osteoarthritic changes in the fossilised remains of a variety of animals, 
prehistoric man and even dinosaurs, points to its extensive history (Jurmain and 
Kilgore, 1995; Rogers et al. 1981). 
Traditional views of the pathogenesis of OA have relied on the concept of 
mechanical 'wear and tear': OA being seen as the inevitable result of ageing. 
However, more recent evidence suggests a far more active process of 
regeneration and metabolic change. It is now believed that the features 
commonly observed in an OA joint reflect the normal repair process (Hutton, 
1 
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1989). It is only when a discrepancy arises between the demands placed on a 
joint and the regenerative capacity of that joint, that failure (i.e. symptomatic 
OA) results (Doherty et al. 1997). 
The belief that OA represents an essentially reparative process has caused 
renewed interest in its study. A better understanding of the development of 
symptoms, and potential treatment options for the prevention of disability are 
key issues for future study. 
1.1.2 Aetiology of osteoarthritis 
Current models for the aetiology of OA involve the complex interplay of 
predisposing factors, constitutional (systemic) and local biomechanical factors 
(Figure 1). 
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Figure 1 Current model of the aetiopathogenesis ofDA (adaptedfrom Dieppe 
and Kirwan, 1994) 
Constitutional 
factors: 
• Age 
• Gender 
• Obesity 
• Hormonal 
Predisposition: 
• Genetic 
• Race 
1 
Susceptibility to OA 
Site and severity of 
OA 
Joint 
Biomechanical: 
• Trauma 
• Occupational 
loading 
• Neuromuscular 
pathology 
• Joint insult / 
abnormality 
OA is no longer thought of as a single disease, but rather as a heterogeneous 
group of conditions affecting different joint sites. This belief has been 
strengthened by recent evidence suggesting that the aetiology of OA may vary 
according to the site of involvement (Cooper et al. 1994). 
It i now understood that different Iisk factors may account for the incid n e of 
di ea at differ nt ite . For e ample obe ity ha con i tentl been Identifi d 
a a p \ rful Ii k fa tor f r th d elopm nt of knee OA . ndmark t al. 
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1999; Hart et al. 1999; Hart and Spector, 1993; Davis et al. 1990), but 
findings have been more inconsistent in relation to hip OA (Oliveria et al. 
1999; Davis et al. 1990). Similarly, prevalence of knee OA is greatest 
amongst women, whereas this is not the case for hip OA (Felson, 1988). 
Given the importance of 'site' in determining the aetiology of OA, it is 
possibly not surprising that past research has produced conflicting results in the 
identification of possible risk factors for ~ A . . It is only through a greater 
understanding of these underlying processes that appropriate measures can be 
developed and implemented for the treatment of ~ A . .
1.1.3 Radiographic assessment of osteoarthritis 
Radiographic assessment of osteoarthritic change is relatively inexpensive, 
reproducible and reflects the major pathophysiological features of the disease 
(Gunther and Sun, 1999; Jacobsson, 1996). Nevertheless, radiographs lack 
sensitivity in a number of situations. They are particularly insensitive in the 
detection of early OA changes, and are limited in their ability to detect disease 
progression. Recent technological advances such as the use of ultrasound, or 
magnetic resonance imaging, may ultimately provide more useful insights into 
the disease process (Boegard et al. 1998; Buckland-Wright, 1997). 
Nevertheless, X-rays currently play an important role in establishing the 
presence of OA for both clinical and epidemiological study. 
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It was not until the 1950s that Kellgren and Lawrence developed the first 
formal classification system for OA (Kellgren and Lawrence, 1957). (Table 1). 
This early grading scheme has been the "gold standard" for many years and 
was adopted as the standard criteria for epidemiological research by the World 
Health Organisation in 1961. A grade of 2 or above is now generally accepted 
as the minimum requirement for the case definition of OA, and many of the 
population surveys conducted to date have relied on this system (McAlindon et 
al. 1993a; Felson et al. 1987). 
Table 1 Kellgren and Lawrence grading scheme for osteoarthritis. 
Grade 
o 
1 
2 
3 
4 
Radiographic Criteria 
Normal 
Doubtful narrowing of joint space, possible 
osteophyte. 
Definite osteophyte, absent or questionable 
narrowing of joint space 
Moderate osteophyte, definite narrowing, 
sclerosis, possible deformity. 
Large osteophyte, marked narrowing, severe 
sclerosis, definite deformity. 
Nevertheless, the Kellgren and Lawrence grading scheme has been criticised in 
recent years. Confusion as to the exact wording of the criteria has led to 
studies of relatively poor comparability; even when the standard criteria were 
claimed to have been used (Spector et al. 1991). In addition, the exclusion of 
grade 1 (mild OA) by the majority of researchers means that early OA changes 
are often ignored. Finally, the over-reliance on osteophyte fOImation as a 
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defining feature of OA has been questioned (McAlindon and Dieppe. 1989; 
Wood, 1976). 
Many researchers now prefer the grading of individual features (osteophyte, 
joint-space narrowing, sclerosis, alignment and bone attrition) within specific 
joints or compartments (McAlindon et al. 1993b; Cooper et al. 1992; Menkes, 
1991). This has led to the development of several new grading atlases (Burnett 
et al. 1994; Altman et al. 1986b). Further development and validation of these 
atlases in a variety of clinical and epidemiological settings is now needed 
(J acobsson, 1996). 
1.1.4 Prevalence of osteoarthritis 
OA is a condition of slow and insidious onset. As such, it has traditionally 
been examined through cross-sectional surveys of prevalence, rather than by 
incidence of disease (Croft, 1990). In addition to the early work by Kellgren 
and Lawrence, several large-scale studies have been conducted over the last 20 
years, the main features of which are summarised in Table 2. 
These studies provide the basis for our growing understanding of the course 
and development of ~ A . . Nevertheless, different studies have produced very 
different estimates of prevalence. Given the variability in different 
epidemiological and radiographic techniques. this is possibly not surprising 
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(Spector and Hochberg, 1994). However, certain aspects of the disease 
consistently emerge. 
OA is by far the most prevalent chronic joint condition (Lawrence et al. 1989). 
Estimates suggest that OA is present in 8.7 to 12.3% of the population 
(Rothfuss et al. 1997). Prevalence varies greatly between joints (van Sasse et 
al. 1989). The most commonly affected joints are the hands, knees, hips and 
apophyseal joints of the cervical and lumbar spine (Bagge et al. 1991; 
Lawrence et al. 1966). 
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Table 2 Summary of recent prevalence studies for knee GA. 
- --
Study Reported by Subjects Study type X-rays X-ray grading Prevalence of 
scheme knee OA 
NHANES- l Davis et al. 4056 US adults aged 45- National probability Anteroposterior non- Kellgren & Lawrence Men (5%) 
1971-1975 (1992) 74 yrs sample. Prospective weight bearing Women (10%) 
National Health & Nutrition cohort study OA = grades 1-4 41 % of these 
Examination Survey symptomatic 
NHEFS Davis et al. 2989 adults from previous Prospecti ve cohort None N/A Men (5%) 
) 980-1982 (1991) NHANES-1 survey study Women (9.5%) 
Nalionalllealth & Nutrition 
Examination Survey 
Epidemiological Follow-up 
Framingham Osteoarthritis Study Felson et al. 1805 adul ts aged 63-94 Part of Framingham Anteroposterior Kellgren & Lawrence 36% X-ray 
1983- 1985 (1987) years Heart Study Cohort. weight bearing. + features 9% X-ray + 
OA = grades 2-4 symptoms 
1992-1993 Felson et al . Unclear Prospective cohort As above As above 15.6% incident 
(1997) 
598 X-ray negative study 
disease since earlier 
X-ray 
subjects from 1983-85 
(X) cohort were X-rayed 
Johnston County Osteoarth.ritis Jordan et al. 1192 African-American & Probability sample. Antero-posterior Kellgren & Lawrence 19% all subjects 
Project (1997) Caucasian adults aged Prospecti ve cohort weight bearing. 
>45 yrs from rural N. study. OA = grades 2-4. 
Carolina 
Zoetermeer Study van Sasse et al. 6585 inhabitants aged >20 Random population Type not specified. Kellgren & Lawrence 18% all subjects 
(1989) yrs of a Dutch village sample. Cross- OA = grades 2-4. 
sectional survey 
Baltimore Longitudinal Study of Lethbridge- 675 Caucasian adults Cross-sectional Antero-posterior Kellgren & Lawrence Men(II%) 
Aging Cejku et al. aged 19-92 years survey weight bearing + individual features. Women (10%) 
1984-1989 (1995) OA = grades 2-4 I 
Goteborg Study Bagge et al . 266 adults aged >70 years Cross-sectional & Antero-posterior Kellgren & Lawrence Men (51%) 
1971-1972 (1992) prospecti ve weight bearing with Women (56%) 
1976-1977 (followed-up for ten slight flexion 
years) OA = grades 2-4. 
Chingford Study Hart and 1003 women aged 45-64 Cross-sectional Antero-posterior Kellgren & Lawrence 12% X-ray 
1988-1989 Spector, (1993) years survey weight bearing 6% X-ray + 
OA = grades 2-4 symptoms 
1993 Hart et al . 830 (83% of original Prospective cohort As above Incidence 3%/year 
( 1999) population) study 
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The importance of age in determining the presence of OA has been consi tentl 
identified (Davis et al. 1992; Felson et al. 1987; Lawrence et al. 1966). 
Lawrence et al. found that almost everyone over the age of 65 years had at least 
one joint with arthritic changes of grade 2 or greater. As is graphically 
demonstrated in Figure 2, prevalence increases steadily with age. However 
prevalence may plateau in later life (Bagge et al. 1992). 
Figure 2 Graph showing the prevalence ofDA (grades 2-4) by age (from Croft, 
1990). Datafrom Lawrence et al. (1966); Kellgren & Lawrence (1958). 
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Somewhat contradictory findings have been found with regard to gender 
differences in the prevalence of OA. Nevertheless, rates are generally reported 
to be higher for women than they are for men (Felson et al. 1987), especially 
for the hand and knee joints, and in the older age groups (van Sasse et al. 
1989). 
Much is still to be achieved in the development of accurate prevalence figures. 
In particular, clarity in the definition of clinically relevant cases will help to 
elucidate the true burden of disease (Petersson, 1996). In addition, the recent 
trend towards increasing numbers of prospective incidence studies is clarifying 
the findings of earlier cross-sectional studies and may prove vital for the 
elucidation of risk factors for disease progression (Oliveria et al. 1999; Hart et 
al. 1999; Felson et al. 1997). 
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1.2 Knee Osteoarthritis 
1.2.1 Defining knee osteoarthritis 
Recognition of the importance of site-specific definitions of OA has led to 
renewed efforts to develop clear and reliable case criteria for epidemiological 
investigation of the knee (Hart and Spector, 1995). Future developments may 
expand our current understanding of the factors relevant to sensitive and 
specific diagnosis. In particular, the development of "biological markers" of 
disease shows promise (Clark et al. 1999; Lohmander and Felson, 1997). 
Nevertheless, for the purposes of this study, the two most commonly held 
definitions of OA (radiographic assessment and clinical assessment) are most 
relevant. 
1.2.1.1 Radiographic definitions of knee osteoarthritis 
Epidemiological studies have traditionally favoured the use of radiographic 
evidence of structural abnormality in establishing case status. As yet, 
consensus in producing an appropriate and consistent classification has proved 
surprisingly difficult. Indeed, until 10 years ago, specific criteria for admission 
to clinical trials were only reported in 200/0 of published studies (Altman, 
1995). 
It is now recognised that no one grading system is suitable for the study of OA 
at all sites (Murphy, 1995). This has led to the development of atlases specific 
to indi\'idual joints. including the knee (Altman et al. 1995: Burnett et al. 
1 1 
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1994). The importance of the patellofemoral joint as an independent factor in 
the development of knee pain has led to recommendations for the inclusion of 
skyline radiographs, which are more sensitive in detecting abnormality and 
change with time (Lanyon et al. 1996; Jones et al. 1993). 
Possibly the greatest debate surrounding the grading of radiographs is in the 
dominance of individual features. The Kellgren and Lawrence scheme heavily 
emphasised the importance of osteophyte formation. It has since been argued 
that osteophytes can represent a normal feature of ageing (Wood, 1976), and 
that the importance of joint space narrowing should not be ignored. More 
recent findings suggest that both aspects may be important in determining 
different aspects of the disease. In particular, the presence of osteophytes 
(especially in the patellofemoral joint) may better predict pain reporting 
(Cicuttini et al. 1996), but joint space narrowing may be a better indicator of 
disease severity and progression (Altman et al. 1987). 
Regardless of the criteria used, discordance between radiographic evidence of 
disease activity and self-reported pain occurs consistently (Creamer and 
Hochberg, 1997). Patients with severe radiological change are more likely to 
report pain than those with mild arthritic change. Nevertheless, the relationship 
between the two is not strong. The pioneering work by Kellgren and Lawrence 
was the first to identify the possible discordance between radiographic 
eyidencc of disease actiyity and self-reported symptoms (Lawrence et al. 
1966). Their population-based surveys of the 1960s re\'ealed considerable 
12 
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levels of discordance (20-80%); actual rates being dependent upon the site of 
in vol vement. 
The continued disparity between symptom reporting and radiographic evidence 
of disease (Davis et al. 1992; Felson et al. 1987) has caused concern about the 
over-reliance on radiographic evidence alone. The American College of 
Rheumatology (ACR) has issued recommendations based on a combination of 
both radiographic and clinical criteria and has emphasised the importance of 
"clinically relevant" cases (Altman et al. 1986a). 
1.2.1.2 Clinical definitions of knee osteoarthritis 
In 1986, a subgroup of the American College of Rheumatology was convened 
in order to establish a reliable set of clinical criteria for the classification of OA 
(Altman et al. 1986a). This work was based on consensus agreement as to the 
most important features of OA. The discriminative ability of these features 
was then assessed in a group of 257 hospital referred OA patients compared 
with a control group (of which 55 had rheumatoid arthritis and 52 had a variety 
of other musculoskeletal complaints). The combination of findings with the 
highest levels of specificity and sensitivity are shown in Figure 3. 
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Figure 3 Summary of the ACR criteria for the clinical classification of knee OA 
(Altman, 1991). 
1 Knee pain for most days of prior month. 
2 Crepitus on active joint motion. 
3 Morning stiffness of the knee ~ ~ 30 minutes. 
4 Age ~ ~ 38 years. 
g5 Bony enlargement of the knee with crepitus. 
6 Bony enlargement of the knee without crepitus. 
Osteoarthritis is adjudged to be present if anyone of the following 
three sets of criteria is fulfilled: 1,2,3 and 4. 
1,2,3 and 5. 
1 and 6. 
These criteria depend on the presence of "knee pain" for a definition of OA, 
and are therefore a measure of symptomatic ~ A . . Such a definition is probably 
most appropriate for epidemiological study, since it is symptomatic patients 
who represent the greatest burden to society. Nevertheless, certain limitation 
have been identified. Firstly, it is no easy matter to identify presence of pain. 
The reporting of pain is known to be highly variable (Bellamy et al. 199 ) and 
to be multifaceted (Creamer et al. 1999). In addition the wording of pain 
questions can influence reported prevalence (O'Reilly et al. 1996; Sp t 
al. 1991). It may e en be pos ible that different que tion re b tt r a lUt d 
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with different aspects of the disease; some being more able to identify 
radiographic changes (Cicuttini et al. 1996) and others disability and pain 
(O'Reilly et al. 1996). Various questions have been used in recent years 
(Table 3), although consensus as to the most appropriate has yet to be reached. 
15 
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Table 3 Summary o/the pain questions used in epidemiological studies. 
Pain question: 
Have you ever had pain 
in or around the knee 
on most days for at least 
a month? 
If so, have you 
experienced any pain 
during the last year? 
Used by: 
NHANES-I (Davis et al. 1992) 
NHEFS (Hochberg et al. 1989) 
Framingham Study (Felson et al. 
1987) 
Bristol Study (McAlindon et al. 
1993a) 
Baltimore Longitudinal Study of 
Ageing (Lethbridge-Cejku et al. 
1995) 
Have you had pain (O'Reilly et al. 1996) 
within the last year in 
or around the knee that 
occurred on most days 
for at least a month? 
Have you had knee pain ACR criteria for clinical 
on nwst days of the last classification 
month? 
16 
Comments: 
• 
• 
• 
• 
• 
Both sections of the 
question must be 
positive for subjects 
to be classified as 
having knee pain, 
NHANES-I also 
classified subjects as 
having knee pain if 
they reported pain 
during range of 
motion assessment. 
The Framingham 
study only used part 
1 of the question. 
The Bristol Study 
scored each knee 
separatel y. 
The Baltimore 
Study of Ageing 
used these questions 
to give an indication 
of "pain ever" (part 
1 only) and "current 
pain" (parts 1 & 2), 
• This is a modified 
version of the 
NHANES-I 
question. It was 
used to assess the 
impact of minor 
word changes on 
pain reporting. 
• Resulted in lower 
estimates of pai n 
prevalence than the 
NHANES-I version. 
• This question ha 
proved very 
in en itive in 
population tudie ' 
• It maybe rno t 
u eful in a ho pital 
etting, 
• A ociate with 
di ability better than 
with pain. 
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Have you had an (Cicuttini et al. 1996) • Patients were asked 
episode of knee pain all three questions. 
lasting:? 15 days in the Responses were 
last month? assessed for their 
Have you had two or 
ability to predict 
radiographic 
more episodes of knee indicators of disease. 
pain in the last year? 
• Question :2 was most 
Have you had a past 
closely associated 
with osteophyte 
episode of knee pain formation (in all 
lasting, :? 15 day"s? comEartments) . 
Have you had any pain Rotterdam Study (Hopman-Rock • This question was 
or other complaints et al. 1996) asked 3 times at 
about your joints in the subsequent 
last month? assessments (twice 
in 1991 and once in 
If yes, can you point to 1993) 
the painful joint? 
• Pain was classified 
as: 
Chronic = yes x 3. 
Episodic = yes x :2. 
SEoradic = ~ e s s x 1. 
Do you get knee pain on Johnston County Osteoarthritis • Indication of 
most days? Project (Jordan et al. 1997) severity was based 
on the worst knee. 
lfyes, how severe is 
that pain: mild, 
moderate or severe? 
A further difficulty with the ACR criteria is that poor reliability and 
reproducibility limit the assessment of clinical features. Considerable variation 
has been found in inter-observer reliability for the assessment of clinical 
features in a hospital population (Jones et al. 1992). In addition, examination 
of levels of agreement between the three possible ACR sets of criteria has led 
to varying estimates of prevalence (Schouten and Valkenburg, 1995) 
Possibly the most fundamental problem for the use of the ACR criteria for 
epidemiological study is that they were developed and tested in a hospital 
setting. The ability to generalise to a community-based sample is as yet 
17 
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unknown (Schouten and Valkenburg, 1995), and the use of controls with 
rheumatoid arthritis (RA) meant that these patients were likely to have some 
degree of joint space narrowing themselves (McAlindon and Dieppe, 1989). 
This may explain the poor discriminative ability of joint space narrowing for 
these criteria. 
Despite these limitations, the ACR criteria represent the first structured attempt 
to accurately define the clinical symptoms of ~ A . . Further work is now 
required to assess the validity and reliability of such measures in a variety of 
both clinical and community settings (Jacobsson, 1996). 
1.2.2 Aetiology of knee osteoarthritis 
The largest body of evidence to examine the putative risk factors for knee OA 
comes from NHANES-I, its subsequent follow-up (NHEFS) and the 
Framingham and Chingford studies. Evidence from the Framingham and 
Chingford studies is particularly informative since it allows risk factors to be 
examined prior to disease onset (Hart et al. 1999; Felson et al. 1997) 
A summary of the most commonly identified risk factors for radiographic knee 
OA is presented (Table 4). 
18 
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Table 4 Riskfactorsfor radiographic knee OA (adaptedfrom Felson, 1990). 
Associated with knee OA • Increasing age 
• Female gender 
• Obesity 
• Muscle dysfunction 
• Knee trauma / injury 
• Occupational knee bending / 
physical labour 
Association not clear • Oestrogen use (may be 
protective in women) 
• Chondrocalcinosis 
• Sport and exercise 
Negative association • Smoking 
Prospective data from the Framingham Study allowed an examination of risk 
factors for new cases of radiographic knee OA in elderly subjects (McAlindon 
et al. 1999; Felson et al. 1997). This study examined radiographs taken at 
baseline (1983-85) and compared them with radiographs taken again in 1992-
93. New cases of knee OA were identified (93 of 598 patients without knee 
OA in the initial survey), and baseline risk factors were assessed in relation to 
subsequent development of ~ A . . The study confirmed many of the earlier 
cross-sectional findings. In addition, it was able to clarify the role of certain 
factors. The presence of chondroca1cinosis at baseline for example, had little 
effect on future development of knee ~ A . . Perhaps more surprisingly, the study 
pointed to considerable increased risk of knee OA in habitually active elderly 
subjects. An adjusted odds ratio (OR) of 3.3 was observed for patients in the 
highest quartile of physical activity at baseline compared with those in the 
lowest quartile. This finding demonstrated a dose response effect, with higher 
risk being found with each increase in physical acti\'ity. The exact nature of 
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the observed relationship is as yet unclear, although a markedly increased risk 
was observed for obese individuals. Previous studies have pointed to the 
possibility of increased risk for runners and elite athletes (Spector et al. 1996). 
Nevertheless, the levels of activity being reported by this elderly population 
were more comparable with normal activity levels observed in younger 
subjects (high physical activity was defined as heavy housework or intensive 
exercise). 
The importance of obesity in the development of knee OA was confirmed in 
the Chingford study (Hart et al. 1999). These investigators examined possible 
risk factors for 715 individuals who developed radiographic evidence of 
disease activity after a 4-year period of follow-up. Those with incident knee 
OA were heavier, older, had more hand OA and reported more knee symptoms 
at baseline. In contrast to the Framingham study, high physical activity 
showed no association with disease incidence, although findings were limited 
by lack of power in relation to highly active individuals. 
Work to date has concentrated on risk factors for the development of OA in the 
tibiofemoral joint. However, different risk factors may be responsible for OA 
within different compartments of the knee. Cooper et al. compared subjects 
with symptomatic OA (tibiofemoral and lor patellofemoral OA) with age and 
sex matched controls (Cooper et al. 1994). Despite relati vely small numbers 
(obesity was observed in only 13 cases with tibiofemoral ~ A . . and 10 with 
patellofemoral OA). some interesting observations were possible. In particular. 
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obesity and meniscectomy were associated with tibiofemoral OA, whereas 
patellofemoral OA was associated with a family history of knee OA and the 
presence of Heberden's nodes. The lack of association between obesity and 
patellofemoral OA has also been found in a hospital-based population 
(Ledingham et al. 1993). Indeed, even palaeopathological evidence has been 
used to suggest that tibiofemoral OA is a relatively 'new' disease, and that this 
may support its association with obesity and menisectomy (Rogers and Dieppe, 
1994). 
Future work into the putative risk factors for OA should recognise the 
importance of these findings, and should make greater effort to identify the 
specific site of involvement. 
1.2.3 Prevalence of knee osteoarthritis 
The knee is one of the most commonly affected joints (van Sasse et al. 1989; 
Lawrence et al. 1966). Exact prevalence rates vary, but radiographic 
tibiofemoral OA is generally reported to be present in 3.8% of those aged 25-
74 years, and between 14% and 30% for persons over the age of 45 years 
(Petersson, 1996). 
As with OA in general, knee OA is strongly associated with age. By the age of 
75 years, prevalence has been found to be as high as 40 - 60% (Bagge et a1. 
1992). Gender is more strongly associated with knee OA than it is at other 
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joint sites. Women are generally reported as having a higher incidence of knee 
OA than men (Croft, 1990). Nevertheless, a reversal of this pattern is found for 
people aged under 45 years. This finding may reflect different aetiological 
processes, with men being more likely to develop early OA as a result of knee 
injury or excessive joint loading (Cooper, 1995). 
1.2.4 Prevalence of symptomatic osteoarthritis 
Few studies have examined the prevalence of pain as an independent issue. 
Considerable variation exists in the available data and is particularly governed 
by the wording of pain questions. For example, the Baltimore Longitudinal 
Study of Ageing reported knee pain prevalence of 23% for "ever having pain" 
and 15% for "pain within the last year" (Lethbridge-Cejku et al. 1995). Using 
the ACR criteria of "pain present for most days of the previous month", rates 
have been reported as low as 2.3% (Spector et al. 1991). Nevertheless, most 
studies report knee pain prevalence in subjects over 45 years as being between 
12 and 38% (Spector and Hart, 1992). 
The discordance between radiographic evidence of OA and symptom reporting 
has already been highlighted. Lawrence et al. (1966) suggested that only 510/0 
of people with knee OA of grade 2 or more (aged over 45 years) reported knee 
pain. Conversely, of those with no or only mild OA (grade 1 or less), 33o/r 
reported pain. Analysis of the NHANES data (Davis et al. 1992) revealed 
similar findings with symptomatic OA in 41 % of those with knee OA of grade 
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2 or more (for ages 45-74), and symptoms in 29% of people with no or only 
mild ~ A . .
More recent studies have revealed an even weaker association between 
radiographic status and pain reporting. The Framingham (Felson et al. 1987) 
and Zoetermeer (Claessans et al. 1990) studies suggest that pain may be 
present in only 29% (Framingham, aged 63-94) to 24% (Zoetermeer, aged 20-
80+) of subjects with a minimum of grade 2 ~ A . . Variation between the studies 
can possibly be explained by differences in methodology. The work by 
Lawrence et al. and the NHANES data are based on non-weight bearing 
radiographs. This would have the effect of underestimating the severity of OA, 
and would result in subsequent misclassification. In addition, different criteria 
for "pain" were used by the different studies. NHANES-I, for example, used 
either self-reported knee pain or pain during formal examination as their 
criteria for symptomatic knee OA (Davis et al. 1992). This would inevitably 
result in higher levels of pain reporting than by questionnaire assessment alone. 
Possible reasons for the poor association between physical change and 
symptom reporting are not entirely clear (Sharma and Felson, 1998). 
Discordance may simply be a result of the relative insensitivity of X-ray 
imaging (in which case, use of more recent imaging techniques may reveal a 
stronger association). The inclusion of the patellofemoral joint in future studies 
may also result in stronger agreement. It has been suggested that up to 24('; of 
females who repOIi knee pain have got isolated patellofemoral 0,,\ (Creamer 
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and Hochberg, 1997). Despite such allowances, it is unlikely that discordance 
will disappear completely. Consequently, it is possible that knee pain and 
radiographic evidence of knee OA represent different entities, and that each has 
different putative risk factors. 
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1.3 Knee pain and osteoarthritis 
1.3.1 The importance of knee pain 
The role of knee pain as an entity for epidemiological study has only recently 
gained credence (Laupacis et al. 1992; Hadler, 1992). The shift away from 
radiographic change as the primary indicator of disease activity is significant, 
for it is symptomatic patients who represent the greatest burden to society. In 
addition, greater understanding of the psychosocial aspects of symptomatic OA 
has resulted in renewed interest in alternative treatment strategies, such as 
patient education or social support (Hadler, 1992). 
1.3.2 Aetiology of knee pain 
Current understanding of the aetiology of knee OA has already been outlined. 
Greater understanding of the aetiology of knee pain reveals a slightly different 
pattern of association. Once again, the Framingham and NHANES studies 
have proved informative (Felson, 1990; Hochberg et al. 1989). A summary of 
our current understanding of the possible interaction of risk factors is presented 
(Figure 4). 
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Figure 4 Summary of the interaction of risk factors associated with 
radiographic knee OA and knee pain 
Risk factors for 
radiologkal knee OA 
-Prior trauma 
-Occupation 
-Physical 
activity 
-Oestrogen use 
-Gender 
-Age 
-Obesity 
-Muscle 
weakness 
Risk factors for knee 
pain 
- Psychological 
well-being 
- Previous pain 
-X-ray severity 
Of the factors outlined in Figure 4, low muscle strength and poor psychological 
well-being are of particular relevance to the current study. Both have been 
identified as risk factors for the development of symptomatic OA and merit 
further discussion. 
1.3.2.1 Muscle weakness 
The knee joint is a complicated structure. Its stability depends on the cruciate 
and collateral ligament the synovial cap ule and the mu cle cro ing the 
J int. Th b ne morphology of the knee c n titute little t it raIl tabIlit 
a r ult, th kn e 1 patti uIad uln rable t ublu ation and d' mag . u n 
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impairment in muscle strength not only reduces joint stability, but also reduces 
the limb's ability to absorb shock during ambulation. 
Weakness in the quadriceps muscles has been associated with knee OA 
(Slemenda et al. 1998; Slemenda et al. 1997; Dekker et al. 1993). Whilst 
reduced muscle strength is a normal feature of ageing, the extent of impairment 
seen in people with OA seems greater than that of controls of similar age 
(Fisher and Pendergast, 1997). However, the importance of this relationship is 
inevitably confounded by methodological problems. The ability to measure 
voluntary muscle contraction is largely dependent on subjective factors such as 
pain, psychological distress and voluntary effort (Ikai and Steinhaus, 1961). As 
a result, it is difficult to quantify the true nature of the deficit. Nevertheless, 
recent work involving the use of electrical stimulation of the muscle during 
muscle testing (twitch superimposition), has proved useful in supporting the 
presence of reduced quadriceps activation in subjects with knee pain (O'Reilly 
et al. 1998). 
The possible causes of such muscle impairment are far from clear. The 
simplest interpretation is that muscle strength is lost due to reduced activity and 
loading of the painful joint. However, whilst disuse appears to plays a role in 
the development of muscle weakness, it is not sufficient to explain the extent of 
impairment observed (Brandt, 1997). A recent community-based study 
examined 462 volunteers aged 65 and over (Slemenda et al. 1997). Subjects 
were divided into four groups according to presence or absence of radiographic 
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OA, and presence or absence of knee pain. This study suggested that muscle 
weakness was greatest in people with radiographic OA, regardless of pain 
status. Loss of muscle function was thus observed in the absence of joint pain 
for some people, and would therefore suggest that disuse is not the primary 
cause of muscle weakness. 
An alternative argument is that the observed reduction in quadriceps strength in 
knee OA is due, at least in part, to arthrogenic muscle inhibition. Arthrogenic 
inhibition is not a new concept (Harding, 1929) and involves the inhibition (or 
reduced activation) of muscle due to abnormal processes in the joint itself 
(Young, 1993). Alternatively it may prove to be other aspects of the diseased 
joint, such as joint laxity, which prove to be more important in the aetiology of 
knee OA (Sharma et al. 1999). 
1.3.2.2 Psychological well-being 
The importance of psychological variables as predictors of pain and disability 
in knee OA was first highlighted by Summers et al. (1988). This small, 
hospital-based study identified depression, anxiety and coping style as being 
important independent risk factors for the reporting of pain and functional 
impairment in both knee and hip ~ A . . Subsequently, several studies have 
examined the impact of psychological variables (Manninen et al. 1997; Davis 
et al. 1992; Salaffi et al. 1991). Some of the factors thought to be associated 
with the presentation of knee pain are outlined in Table 5. 
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Table 5 Psychological factors associated with knee pain and disability. 
Cognitive-behavioural 
factors: 
Anxiety and depression 
Coping strategies 
(the ability of a person to adapt to a 
challenge or to successfully confront 
a stressor) 
Self-efficacy 
(the belief that one can perform a 
specific behaviour or task in the 
future) 
Personality type 
Locus of control 
(the belief that outcomes are under 
the control of either one's own 
behaviour [internal locus of control) 
or by factors such as chance or other 
people [extemallocus of control} 
Learned helplessness 
(the degree of in ertia and inactivity 
ob erved when people experience 
WI ontrol/able stressors) 
Health impact: 
• Increased anxiety and depression are associated 
with increased pain and disability. (Manninen et 
al. 1997; Summers et al. 1988) 
• Also associated with increased health care costs 
(Andersson et al. 1999) 
• Mental distress (including depression, 
nervousness, loneliness and sleep disorders) is 
associated with an increased risk of hip fracture 
(Forsen et al. 1999) 
• Strategies associated with improved 
psychological well-being and greater self-efficacy 
include: information seeking, problem solving 
and cognitive restructuring (thinking about 
people worse-off than self) 
• Strategies associated with worse psychological 
well-being, reduced self-efficacy, and increased 
pain, depression and helplessness include: 
wishful thinking, self-blame and activity 
avoidance. 
(Blalock et al. 1995; Manne and Zautra, 1992) 
• High self-efficacy is related to better functional 
capacity and health status (Lorig et al. 1985) 
• May be the critical element in successful 
education programmes (Lorig et al. 1989a) 
• May be a mediating factor in successful exercise 
therapy (Rejeski et al. 1998) 
• Introverts may have a lower pain threshold than 
extroverts (Bird and Dixon, 1987) 
• Hypochondriacs are more likely to report pain 
(Lichtenberg et al. 1998) 
• An external locus of control is associated with 
increased depression, and distress associated with 
pain (Skevington, 1983) 
• Associated with pain and disability (Creamer et 
al. 1999; Nicassio et al. 1985) 
• Al 0 linked with depression (Stein et al. 1988) 
Table 5 (continued). 
Environmental factors: 
Social support 
Social participation 
Stressful life events 
(taxing environmental events) 
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Health impact: 
• High social support is generally associated with 
improved function (Wallston et al. 1983) 
• Low social participation has been associated with 
increased mortality (Steffen et al. 1998) 
• These may include work-related stressors (e.g. 
job insecurity), or social and family pressures 
(e.g. illness or marital difficulties) 
• Associated with increased pain and disability 
Understanding the impact of psychosocial factors is limited by methodological 
difficulties. Most notably, the predominance of cross-sectional surveys means 
that causal relationships cannot be established. This is particularly important in 
seeking to understand the relationship between pain, anxiety and depression. 
Nevertheless, a few prospective studies have suggested that depression may be 
an important risk factor for the development of future musculoskeletal pain 
(Croft et al. 1995; Magni et al. 1994) and disability (Manninen et al. 1997). 
Further work is now needed in order to establish the exact nature of this 
relationship. Certainly, an association has been observed between depression 
and the extent to which individuals access medical facilities (Dexter and 
Brandt, 1994; Katz and Yelin, 1993). Greater understanding of the impact of 
psychological variables may be especially pertinent for patients seeking 
medical assistance. 
A more fundamental problem in elucidating the role of psychological factor 
the di fficulty of quantifying p ychological proce e. Many outcome 
in trum nt have b n de el pdf r a rang of p ch ocial uriabl 
including: anxiety and depression, coping strategies, learned helplessness, self-
efficacy, locus of control, social support and social participation (Boston et al. 
1 9 9 0 ~ ~ Lorig et al. 1 9 8 9 b ~ ~ Regan et al. 1 9 8 8 ~ ~ Brown and Nicassio, 1 9 8 7 ~ ~
Nicassio et al. 1 9 8 5 ~ ~ Radloff, 1 9 7 7 ~ ~ Holmes and Rahe, 1967). The variety and 
complexity of these instruments often prohibits meaningful comparison and has 
resulted in potentially conflicting results (Blalock et al. 1995). 
For example, in comparing two scales designed to address the use of different 
coping strategies, the importance of specific questions is apparent. The Pain 
Management Inventory (Brown and Nicassio, 1987) identifies "active coping" 
as an appropriate coping strategy, whereas the Coping Strategies Inventory 
(Tobin et al. 1989) identifies "problem avoidance" as a maladaptive coping 
strategy. Intuitively, such classification appears logical and informative. 
However, closer examination of specific questions reveals surprising 
similarities between the two sub-scales (Table 6). 
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Table 6 Summary of questions relating to coping strategies as assessed by the 
Pain Management Inventory and the Coping Strategies Inventory. (Adapted 
from Blalock et al., 1995) . 
. Active coping strategies Problem avoidance strategies 
. {associ,ated<withpositive outcomes). (associated with negative outcomes). 
"ignoring the pain" "] go along as ifnothing is happening " 
"distracting attention from the pain " "] make light of the situation and 
refuse to get too serious about it ". 
Despite such limitations, recognition of the importance of psychosocial 
variables in the development of knee pain has resulted in the provision of new 
and unusual treatment options. In particular, the development of cognitive-
behavioural programmes such as the Arthritis Self-Management Programme 
(Lorig et al. 1999; Lorig et al. 1993b; Lorig et al. 1984) has emphasised the 
importance of patient education and behaviour modification in the treatment of 
~ A . .
1.3.3 Knee pain and disability 
The importance of knee pain as an indicator of disability has been identified in 
several cross-sectional surveys (Jordan et al. 1997; Hofman et al. 1991; 
Hochberg et al. 1989). Knee pain is particularly associated with lower limb 
di ability; especially in ituation involving weight tran fer. Walking, Ii ing 
fr m itting, lirnbing tair and getting in / out of a car or b d hav all b n 
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reported to be increasingly difficult in the presence of knee pain (Odding et al. 
1998; Davis et al. 1991). A more unexpected finding is the association 
between knee pain severity and impairment in upper limb function. The 
Johnston County OA project (Jordan et al. 1997; Jordan et al. 1996) 
interviewed 1,272 African-American and Caucasian individuals aged 45 years 
and over. After adjusting for age, race, sex, BMI and radiographic severity, 
moderate to severe knee pain was associated with impairment in all 20 of the 
activities of daily living (from the Health Assessment Questionnaire - HAQ). 
Indeed, even mild knee pain was associated with 16 of the possible 20 
activities. Similar findings were observed in the NHANES-I follow-up study 
for women with knee OA (Davis et al. 1991). 
Several probable reasons for an association between knee pain and upper limb 
disability have been identified (Jordan et al. 1997). Firstly, the presence of 
generalised OA would result in greater upper limb involvement than might be 
predicted from an examination of a single joint. This may explain the stronger 
effect seen in women since generalised OA is more common in females 
(Gunther et al. 1998). A further explanation could be the influence of 
comorbidity, which again is a common feature of people with OA (Gabriel et 
al. 1999; Hochberg et al. 1995). Finally, the impact of psychological distress 
should not be ignored. Depression and anxiety have been associated with 
increased pain reporting (Creamer et al. 1999: Croft et al. 1995), and may well 
be associated with increased willingness to report disability at multiple sites 
(Summers et al. 1988). 
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Recent studies have pointed to several important factors in determining knee 
related disability. As with knee pain, both muscle strength and psychological 
variables are important. A cross-sectional study of 200 patients, examined the 
relationship between radiological, kinesiological and psychological 
characteristics in patients with hip or knee OA (van Baar et al. 1998a). This 
study identified significant associations between disability and muscle 
weakness, range of joint motion and pain coping strategies, but not with 
radiographic severity. In particular, patients were more disabled if they had 
weaker muscles (flexion and extension), reduced range of movement, and if 
they employed coping strategies which involved either resting or worrying. 
For hip OA (but not knee OA), the presence of pain was also associated with 
disability. 
Similar findings were observed in a community-based study of subjects both 
with and without knee pain (McAlindon et al. 1993a), although in this study, 
knee pain was significantly associated with reported disability (along with 
reduced muscle strength and increased age). Once again, the addition of 
radiographic status did not improve the model and was assumed to make no 
independent contribution to disability in these subjects. 
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1.4 Treatment of knee osteoarthritis 
Given the prevalence of OA and its associated morbidity, it is possibly 
surprising that access to health service provision is not substantially higher than 
is currently seen (Dieppe et al. 1999). The ability to cope with knee OA is 
associated with a range of psychosocial factors, but seems to be largely 
unrelated to disease severity (Salaffi et al. 1991). The need to seek medical 
assistance for the relief of knee pain may reflect a person's difficulty in coping 
with the pain and disability of OA, rather than being the inevitable result of the 
disease itself (Hadler, 1992). Greater understanding of this fact allows 
flexibility in the investigation of potential treatment options and has led to 
renewed interest in the benefits of non-pharmacological interventions. In 
addition, the importance of improving communication between patient and 
physician (Donovan and Blake, 2000; Britten et al. 2000) and an emphasis on 
joint decision-making, have gained credence in recent years (Holman and 
Lorig, 2000; Clark and Gong, 2000). 
The current guidelines for the medical management of knee OA, are 
summarised in Figure 5. Whilst the impact of pharmacological therapies 
(particularly the use of NSAIDs) for the treatment of OA has been widely 
explored (Moore et al. 1998; Paakkari, 1994; Dieppe et al. 1993), less is 
known regarding the use of non-pharmacological therapies. This may be due, 
at least in part, to the methodological difficulties inherent in the investigation 
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exercise therapy (Dieppe and Szebenyi, 2000). Other interventions are 
available for the treatment of knee pain, such as surgery or osteopathy. but 
these areas fall outside the remit of this thesis. Further discussion of treatment 
options has therefore been limited to the two areas most relevant to this body of 
work, namely physical therapy and psychosocial support. 
Figure 5 Summary of guidelines for the medical management of knee OA (from 
ACR subcommittee on OA guidelines, 2000). 
Non-pharmacological therapy: 
• Patient education (self-management programs) 
• Health professional social support via telephone contact 
• Weight loss (if overweight) 
• Physical therapy: 
- range of motion exercises 
- quadriceps strengthening exercises 
- aerobic exercise programs 
- assistive devices for ambulation 
• Knee support 
- patellar taping 
- appropriate footwear 
- lateral-wedge insoles 
- bracing 
• Occupational therapy: 
- joint protection and energy conservation 
- assistive devices for activities of daily living 
Pharmacological therapy: 
• Oral 
- Acetaminophen 
- COX-2-specific inhibitor . .. 
- Nonselective NSAID plus misoprostol or a proton pump mhlbltor 
- Nonacetylated salicylate 
• Other pure analgesics 
- Tramadol 
- Opioids 
• Intrarticular 
-.Glucocorticoids 
- Hyaluronan 
• Topical 
- Capsaicin 
- Methylsalicylate 
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1.4.1 Physical therapy 
The use of physical therapy in the treatment of OA is somewhat controversial. 
Until relatively recently, exercise was thought to aggravate symptoms and to 
hasten disease progression (Ytterberg et al. 1994). Patients were instructed to 
rest an inflamed joint and to avoid weight-bearing activity. However, more 
recent opinion is that exercise therapy can be both effective and safe in an 
elderly arthritic popUlation (van Baar et al. 1999; Minor, 1996; Semble et al. 
1990). 
Exercise therapy for knee OA generally falls into two categories: 1) muscle 
strengthening (particularly the quadriceps muscles) and 2) aerobic conditioning 
(Ytterberg et al. 1994). Both forms of exercise are reported to result in 
functional improvement and pain reduction in patients with knee OA (Ettinger 
et al. 1997; Kovar et al. 1992). The ideal combination of aerobic and 
quadriceps strengthening exercises is currently unknown, although it seems 
likely that activities that can most easily be built into existing lifestyles will 
prove to be most beneficial. The wide variety of exercise programmes seen to 
date hinders direct comparison and further research is required in establishing 
the most effective and safe exercise programme (Maurer et al. 1999: van Baar 
et al. 1999). 
Whilst exercise is now generally accepted as beneficial in the treatment of OA. 
this belief has been founded on relatively little scientific evidence. Many of the 
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primary studies are limited by poor methodology. With a few exceptions, 
almost all early studies have been short-term «16 weeks). They have 
frequently been uncontrolled, have been based on small sample sizes and have 
failed to conduct intent-to-treat analysis (van Baar et al. 1999; Marks, 1993). 
In addition, the psychosocial aspects of delivering an exercise intervention 
have been relatively ignored. However, the last 3 years have seen a 
considerable increase in the number of well-conducted, and informative 
studies. A summary of recent exercise studies for the treatment of knee OA is 
presented (Table 7). With the exception of the Kovar et al. study (1992), all 
have been reported within the last 3 years and represent a considerable advance 
in our understanding of the possible impact of exercise therapy in the treatment 
of knee pain and knee OA. Nevertheless, most studies have still been short-
term in duration (excluding the Ettinger study in 1997), have involved intensive 
exercise programmes (usually supervised exercise, 3 times per week) and have 
employed strict inclusion criteria. Only one study employed a pragmatic 
approach, with realistic treatment provision, intent-to-treat analysis and broad 
inclusion criteria (O'Reilly et al. 1999). This study was of 6-month duration 
but did not control for the psychosocial aspects of exercise provision. 
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Table 7 Summary of recent exercise studies. 
Authors Subjects 
Deyle et al. 83 patients who were eligible 
(2000) for military healthcare 
Inclusion criteria: 
USA study • ACR criteria for knee OA 
(Army medical 
centre) 
O'Reilly et al. 191 community-based subjects 
( 1999) aged 40-80 years 
Inclusion criteria: 
British study • Self-reported knee pain 
Maurer et al. 113 physician referred patients 
( 1999) aged 50-80 years 
Incl usion criteria: 
USA study • ACR criteria for knee OA 
• Knee pain for ~ 3 3 months 
• X-ray grade ~ 1 1
• No OA medication other 
than oral NSAIDs or 
analgesics 
Interventions 
Manual physical 
therapy and 
supervised exercise 
(n = 42) 
Placebo treatment-
subtherapeutic 
ultrasound 
(n = 41) 
Daily home-exercise 
(4 treatment sessions) 
(n = 113) 
No intervention 
(n = 78) 
Supervised strength 
training (3 times / 
week) 
(n = 57) 
Education (4 lectures) 
(n = 56) 
Duration ITT , " Adheren'ce ';', ., Jmpact on knee Comments 
analysis , 
, ~ ~ - ; ~ ~,"', ~ : : pabi , 
, i . . ~ , , , ~ ' S ~ " " ~ ~ ~
Interventions No Not reported Total WOMAC Individual 
deli vered in score including treatment 
8 sessions pain, stiffness and schedule used. 
(4 weeks) , physical function. Study population 
assessed at Exercise = 36% and medical 
24 months improvement facilities possi bl y 
not representati ve 
Placebo = 12% of wider 
improvement population 
6 months Yes Not reported Exercise = 22.5% Pragmatic study 
improvement 
No psychosocial 
Control = 6.2% control 
improvement 
8 weeks of No Not reported Exercise = 36% Treated most 
intervention, improvement symptomatic knee 
assessed at only 
12 weeks Education = 22% 
improvement Lacked a no 
intervention 
control group 
Limited sample 
SIze 
-
~ ~
o 
I 
Authors 
van Baar et al. 
(1998) 
Dutch study 
Ettinger et al. 
( 1997) 
USA study 
Bautch et at. 
( 1997) 
USA pilot study 
L-______ 
, 
Subjects 
201 GP referred patients aged 
40-85 years 
Inclusion criteria: 
• ACR criteria for knee or hip 
OA 
439 community-based subjects 
aged ~ 6 0 0 years 
Inclusion criteria: 
• Self-reported knee pain. 
• Difficulty with ~ 1 1 activity 
of daily living 
• Tibiofemoral OA (grade not 
specified) 
34 patients recruited from the 
community and hospital 
clinics aged ~ S 8 8 years 
Inclusion criteria: 
• ACR criteria for knee OA 
Interventions 
Individual 
physiotherapy (1 to 3 
times / week 
depending on pain) + 
GP education 
(n = 99) 
GP education 
(n = 102) 
Aerobic or resistance 
exercise (3 months 
supervised 3 times / 
week, followed by IS 
months home 
exercise, supported 
by visits and phone 
calls) 
Education (3 group 
sessions followed by 
regular telephone 
contact) 
Exercise (3 times / 
week) + education 
(n = 17) 
Education (weekly) 
(n = 17) 
Duration ITT Adherence Knee pain Comments 
analysis 
12 weeks Yes 91% Exercise = 46% Not possible to 
improvement isolate patients 
with knee OA in 
Education = 13% results 
improvement 
Expensive 
individual 
physiotherapy 
18 months. Yes 8S% at 3 Aerobic exercise 1st long-term 
months = 12% study 
improvement over 
70% at 9 education Intensive 
months programme 
Resistance (unlikely to reflect 
50% at 18 exercise = 8 % actual treatment 
months improvement over proVISIOn In 
education community) 
Education = not Lacked a no 
reported intervention 
control group 
12 weeks No Not reported Exercise = 37% Exercise 
improvement participants had 
Education = more severe 
42.S% worse di sease and higher 
BMI at baseline 
Table 7 (continued). 
~ - - -
. Adherence Authors Subjects Interventions Duration ITT 'I' ... ,Knee pain Comments 
'" 
:t> 
, ~ ~
I analysis" "ili"i 
Kovar et al. 102 hospital patients aged ~ 4 0 0 Hospital-based 8 weeks No 92% Exercise = 27% Intensive 
(1992) years supervised walking (3 improvement. programme of 
Inclusion criteria: times / week) + Control = 2% short-term 
USA study • Radiographic OA education improvement duration 
• ~ 4 4 month history of knee (n=51) 
pam 
• NSAIDs used ~ ~ 2 / week. Routine care (n = 51) 
Sulli van et aJ. 52 subjects from earlier study Follow-up of earlier 12-month No Returned to Returned to Limited sample 
( 1998) (Kovar et aL 1992) study follow-up baseline baseline size but useful 
USA stud y Walking (n = 29) follow-up data 
- --
Control (n = 23) 
-~ ~
... 
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Whilst the majority of studies have concentrated on the effects of muscle 
strength training, improved health status has also been reported for aerobic 
exercise, which has the advantage of being easily incorporated into daily life. 
One influential study (Kovar et al. 1992) described a group of hospital and GP 
referred patients who had radiographic evidence of knee OA, self-reported 
knee pain and regularly used non-steroidal anti-inflammatory drugs (NSAIDs). 
The initial study was for an 8-week period and involved both supervised fitness 
walking and supportive fitness education. Controls for the study received 
normal medical care, with no further intervention from the investigators. This 
study was able to demonstrate clinically meaningful improvement in walking 
distance, functional status, pain and medication use in those subjects in the 
fitness walking group compared with controls. However, a follow-up study 
showed that the majority of patients failed to maintain their regular walking 
activity after one year(Sullivan et al. 1998). As a result, the functional benefits 
associated with the programme were lost. It is clear that future work needs to 
examine ways in which patients can become more pro-active in their own 
treatment regime, and to establish factors that may influence future adherence 
(Clark and Gong, 2000; Jensen and Lorish, 1994). 
A study that addressed the issue of adherence examined exercise beliefs in 
relation to an indi vidual's likelihood to participate in exercise (Gecht et al. 
1996). Arthlitic subjects aged 27-80 years were asked about their participation 
in six types of exercise: all of which are commonly recommended for people 
with OA (e.g. swimming. water c:\ercises, brisk walking. range of motion 
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exercises). An exercise belief questionnaire was used to assess individuals' 
beliefs regarding self-efficacy (the extent to which they felt capable of 
performing an activity), the possible barriers to exercise and the potential 
benefits of exercise. This cross-sectional survey suggested that those people 
most likely to exercise 1) believed in the positive benefits of exercise and 2) 
had higher self-efficacy scores than those who did not exercise. 
Both self-efficacy and pain have been identified as mediating factors in 
effective exercise therapy (Rejeski et al. 1998) and are useful in predicting 
future adherence (McAuley et al. 1993). Findings such as these support the 
growing recognition of the importance of cognitive-behaviour programmes in 
the treatment of ~ A . . Such programmes commonly include exercise therapy as 
just one element of a wider education programme, and are designed to alter 
patient's knowledge, behavioural skills, attitudes and emotions (Lorig et al. 
1993a) (Lorish and Boutaugh, 1997). 
Finally, the attitude of health professionals is worth noting. To date, OA 
patients have received somewhat conflicting advice with regard to exercise 
activity. Conflicting advice has been identified as an importance source of 
misunderstanding between patient and physician and may be an important 
factor in reduced treatment adherence (Britten et al. 2000). It is clearly 
imp0l1ant for consistent information to be delivered by GPs, rheumatologists, 
nurse practitioners and self-help groups (Holman and Lorig, 1997). 
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1.4.2 Telephone support 
Telephone support from health professionals was identified as an effective 
treatment option in the guidelines for the medical management of OA (ACR 
. 
subcommittee on osteoarthritis guidelines, 2000). Support and advice from 
health professionals is of key relevance in assessing the efficacy of exercise 
therapy, and yet few studies have adequately controlled for the effects of 
contact with a health professional. 
The possible effectiveness of telephone support in relation to OA was first 
identified by Weinberger and his colleagues over a decade ago (Weinberger et 
al. 1986). This initial uncontrolled study examined the effect of bi-weekly 
telephone calls to patients with OA over a period of 6 months and was able to 
demonstrate significant improvement in functional status. 
A subsequent study by Weinberger et al. (1989) expanded on this early work 
with a large RCT involving 439 subjects. Once again, the study looked at the 
provision of information and support, with subjects being randomised to one of 
four treatment groups. These included: a) monthly telephone contact by trained 
lay-personnel, b) contact with lay-personnel during normal clinic visits, c) 
combined telephone contact and clinic contact and d) no change to existing 
treatment. Telephone support was identified as producing significant 
improvement in both physical function and pain, with a slight additional 
improvement in psychological health. However, this study was based on a 
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sample of predominantly black females, of low socio-economic class. The 
ability to generalise findings to a wider population was therefore limited. 
More recently, a study by Maisiak et al. (1996) examined the impact of two 
different types of telephone intervention in subjects with both OA and RA. 
This study involved 405 subjects of a more representative demographic mix 
than was used in the Weinberger study, and extended over a nine-month period. 
The two telephone treatment arms involved: 1) treatment counselling (designed 
to increase patient involvement), 2) symptom monitoring (provided social 
support, but no advice or direct patient involvement). The control group 
recei ved their normal level of medical care. Once again, an overall 
improvement in physical health was observed with significant improvements in 
physical function and pain for the treatment counselling group, (improvements 
were also seen in the symptom monitoring group, although these did not reach 
significance at the 5% level). 
It would seem that telephone support produces significant improvements in 
health status, and that the magnitude of this effect may be of some clinical 
significance. However, the exact mechanism for this improvement is poorly 
understood. Weinberger et al. found little support for an impact on any of the 
most obvious intervening factors, including treatment adherence, morale, social 
support or satisfaction with care (Rene et al. 1992). Nevertheless, limited 
evidence is avai lable to support the belief that support reduces the stress 
associated with chronic illness (\\' einberger et al. 1990). Others ha\'e 
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suggested that regular contact encourages people to concentrate on improving 
their functional status (with self-help activities), rather than ignoring health 
issues (Maisiak et al. 1996). 
Regardless of the mechanisms involved, telephone support (from either health 
professionals or trained lay-personnel) appears to represent an extremely cost-
effective method of achieving and maintaining health benefits in OA patients. 
As such, its further investigation and recognition is certainly warranted . 
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1.5 Economic evaluation of osteoarthritis 
1.5.1 Economic evaluation techniques 
Economic evaluation has been defined as: 
"the comparative analysis of alternative courses of action in 
terms of both their costs and consequences." Drummond et al. 
(1997) p. 8. 
This definition includes two key concepts, which are fundamental to any 
economic analysis. Namely, the inclusion of both costs and consequences, and 
the concept of the comparison of competing alternatives. These two aspects 
can be used to identify the type of analysis being undertaken and to distinguish 
between partial and full economic analyses. This concept is demonstrated 
more fully in Table 8. 
Table 8 Factors used to distinguish the characteristics of different health care 
evaluations (from Drummond et al. 1997). 
Ar b th e 0 cos t d an consequences 0 f th It ea t a . ed? erna 1 ves ex ffiln 
NO YES 
Examines only Examines only costs 
consequences 
NO PARTIAL PARTIAL PARTIAL EVALUA TIO EVALUATION EVALUATION 
Outcome Cost description Cost-outcome de cription 
description 
P RTI L P RTIAL FULL ECONOMIC 
EVALUATION EVALUATION EVALUATION 
Effi a y r Co t anal y i Co t-minimizatl n 
YES f ~ ~ ti n C t-effect! ene 
e aluati n o t-utilit 
C o ~ ~ - b e n e f i t t
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For the purposes of this study, two types of economic evaluation are 
particularly relevant: 
a) cost-effectiveness analysis 
b) cost-utility analysis. 
Whilst these two forms of analysis are essentially very similar, it is important 
to recognise the difference between the two, and the potential strengths and 
weaknesses of each. 
1.5.1.1 Cost-effectiveness analysis 
Definition: This analysis measures the cost of compared medical treatments in 
relation to clinical outcomes, which are measured in physical units (e.g. life-
years saved, number of operations performed or changes in functional ability). 
Results are presented as a ratio statistic in terms of cost per unit of outcome. 
Cost-effectiveness analysis is a useful tool in comparing the health 
consequences of treatments designed to elicit similar health outcomes. Its 
primary use is in estimating the incremental costs of providing one intervention 
over another, rather than in attempting to value outcomes per se. Cost-
effectiveness analysis is not able to make comparisons between evaluations in 
the same or different treatments and disease areas where the measures of 
outcome differs. For example, it is of little use comparing the consequences of 
open-heart surgery (possibly in terms of life-years saved) with that of knee 
replacement surgery (possibly in terms of physical disability or pain). In order 
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to include the benefits of a range of relevant beneficial and adverse outcomes 
in one measure cost-utility analysis has developed. 
1.5.1.2 Cost-utility analysis 
Definition: This analysis measures the cost of medical treatments in relation to 
quality-of-life (e.g. quality-adjusted life-years, or QAL Ys). Results are 
presented in terms of cost per QAL Y. 
Cost-utility analysis is based on utility theory and measures the expected gain 
(or utility) from the consumption ofa good or service. In terms of health care, 
this equates to the value placed on health gains derived from the use of health 
care interventions. Fundamental to cost-utility analysis is the concept of the 
quality-adjusted life-year (QAL Y). The advantage of the QAL Y is that it 
combines the quality of life (morbidity) with the quantity of life (mortality) into 
a single measure. 
The immediate appeal of cost-utility analysis is that it provides a common 
'currency' (QAL Ys) with which to compare disparate treatments. In this way, 
decisions can be facilitated regarding the appropriate allocation of funds across 
a range of treatments, whilst avoiding the pitfalls of trying to place a monetary 
value on intangible items such as pain and suffering (the major difficulty faced 
by cost-benefit analysis). Unfortunately, it is this very comparability which has 
led to one of the major debates surrounding cost-utility a n a l y s i s ~ ~ namely the 
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use of 'cost per QAL Y gained' league tables. In such tables items are ranked 
according to their cost per QAL Y. Rank order, rather than patient need 
governs recommendations for treatment priority. Such methods have caused 
controversy in the past and whilst league tables have a unique role to play in 
health policy decision-making, they should nevertheless be treated with caution 
(Gerard and Mooney, 1993). In particular, doubt has been cast on the 
comparability of QAL Y measures when fmdings are based on poorly executed 
and methodologically varied primary studies. The relative insensitivity of 
some generic utility measures also means that interventions resulting in only 
small changes in perceived quality-of-life might be dismissed as ineffective. 
Whether little difference in utility in the presence of clinical improvements 
reflects insensitivity in the instrument or changes that the patient or society do 
not value is still a matter of debate. 
Despite these limitations, cost-utility analysis has a unique role to play in 
informing policy decision making and has become increasingly recommended 
by health policy decision-makers. 
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1.5.2 Presentation of cost data 
1.5.2.1 Cost-effectiveness plane 
An indication of cost-effectiveness (CE) is often presented using the cost-
effectiveness plane, as shown in Figure 6. The CE plane is divided into four 
quadrants, which represent four possible situations in relation to the relative 
cost and health outcomes of a new therapy compared to standard care. In 
quadrants II and IV, one therapy is simultaneously cheaper and more effective 
than the other and is said to dominate. In reality, most interventions fall within 
either quadrants I or III. In these cases, a decision must be made. In quadrant I 
the new treatment is considered to be more effective, but more costly (the most 
common scenario). In quadrant III the new therapy is less costly, but is also 
less effective. 
Figure 6 The cost-effectiveness plane (taken/rom Briggs & Fenn, 1998). 
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In order to make a decision as to the cost-effectiveness of a given intervention, 
it is necessary to identify an acceptable value (or criticial ratio) for the 
incremental cost-effectiveness ratio (lCER = ~ ~ cost / ~ ~ effect). Below this 
value a therapy may then be labelled as cost-effective. Such a value is 
represented by the dashed line on Figure 6. This line has its origin at the point 
where the new therapy is equivalent to the old therapy. For points lying below 
the line, new interventions are labelled as being cost-effective. For points 
above the line, the new therapy should be labelled as ineffecti ve. This line or 
"acceptability surface" can be used to calculate the probability that the ICER is 
under a certain acceptable limit and is presented in the form of an acceptability 
curve (van Hout et al. 1994). 
1.5.2.2 Cost-effectiveness acceptability curves 
Acceptability curves were first described by van Hout et al. (1994), and 
represent an intuitive means of interpreting cost-effectiveness data. The 
increasing use of economic analysis alongside clinical trials has allowed the 
collection of patient-specific data relating to both costs and health outcomes. 
An acceptability curve illustrates the probability that a given intervention is 
cost-effective for different estimates of an acceptable cost limit. This 
represents a considerable advantage over alternative means of describing 
uncertainty within the dataset and makes it a useful tool for medical decision-
makers faced with varying financial and political constraints (Briggs and Fenn, 
1998). An example of a typical acceptability curve is illustrated in Figure 7. In 
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this example, there is a 80% probability that the intervention will be cost-
effecti ve if the provider is willing to pay over £480 per unit of effect. 
Probability at the 50% level (£140) represents the point estimate of the mean 
ICER that is traditionally reported. 
Figure 7 Example of a typical acceptability curve. 
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Whilst acceptability curves provide an indication of variability in the dataset, 
there are other areas of uncertainty inherent in the process of gathering cost 
data for cost-effectiveness analysis. The usual means of exploring these areas 
of uncertainty is through sensitivity analysis. This may include uncertainty 
regarding unit costs, methodological considerations or issues of generalisability 
(Briggs and Fenn, 1998). Sensitivity analysis involves the systematic 
application of alternative estimates relating to parameters included in the 
analysis (including uncertainty relating to both costs and outcomes). In this 
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way the impact of assumptions made during the analysis process can be 
quantified and the robustness of the resulting cost-effectiveness ratio can be 
explored. The choice of parameters to be included in the analysis should be 
justified, as should the plausible range of values employed (Briggs et al. 1994). 
A recent review suggested that appropriate sensitivity analysis was still lacking 
from many economic evaluations published in the literature (Briggs and 
Sculper, 1995). Whilst general agreement now exists to suggest that sensitivity 
analysis should be conducted (Drummond et al. 1996), few guidelines exist as 
to the exact nature of the sensitivity analysis required (Jefferson et al. 1996). 
Several forms of sensitivity analysis have been reported. These include one-
way; multi-way; extreme; threshold; and probabilistic sensitivity analysis. The 
simplest and most common form of analysis is one-way or univariate 
sensitivity analysis. This examines the impact on the CIE ratio of varying the 
estimated value of one parameter at a time. One-way sensitivity analysis is 
commonly used, but has been criticised for being too simplistic in nature; 
particularly as it ignores the possible interaction of different parameters 
(Johnston et al. 1999). In order to address this issue, multi-way analysis can 
be performed. This involves the systematic manipulation of several parameters 
at one time. Extreme sensitivity analysis is used to present the possible 'best' 
and 'worst' case scenarios by combining the most extreme estimates for each 
parameter. It has been argued that this method is only useful if the results are 
very insensitive to change. Otherwise, a broad (and possibly unrealistic) band 
of uncertainty may be identified (Gold et al. 1996). Threshold analysis 
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requires the manipulation of parameters to the point whereby the most cost-
effective treatment is no longer dominant. Finally, probabilistic sensitivity 
analysis involves the use of Monte Carlo simulation techniques to address 
areas of uncertainty in the dataset. Values are selected at random from a given 
distribution to generate the value of a parameter, over several iterations. In this 
way various parameters can be considered across a range of plausible values at 
one time (O'Brien et aL 1994). 
1.5.3 Cost analysis within rheumatology 
The last decade has seen an increase in the total number of economic 
evaluations within the medical literature (Elixhauser, 1993). Despite this 
increase, several reviews have pointed to the relatively poor quality of 
economic research (Rothfuss et aL 1997; Adams et al. 1992; Udvarhelyi et al. 
1992). Udvarhelyi et al. (1992) compared studies published from 1978-1980 
with those published from 1985-1987. They found little evidence for any 
improvement in quality over time, although articles published in general 
medical journals were more likely to use appropriate analytical techniques than 
those published in medical subspecialties. A review of economic analyses 
conducted alongside RCTs between 1966 and 1988 (Adams et al. 1992) 
revealed that only 121 of over 50,000 studies (0.2%) included economic 
analysis. Of those studies involving economic analysis, the most common 
deficiencies were the inappropriate allocation of overheads, a lack of sensitivity 
analyses and the presentation of costs and benefits in a disaggregated form. 
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Within the field of rheumatology several more recent reviews have been 
published. Ferraz et al. (1997) concluded that well-conducted economic 
evaluation in the discipline was still lacking. Following an extensive 
MEDLINE search (covering the period 1966 - 1995), they found just 13 full 
economic evaluations relating to OA (8 of which investigated the use NSAIDs. 
Large gaps existed in the investigation of many aspects of the treatment and 
management of ~ A . . In addition, the poor comparability of those studies that 
did exist, meant that inconsistent results were difficult to interpret. 
More encouragingly, a review of cost-effectiveness analyses conducted during 
the year 1996-1997 suggested an improvement in the quality of economic 
analysis within the field (Maetzel et al. 1998). These investigators identified 
the major shortcoming of more recent studies to be the over-reliance on 
estimated costs, rather than on prospectively collected resource use data. 
One explanation for an improvement in the quality of studies in recent years is 
the establishment of explicit guidelines for conducting economic analysis 
(Ruchlin et al. 1997; Russell et al. 1996; Weinstein et al. 1996; Drummond et 
al. 1996). It is hoped that the wider acceptance of such guidelines will greatly 
improve the reliability and generalisability of results across all disciplines. A 
composite of the guidelines is outlined in Table 9. 
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Table 9 Summary of the guidelines for economic analysis (adapted from 
Drummond & Jefferson, 1996; Weinstein, 1996 and Ruchlin, 1997). 
1. Clear specification of the question: 
Alternative clinical interventions should be stated. 
2. Choice of an explicit point of view: 
Societal, health provider or individual? 
3. Description of medical effectiveness: 
Source(s) and reliability of data. 
4. Appropriate identification of costs: 
Direct medical costs, indirect costs and intangible costs . 
5. Presentation of both input and output in physical units. 
6. Identification of credible unit costs: 
Distinction should be made between fi xed and variable costs. 
7. Discounting: 
Adjusting future costslbenefits to present day values. 
8. Incremental analysis: 
Difference between an intervention and the next best alternati ve shouJd be 
presented for both costs and consequences. 
9. Sensitivity analysis: 
Identification of uncertainties and bias. Are the study results sensitive to 
change? 
10. All issues included in results: 
Difficulties, assumptions and ethical considerations. 
57 
CHAPTER 1: INTRODUCTION 
1.5.4 Economic impact of osteoarthritis 
Until quite recently, the socio-economic impact of OA was considered to be 
relatively slight (particularly in comparison with RA, which incurs higher direct 
medical costs and has greater associated disability) .. However, the markedly 
higher prevalence ofOA (8.7%-12.3% for OA versus 0.2%-1% for RA) means 
that the cost to the health provider is nearly seven times greater for the treatment 
ofOA than it is for the treatment ofRA (Lanes et al. 1997). The economic 
impact of musculoskeletal disorders has been estimated to be as great as the 
economic consequences of cancer (Badley, 1995b), and yet cost-of-illness studies 
for OA are markedly lacking (Huijsman, 1995). The majority of studies to date 
are based on American datasets and deal either with musculoskeletal conditions 
in general (Yelin and Callahan, 1995), or concentrate exclusively on rheumatoid 
arthritis (Cooper, 2000; van laarsveld et al. 1998; Rothfuss et al. 1997). To 
isolate the costs incurred by OA is difficult. Nevertheless, several recent studies 
have attempted to address this issue. For ease of comparison, all figures are 
quoted with 1996 £ sterling equivalent values in brackets. Conversions were 
made using the current exchange rate of £0.69 per US$ and adjusted for inflation 
using the hospital and community health services pay and prices index. 
Lanes et al. (1997) looked at the provision of medical services for OA patients 
over the period 1993 to 1994. They reported average direct medical costs for the 
treatment ofOA related conditions of$543 (1996, £394) per patient per year. 
Almost half 0 f this amount was accounted for by hospital care (46% ). despite 
only 50/0 ofOA patients having received such care. The distribution of 
58 
CHAPTER 1: INTRODUCTIO::\ 
costs was thus highly skewed. The majority of patients incurred costs of less 
than $400 (1996, £290) per year. 
Other work by Gabriel et al. has contributed greatly to our understanding of the 
economic impact of OA (Gabriel et al. 1997a; Gabriel et al. 1997b; Gabriel et 
al. 1995). In particular, the importance of examining all medical costs rather 
than those attributable to OA alone has been highlighted. OA patients show 
significantly higher direct medical costs for a range of conditions (respiratory, 
cardiovascular, gastrointestinal, neurological, psychiatric and general medical 
care) than non-arthritic controls (Gabriel et al. 1997a). Comorbidity is known 
to be high amongst OA patients, although exact reasons for this remain unclear. 
Some conditions (such as diabetes) may be associated with the aetiology of 
OA, whilst others (such as gastrointestinal complications) may stem from OA 
treatments themselves (Hochberg et al. 1989). 
The impact of indirect costs and non-medical expenditure is also high. (Gabriel 
et al. 1997b; Gabriel et al. 1995; Yelin and Callahan, 1995). OA subjects are 
more likely than age-matched controls to report a reduction in work hours due 
to illness (10.5% of OA and 1.7% of controls reported reduced hours), and are 
more likely to have taken early retirement (13.7% of OA and 3.4% of controls) 
(Gabriel et al. 1995). This finding is confirmed by Hochberg et al. (1995) 
who identified OA as being the second most common cause of early retirement 
in the US (>5% per year). 
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Gabriel et al. also noted that OA patients need high levels of infonnal care 
(help from family and friends) as a result of their condition, and that they incur 
additional expenditure for the purchase of equipment (medical equipment, 
assistive devices and the installation of ramps or rails). Disregarding wage 
losses (which were excluded from analysis because of large differences in 
hourly wages across the 3 groups) average indirect and non-medical 
expenditure for 1992 was $593 (1996, £445), $282 (1996, £211) and $57 
(1996, £43) for RA, OA and non-arthritic controls respectively. 
In summary, OA inflicts a sizeable economic burden on society. Whilst direct 
medical costs can be relatively modest in the majority of cases, the large 
number of people affected ensures that the health service incurs a substantial 
cost. Analysis of the indirect costs of arthritis suggests that the wider burden 
on society is even greater. 
1.5.5 Intangible costs associated with osteoarthritis 
Intangible costs reflect the cost of pain, suffering and disability incurred by OA 
sufferers and their family. By their very nature, intangible costs are difficult to 
value in monetary tenns. Nevertheless, consideration of the impact of such 
costs on daily life is important. 
Until fairly recently, the psychosocial impact of OA had been relatively 
neglected. However, survey data have revealed considerable levels of pain, 
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limited functional capacity and social isolation (Hochberg et al. 1995; Badley 
et al. 1994; Davis et al. 1991). 
The 1990 Ontario Health Survey contacted 45,650 individuals aged 16 and 
over (Badley, 1995a). Their findings showed OA to be the primary cause of 
long-term disability in Canada (2.3%); ahead of circulatory disease (1.4%). 
Disability was higher in women (3.8%) than men (1.6%), and showed a marked 
increase with age (from 0.1 % for the 16-24 age group to 20.6% for those aged 
85 years and older). Of those reporting OA associated disability, three quarters 
were dependent on others for help at least occasionally, and almost half needed 
help at least every few days. These findings were mirrored in the degree to 
which people with disability suffered from social isolation, with 13.2% never 
visiting friends or relatives. 
1.5.6 Cost of knee osteoarthritis 
Given the difficulty in isolating the economic impact of OA from other 
musculoskeletal conditions, it is possibly not surprising that cost data relating 
specifically to the knee joint are lacking. The relative importance of knee OA 
in dictating health service resource use compared with other forms of OA such 
as back or hip arthropathy requires further investigation. 
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1.5.7 Economic evaluation of treatment provision 
Although arthritis has serious health consequences, Rothfuss et al. reported that 
"the gap between the importance of the socioeconomic effects 
of RA and OA and the research conducted in this field is 
considerable. " (Rothfuss et al. 1997 p 771 ). 
Following an extensive MEDLINE search, they found 44 studies that presented 
original cost data (the majority of which concentrated on RA rather than OA), 
only 6 of which had performed an economic evaluation of the provision of a 
rheumatology service, and no cost-utility analyses. Clearly the need for well-
directed and thorough economic evaluation is of paramount importance if 
rheumatological services are to compete for finite resources within the health 
sector. 
Existing cost-effectiveness data concentrates primarily on either the cost-
effectiveness of surgical management (Chang et al. 1996; Liang et al. 1986) or 
on treatment with prescribed drugs (Gabriel, 1995; Paakkari, 1994; Hillman 
and Bloom, 1989). Whilst these areas are clearly important elements in the 
treatment of arthritis, patient education, telephone support, weight loss, 
physical therapy and occupational therapy should not be ignored. It is these 
aspects of care which are of greatest relevance to the current study and which 
have been relatively neglected in the literature to date. 
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As previously discussed, Rene et al. (1992) and Weinberger et al. (1989) 
reported reduced knee pain and improved physical health following monthly 
telephone calls by non-medical staff. A subsequent cost-effectiveness analysis 
Weinberger et al. (1993) revealed telephone support to be highly cost-effective, 
largely as a result of its extremely low implementation costs ($14.88 per 
person, 1996 £13). No differences were found in levels of health care 
utilisation. The authors were unable to provide an accurate comparison with 
any alternative form of treatment, such as an exercise programme, although 
they did hypothesise that telephone support and physical therapy would 
probably have similar costs per unit of effectiveness gained. 
Other studies have concentrated on the provision of information and self-
management with a view to encouraging patients to access health care systems 
more appropriately. Lorig et al. reported the Arthritis Self-Management 
Programme (ASMP) as being able to produce sustained improvement in 
indicators of pain and depression, whilst reducing physician visits by up to 
400/0 (Lorig et al. 1995). Estimated savings over a 4-year period were of the 
order of$648 (1996, £573) per RA patient and $189 (1996, £167) per OA 
patient (Lorig et al. 1993b). Similar findings were reported by (Cronan et al. 
1997 a), who examined the impact of social support, education or a combination 
of the two in reducing health care costs of patients with OA. They reported 
potential annual savings of $1,156 (1996 £818) per person, with no obvious 
decrease in health status. The markedly higher potential saving demonstrated 
by the latter study partially reflects the characteristics of the study' population. 
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This was a group of extremely high service users (mean number of contacts 
during the one year baseline period was 16.9 visits). In addition, control 
subjects showed a significant increase in the number of inpatient days during 
the study period. This produced incremental costs in excess of 100% of 
baseline after 2 years (compared with increases of between 23 and 31 % for the 
intervention groups). The interpretation of cost data based on relatively small 
changes in high cost events such as these should be treated with great caution. 
A recent British study, which assessed the cost-effectiveness of health 
education for the treatment of knee OA in a primary care-based setting, 
suggested that education programmes might not be cost-effective (Lord et al. 
1999). These investigators failed to observe any improvement in health 
outcomes after one year. Furthermore, the cost of delivering the education 
programme (£140 per person) was not offset by any reduction in the utilisation 
of health service resources. 
Studies investigating the cost-effectiveness of physical therapy for the 
treatment of rheumatological conditions are less common. One study 
compared the cost-effectiveness of providing group physical therapy in 
addition to individualised home exercise in patients with ankylosing spondylitis 
(Bakker et al. 1994). Group therapy was provided in groups of 12 patients and 
consisted of 1 hour of physical training, followed by 1 hour of sporting 
activities (e.g. \'olleyball or badminton) and 1 hour of hydrotherapy'. The cost 
of delivering the home exercise programme was fixed at zero since both groups 
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received the same intervention. Outcomes were assessed at 9 months and the 
final cost-effectiveness analysis was based on data for those patients who 
returned a completed cost diary at the end of the study (77% of the original 
sample). 
The cost of providing group therapy in addition to home-exercise was 
approximately $5311patientlyear ($44 per month, 1996, £33). This consisted of 
$177 (1996, £133) for the sports facilities, $256 (1996, £192) for the therapist 
and $98 (1996, £74) for materials and equipment. During the period of the 
study, direct medical costs were reduced in both treatment groups. This was by 
$122 (1996, £92) more for those allocated to group therapy than for those who 
received home exercise. The significance of this finding is difficult to 
determine since mUltiple significance tests were performed relating to 18 
different types of service use. In addition, the dominance of high cost, but 
relatively infrequent events (such as inpatient stays), was again noted. 
Nevertheless, at the end of the 9-month trial, 75% of the patients wanted to 
continue with the programme and were willing to pay for it. 
Economic evaluation of a community-based exercise programme for the 
treatment of low back pain has been reported (Moffett et al. 1999). This study 
assessed the impact of providing group exercise sessions led by a 
physiotherapist (8 sessions over a period of four weeks). The cost of deIi\'ering 
the exercise programme was estimated to be £25.20 per person treated (1996 £ 
sterling). Patients in the intervention group tended to use fewer healthcare 
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resources than those allocated to the control group (mean difference £148 per 
patient). However, this difference was not statistically significant and wide 
confidence intervals were reported (-£442 to £146). The possible impact of 
exercise therapy on indirect costs was also highlighted. Patients allocated to 
the control group reported almost twice as many days off work due to back 
pain than those in the exercise group (607 days off versus 378 days over the 
12-month study period). 
In conclusion, it would appear that exercise therapy could be used in order to 
provide cost-effective patient care. However, data relating to physical therapy 
for the treatment of knee OA are still lacking. The scarcity of reliable and 
well-conducted economic research within the field of rheumatology is 
particularly marked and should be urgently addressed. Emphasis on the 
potential costs and benefits of all non-pharmacological interventions is urgently 
needed. 
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1.6 Summary 
• ,Knee pain is an extremely common condition, which is 
associated ~ i t h h considerable morbidity 
• Discordance exists between the presence of radiographic 
knee OA and knee pain 
• The use of case criteria based on the presence of knee pain 
is important for epidemiological research, since it is 
symptomatic OA that reflects the community burden of the 
condition 
• The efficacy of exercise therapy for the treatment of knee 
pain remains unclear 
• Social support from health professionals, or lay personnel, 
has been associated with positive health benefits. It is 
important to recognise psychosocial factors in detennining 
the efficacy of physical therapy 
• The economic consequences of the conservati ve 
management of knee pain have been largely ignored 
67 
CHAPTER 1: INTRODUCTION 
1.7 Contribution of current study 
This study describes a large, prospective randomised controlled trial (RCT), 
which examines the cost-effectiveness of a home-based exercise programme in 
relieving the severity and disability of knee pain. Exercise therapy is compared 
with monthly telephone support, a placebo health-food product or no 
intervention. Health outcomes are measured over a two-year period and results 
presented in terms of both cost-effectiveness and cost-utility ratios. 
The investigation of any complex health intervention presents methodological 
difficulties. This may serve to explain the apparent dearth of relevant research 
in the field (Dieppe and Szebenyi, 2000). Nevertheless, recent focus groups 
have revealed a disparity between the research that is being carried out (namely 
drug trials), and that which consumers feel to be necessary (further 
investigation of non-pharmacological treatments) (Dieppe et al. 1999). It is 
hoped that the current study goes some way to addressing this need. 
1.7.1 Study design 
Previous studies investigating the efficacy of physical therapy for the treatment 
of knee OA have been limited by methodological constraints. The current 
study addresses some of these issues through a large-scale, randomised 
controlled trial (RCT). The study is unique in that it employs a randomised 
factOlial design with four possible treatment arms: home-based exercise 
therapy, monthly telephone support, a placebo health-food product and no 
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intervention. Such a design allows greater understanding of the mediating 
factors associated with improved health outcomes following physical therapy 
(including the impact of social support and a possible placebo effect). The 
failure to include a no intervention control group in addition to education or 
social support control groups has been a major weakness of earlier studies 
With the exception of the Ettinger study (1997), which examined outcomes 
after 18 months, the long-term impact of physical therapy for the treatment of 
knee OA has not been explored. The current study examines outcomes 
prospectively over a 2-year period and is thus able to address issues of 
treatment adherence and possible adverse side effects over an extended time 
period. 
1.7.2 Pragmatic nature of the trial 
Throughout the study a pragmatic approach has been adopted. This means that 
limited exclusion criteria have been employed, study interventions are provided 
in addition to existing levels of care, all treatments are provided with a 
minimum of input from the research team, and results have been analysed on 
an intent-to-treat basis. 
Pragmatic studies are particularly appropriate when economic data is collected 
concurrently (Langley, 1995). In attempting to isolate the effectiveness of a 
pat1icular treatment. investigators frequently eliminate possible confounding 
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factors such as comorbidity, poor treatment adherence and treatment error. 
Using such data as the basis for cost-effectiveness estimates presents clear 
difficulties and it is hoped that the pragmatic nature of the current study avoids 
such problems. 
1.7.3 Case criteria 
As this was a community-based knee pain study, inclusion criteria were based 
solely on self-reported knee pain (using the NHANES pain question Davies et 
al. 1992). In this way, it has been possible to circumvent the debate 
surrounding the appropriate definition of knee OA (radiographic evidence of 
change versus symptom reporting). It is hoped that subjects enrolled in the 
study are broadly representative of symptomatic patients in a primary care 
setting. 
1.7.4 Concurrent economic evaluation 
To develop economic analysis alongside a RCT has distinct advantages and its 
use has been promoted in recent years (Griffiths et al. 1995; Adams et al. 
1992). As yet, little is known regarding the cost-effectiveness of physical 
therapy and/or social support. The availability of prospectively collected cost 
data provides a unique insight into the economic impact of these treatments, 
and allows an examination of the economic impact of both positive and 
neaati ve health consequences. 
c 
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1.8 Summary of Study Design 
Study Design 
Chapter 2: 
Intervention study - RCT 
(n = 786) 
Chapter 3: 
Cost-of-illness 
(n=759) 
Chapter 4: 
Economic Evaluation 
(n = 759) 
Aims and objectives 
1. To determine the prevalence of knee pain 
in adults aged >45 years. 
2. To determine whether regular quadriceps 
muscle exercise improves long-term 
outcomes in subjects with knee pain 
3. To determine the importance of social 
support in explaining positive health 
outcomes 
4. To isolate the factors most closely 
associated with positive outcomes 
1. To assess the cost of knee pain in the 
study sample 
2. To establish some of the factors 
associated with the accessing of health 
facilities 
1. To perform a cost-effectiveness analysis 
based on outcome measures obtained 
from the intervention study 
2. To perform a cost-utility analysis in 
which outcomes are measured in Quality-
Adjusted Life-Years 
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2 Intervention study 
2.1 Aims and objectives 
This intervention study, which provided effectiveness data for the subsequent 
economic analysis, had four primary objectives. 
1. To determine the prevalence of knee pain in adults aged >45 years. 
2. To determine whether regular quadriceps muscle exercise improves long-
term outcomes (symptoms and function) in subjects with knee pain. 
3. To determine the relative contribution of psychosocial factors in explaining 
these health outcomes. 
4. To isolate the factors most closely associated with positive outcomes. 
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2.2 Method 
2.2.1 Ethics 
All aspects of these studies were approved by the City Hospital and 
Nottingham University Local Research Ethics Committees. Support from 
participating GPs was made clear in the initial contact letter and informed 
consent was obtained for participation in the trial prior to initial assessment. In 
addition, signed consent was obtained for the accessing of GP notes as part of 
the economic evaluation (chapters 3 and 4). Copies of the relevant consent 
forms are appended (Appendix 1). 
2.2.2 Study population 
The study population consisted of men and women (aged 45 years and over), 
who were registered at one of two general practices in the Nottingham area. 
• Practice A - Torkard Hill Medical Centre, Hucknall. (List size: 11,967). 
• Practice B - Arnold Health Centre, Arnold. (List size: 15,000). 
Both practices are situated on the northern outskirts of Nottingham. 
A study population aged 45 years and over was chosen in order to reflect 
general prevalence patterns for knee OA (Croft, 1990). No upper age limit was 
set in order to increase the generalisability of study findings. 
Plior to the distribution of questionnaires. recruitment lists were examined by 
GPs according to the following exclusion criteria: 
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Age <45 years. 
Terminally ill patients (with a life expectancy of less than 2 years). 
Psychiatric history leading to an inability to give informed consent. 
Patients unable or unwilling to give informed consent (including those 
living in nursing homes). 
• Non-residence in the Nottingham area. 
This procedure resulted in a potential study population of approximately 4,540 
(practice A) and approximately 6,500 (practice B). 
A list of eligible subjects was obtained for all patients aged 45 years and over 
as of 1 st January 1996 for practice A and from 1 st July 1996 for practice B, 
(recruitment for practice B was started 6 months after recruitment for practice 
A). Questionnaires were subsequently distributed to all patients from practice 
A and to 73% of patients from practice B. 
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2.2.3 Sample size 
The sample size for the postal survey was based largely on the need to ensure 
adequate numbers of knee pain positive volunteers for the subsequent RCT 
(n = 800). This yielded sufficient numbers for the intervention study to detect a 
20% difference in WOMAC pain scores with greater than 90% power, based 
on a prevalence of knee pain of 25% (McAlindon et al. 1992). These power 
calculations were supported by data from a recent survey in Nottingham, which 
provided confirmation of a similar age-stratified prevalence of knee pain 
(O'Reilly et al. 1998). 
2.2.4 Questionnaire 
The questionnaire used in the postal survey was based on one used in an earlier 
study (O'Reilly et al. 1998). A full copy is appended (Appendix 2). A 
covering letter was sent with each questionnaire. This outlined the nature of 
the trial and encouraged volunteers to seek assistance should they have 
problems completing the questionnaire. It also made clear that participation in 
the trial was being sought with the full support and understanding of their GP. 
2.2.5 Distribution of questionnaires 
Questionnaires were distributed in batches of 500 at three weekly intervals with 
a pre-paid envelope enclosed. Questionnaires for practice A were posted 
between December 1995 and April 1996. Those for practice B \\cre distributed 
between May 1996 and November 1996. A reminder and second questionnaire 
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Age <45 years. 
Terminally ill patients (with a life expectancy of less than 2 years). 
Psychiatric history leading to an inability to give informed consent. 
Residence in a nursing home. 
• Non-residence in the Nottingham area. 
This procedure resulted in a potential study population of approximately 4,540 
(practice A) and approximately 6,500 (practice B). 
A list of eligible subjects was obtained for all patients aged 45 years and over 
as of 1 st January 1996 for practice A and from 1 st July 1996 for practice B, 
(recruitment for practice B was started 6 months after recruitment for practice 
A). Questionnaires were subsequently distributed to all patients from practice 
A and to 73% of patients from practice B. 
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Treatment arms consisted of six groups including a combination of four factors. 
a) physical therapy (home-based quadriceps strengthening and walking) 
b) monthly telephone support 
c) a placebo health-food product 
d) no intervention. 
Such a design allowed comparison by group (groups 1 - 6) or by factor 
(physical therapy, telephone support, placebo or nothing). It also provided 
some exploration of the possible interaction of treatment effects (Figure 8). 
Figure 8 Summary of treatment allocation. 
Group 1 Group 2 
Exercise & Exercise, 
telephone telephone 
& dolomite 
(n = 121) (n = 114) 
Randomised 
(n::; 786) 
Group 3 Group 4 
Exercise Telepbone 
only only 
(n = 235) (n = 160) 
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(n = 78) (n = 78) 
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2.2.7 Subjects 
Subjects for the intervention study were recruited using the initial postal 
questionnaire. Entry into the trial was based on self-reported knee pain 
according to the NHANES-I criteria (Davis et al. 1992). Evidence of 
radiographic change was not employed as an entry criterion for this study since 
the principle interest was of symptomatic knee problems. Subsequent 
radiographs revealed that evidence of structural knee OA (> grade II) was 
present in 330 (47%) of subjects entering the trial. 
Exclusion criteria for this stage of the study included the criteria previously 
outlined for the postal survey. In addition, volunteers were excluded upon 
telephone contact according to the following criteria: 
• No knee pain in the last week. 
• Total knee replacement. 
• Lower limb amputees. 
• Use of a cardiac pacemaker. 
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2.2.8 Materials and Procedures 
2.2.8.1 Subject Recruitment 
Initial contact was made by telephone to all potential volunteers (those subjects 
who had returned the postal survey with self-reported knee pain). Volunteers 
were asked if they had experienced pain within the last week in order to 
establish current knee pain status (this was done because of the inevitable delay 
between questionnaire completion and subsequent recruitment). If volunteers 
responded positively to this question, they were invited to attend at their local 
health centre for further assessment. 
2.2.8.2 Assessment procedure 
Assessments for consenting volunteers were conducted at their own OP surgery 
and took approximately one hour. Upon arrival, volunteers were given an 
information sheet to read and any unanswered questions were addressed. 
Signed consent was obtained. The initial assessment procedure included three 
sections as outlined in Table 10. A copy of the assessment questionnaire is 
appended (Appendix 3). 
79 
CHAPTER 2: INTERVE TIO STUDY 
Table 10 Assessment procedure. 
Self-completion • WOMAC (knee specific - pain, 
questionnaires stiffness and physical function) 
• SF-36 (generic health status) 
• HAD (anxiety and depression) 
• EuroQol EQ-5D (generic utility 
measure of Quality-of-Life) 
, 
• Cost data relating to the accessing 
of health provision, personal costs 
and work-related health difficulties 
Physical assessment • Height and weight 
• Knee examination - effusion, 
warmth, crepitus, bony swelling, 
joint line tenderness and range of 
movement 
• General examination - hands 
(Heberden's nodes, thumb IPJ 
nodes), hips (pain on rotation), 
back (pain on extension and 
flexion) 
• Hypennobility screen 
• Fibromyalgia screen 
Muscle strength testing • Isometric maximum voluntary 
contraction (MVC) 
At the end of the initial assessment, volunteers were infonned of the 
subsequent two-year intervention trial. A further information sheet was 
provided and questions addressed. Those volunteers agreeing to enter the trial 
were asked to sign a second consent form (this included informed consent to 
enrolment in the tIial, and agreement for the researcher to access medical 
records as necessary). Volunteers were gi en an information leaflet about the 
tlial and further infonnati n regarding the general management of nee paIn 
(App ndi 4). V lunt er \ ere in tructed to c ntinue all medi atI nand th r 
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treatments as prescribed by their existing health professional. In this way, 
treatment effects observed within the trial reflect incremental benefits over and 
above those achieved through existing care. 
Follow-up assessments were conducted at 6, 12, 18 and 24 months. The 18-
month assessment was a shortened version including only the WOMAC 
(primary outcome measure) and muscle strength testing. An additional short 
questionnaire was added at this assessment in order to assess patient 
satisfaction with the study treatments (Appendix 5). Those volunteers who 
dropped out of the study were contacted by post at 24 months and asked to 
complete a shortened version of the final assessment questionnaire (including: 
WOMAC, EuroQol EQ-5D and the short additional questionnaire). This 
procedure had two principle aims: i) to provide 24-month outcome data for all 
subjects, regardless of treatment adherence and ii) to more accurately 
determine any adverse effects resulting from participation in the trial. 
2.2.8.3 Muscle strength assessment 
Isometric muscle strength was assessed using a modified Tomvall chair (Jones, 
1 9 9 4 ~ ~ Tomvall, 1963). This technique was chosen as the most appropriate for 
the current study since measurement is relatively quick and simple to perform. 
Similar equipment has been successfully employed in both hospital and 
community settings, for patients both with and without knee pain (O'Reilly et 
al. 1 9 9 8 ~ ~ Jones, 199-+). The use of a Tomvall chair allows the accurate 
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positioning of each volunteer, with both hips and knees being flexed to 90°. 
Volunteers were strapped into the chair at the waist with extra cushioning 
provided to support the back. A strain gauge (+ 50 KgF) TKA load cell 
(Techni Measure, Studley) was attached to the back of the chair and could be 
adjusted horizontally to allow for the measurement of both left and right legs. 
A strap was placed around the ankle of each volunteer and attached to the load 
cell via a portion of chain. The output from the gauge (+ 2V) was connected to 
an amplifier and digital read-out (TML model TD-91M, Tokyo Sokki 
Kenkyujo Co. Ltd., Japan). The final output was read onto an Xyt chart 
recorder (BD92, Kipp and Zonen Delft BV, Netherlands) at practice A, and to a 
PC laptop at practice B. 
Following explanation, volunteers were required to perform three voluntary 
contractions at maximum effort. If contractions were still increasing in 
strength at the third attempt (by at least 1 KgF), then volunteers were asked to 
perform a fourth pull. The highest reading obtained was used as the maximum 
voluntary contraction (MVC). 
2.2.8.4 Radiographic assessment 
All volunteers agreeing to enter the trial were asked to attend the Nottingham 
City Hospital Radiology department for radiographic assessment of their knees. 
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The following views were obtained: 
• Standing weight-bearing antero-posterior radiograph of the 
tibiofemoral joint in full extension (Jacobsson, 1996). 
• Skyline radiograph of the patellofemoral joint in 30° of flexion 
(Lanyon et al. 1996). 
Of the 786 volunteers entering the trial, 706 (90%) attended for radiographic 
assessment. Radiographs were read by a single observer (Dr S.O.) and 
indi vidual features were graded using a standardised atlas (Altman et al. 1995). 
For the purposes of this study, definite OA was defined by the presence of 
> Grade I osteophyte in the tibiofemoral compartment and / or ~ ~ Grade II 
osteophyte in the patellofemoral compartment (with or without joint space 
narrowing). 
2.2.9 Randomisation and blinding 
Following assessment, volunteers were randomised in permuted blocks of ten 
into one of six treatment groups: 
Group 1 (15%) 
Group 2 (15%) 
Group 3 (30%) 
Group 4 (20%) 
Group 5 (100/0) 
Group 6 (10%) 
Home-based exercise + telephone support 
Home-based exercise + telephone support + placebo 
Home-based exercise 
Telephone support 
Placebo 
Nothing 
83 
CHAPTER 2: INTERVENTIO:\ STUDY 
The nature of the interventions meant that it was not possible to blind 
participants to treatment allocation. Nevertheless, researchers responsible for 
conducting the assessments were blinded throughout the trial. For the purposes 
of randomisation, four computer-generated lists were employed (stratified by 
age and sex to include: males <65 years; males >65 years; females <65 years 
and females > 65 years). Volunteers were preferentially allocated to the 
exercise groups, as pilot work suggested that drop out rates would be highest 
amongst these subjects (O'Reilly, 1996). 
2.2.10 Exercise intervention 
The exercise programme was designed to be simple to use, applicable for all 
age groups and readily assimilated into daily life. It consisted of flexibility 
exercises, unresisted and resisted strengthening exercises, functional exercises 
and aerobic exercises. The various exercises were introduced at different 
stages throughout the two-year programme with the primary aim of improving 
and maintaining quadriceps muscle strength over time (Table 11). 
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Table 11 Timetable for the exercise intervention. 
Visit 
Visit 1 (0 months) 
Visit 2 (2 weeks) 
Visit 3 (4 weeks) 
Visit 4 (2 months) 
Visit 5 (7 months) 
Visit 6 (13 months) 
Visit 7 (19 months) 
Exercises Taught 
Flexibility + unresisted 
strengthening exercises 
Additional flexibility + unresisted 
strengthening exercises 
Resisted exercises 
(trainer band) 
Resisted (stronger band) + 
functional exercises 
Selection of above (+ stronger 
band) + aerobic exercises 
Review + stronger band if 
necessary 
Review + stronger band if 
necessary. 
The program was taught in volunteers' homes by a trained therapist. This was 
a pragmatic study and exercise visits were kept to a minimum. Such a design 
helped to provide more realistic costing data than would commonly be 
achieved through more intensive trials (van Baar et al. 1998b; Ettinger et al. 
1997), whilst also reducing the potential for strong psychosocial input. A total 
of seven visits were undertaken throughout the two-year period as outlined in 
Table 11. It was recommended that exercises be carried out on a dai ly basis, 
and that they should take no more than 20-30 minutes to complete. 
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All volunteers were given an exercise diary containing written instructions on 
the individual exercises, general advice regarding exercise participation and a 
contact name and number (Appendix 6). The diary was also used to document 
treatment adherence throughout the period and was subsequently scored 
according to set criteria (see later section). New diaries were distributed every 
six months and old ones collected by the therapist. 
Resisted exercises were taught using rubber exercise bands (Dynabands ™ and 
Clinibands TM). The required band strength was assessed according to muscle 
strength readings taken during initial assessment. Stronger bands were issued 
at visits 5, 6 and 7, if subsequent strength gains were observed. Prior to 
exercising with a full-strength band, volunteers were left with a weaker, 
training band for 4-5 weeks in order to familiarise themselves with the exercise 
technique. (Table 12) 
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Table 12 Summary of exercise bands used according to MVC recordings. 
MVCof Trainer Band 1 Progression 
weakest leg band bands 
(Visit 3) {Visit 4} (Visits 5-7) 
<10 KgF Red Red Pink / Green 
10.1-12 KgF Red Pink Green / Blue 
12.1-15 KgF Red Green Blue / Red 
Doubled 
15.1-18 KgF Red Blue Black / Purple 
18.1-21 KgF Red Black Purple / Pink 
Doubled 
21.1-30 KgF Pink Purple Green Doubled 
> 30 KgF Green Green Blue Double / 
Doubled G r e ~ ~
In order to establish the force generated by each of the bands, weights were 
attached to I-metre lengths under laboratory conditions (Appendix 7). To 
achieve an increase in muscle strength during strength training, loads must be 
at least 60-70% of a person's maximum voluntary strength (Jones and Round, 
1990). For the purposes of this study it was assumed that there would be an 
increase in band length of at least 100 cm, and that the force required in order 
to achieve this is represented in Equation 1. 
87 
CHAPTER 2: INTERVEl\TIO:\ STUDY 
Equation 1 Equation used to calculate the allocation of exercise bands by 
muscle strength. 
MVC required = 60% (min. effort required) x 60% (adjustment 
for different positioning of leg during testing versus training) x 
MVC (measured during assessment). 
2.2.10.1 Assessment of exercise adherence 
Adherence with the exercise programme was assessed using the exercise 
diaries completed by study volunteers. Volunteers were instructed to record 
the type of exercise done and the number of repetitions for each leg on a daily 
basis. 
Summary data for exercise adherence were produced according to set criteria 
(Appendix 8). The scoring scheme recognised: 
• frequency of exercise completion (scored 1 - 5) 
• number of repetitions per leg (scored 1 - 3) 
• number of exercises completed per session (scored 1 -2) 
This produced a score with a range of 1 to 8 (l representing low adherence and 
8 representing high adherence). Diaries were coded by therapists other than 
those responsible for teaching of the exercise programme, and were coded at a 
single time point for each 6-month period. In addition, 10<Jc of all diaries were 
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re-coded by a second therapist and the resulting scores were compared for 
reproduci bili ty. 
Whilst volunteers were strongly urged to complete the exercise diary, full 
details were not always recorded. In this instance, the therapist was instructed 
to ascertain general exercise adherence at the follow-up visit and to record 
details of such in the diary as appropriate. The criteria used are listed in Table 
13. 
Table 13 Coding of exercise adherence if daily exercise diary was not 
completed. 
Self"'reported exercise frequency 
Everyday or 5-6 days per week 
3-4 days per week 
1-2 days per week 
None 
2.2.11 Telephone support 
Adherence 
code 
7 
4 
2 
1 
Telephone support was primarily included in the study design as a control 
intervention for the psychosocial benefits of exercise participation. In thi v a 
it has been pos ible to di tinguish between a) the physical benefit of e er i e 
th rapy and b) th impa t of r gular patient onta t. vertheI tal 
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support of this kind has been reported as producing clinically meaningful 
improvements in health status (Rene et al. 1992; Weinberger et al. 1986). Its 
importance as an independent treatment alternative has not therefore been 
ignored. 
Treatment consisted of monthly telephone calls from a single researcher. The 
principle aim of calls was to monitor symptoms and to offer simple advice on 
the management of knee pain. For those volunteers receiving both telephone 
contact and exercise therapy, discussion of the exercise programme was 
discouraged and specific problems were referred back to the therapist 
responsible for teaching the programme. Health problems unrelated to the 
study were referred back to the volunteer's GP. 
Calls were standardised in terms of content through the use of a simple 
checklist (Appendix 9). This checklist was not prescriptive however, and 
general social support was encouraged once rapport had been established. All 
calls were timed in order to facilitate economic evaluation of the trial. 
2.2.12 Placebo intervention 
In an attempt to encourage continued participation in the trial, half of the 
control group were allocated to receive a health-food product twice a week. 
This also allowed some examination of possible placebo effects operating 
within the trial. 
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Dolomite is a health food product containing calcium and magnesium. 
Although there are no clinical data, the producers of dolomite claim that it is 
beneficial for arthritis. Volunteers were required to take one tablet twice a 
week (considerably less than the recommended dose of 3 tablets per day). It 
has no known side effects. 
2.2.13 No intervention control group 
In order to control for participation in the trial, 10% of volunteers received no 
further intervention. These volunteers returned to the surgery for 6-monthly 
assessments, but had no other contact with the study team. 
2.2.14 Scoring of health outcomes 
Four well-validated instruments were employed during this intervention trial 
(Table 14). These are all self-completion questionnaires and were completed at 
the surgery during the 6-monthly assessments. The WOMAC osteoarthritis 
index (Bellamy, 1989) is a knee specific instrument (measuring knee pain, knee 
stiffness and knee-related physical function). The Likert (ordinal) version was 
used. The SF-36 (Garratt et al. 1993) is a generic health status instrument, the 
HADS (Zigmond and Snaith, 1983) is a generic measure of anxiety and 
depression, and the EuroQol EQ-5D (EuroQol Group., 1990) is a generic 
quality-of-life instrument. Table 1..+ outlines the domains used for each scale. 
Missing values wcrc handled in accordance with the authors' guidelines. 
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Table 14 Summary of outcome measures used. 
Instrument Dimension No. of items 
WOMAC • Pain 5 
• Stiffness 2 
• Physical function 17 
SF-36 • Physical function 10 
HADS • Anxiety 7 
• Depression 7 
EuroQol EQ-5D • Mobility 1 
• Self care 1 
• Usual activities 
• Pain / discomfort 
• Anxiety / depression 
• Health utility 5 
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2.2.15 Outcome measures 
2.2.15.1 Primary outcome measure 
The primary outcome measure for this study was the WOMAC knee pain score 
achieved at 2 years. This involved 5 questions relating to the degree of pain 
experienced during daily activities such as walking, standing and sitting. Each 
question was scored on a 5-point Likert (ordinal) scale. 
2.2.15.2 Secondary outcome measures 
Secondary outcome measures included: 
• Knee related stiffness and physical function - derived from the WOMAC 
(range 0-8 and 0-68 respectively). 
• General physical function - derived from the SF-36 (range 0-100). 
• Anxiety and depression - derived from the HADS (range 0-7 for both). 
• Isometric muscle strength - measured in Newtons. 
• Programme adherence - assessed through self-completion diaries (range 1-
8). 
• EuroQol - generic utility scale (range 0 - 1). Reported in Chapter 4. 
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2.3 Data management 
2.3.1 General data management 
All data were entered onto a customised database (Microsoft® Access 97), and 
analysis was conducted using SPSS for Windows version 8.0 (SPSS Inc., 
Chicago, IL). Data for the primary outcome measure (WOMAC scores at 24 
months) were entered twice. Errors were amended as necessary prior to further 
analysis. For all remaining data, a 10% random sample was double entered. 
Accuracy in all instances was above 98%. 
2.3.2 Handling of missing values 
Where subjects failed to answer all necessary items, missing values were 
handled in accordance with the authors' guidelines for each instrument (i.e. the 
mean of the existing values was imputed for the missing value). For cases in 
which too many items were missing, values were carried forward from the 
previous assessment. This was not possible for baseline values and it was 
therefore necessary to exclude a small number of subjects from some scales. 
As a result, baseline group sizes vary for different outcome measures. 
2.3.3 Intent-to-treat analysis 
Between group comparisons were conducted on an intention-to-treat basis 
(Hollis and Campbell, 1999). This meant that data were analysed according to 
randomised groupings regardless of treatment adherence or study attrition. For 
subjects who dropped out, missed assessments or died during the period of the 
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study, values were carried forward from the last available assessment. 
Alternati ve means of dealing with uncertainty in the dataset were tested in 
sensitivity analysis and included i) the return of missing values to baseline 
scores and ii) the exclusion of subjects with incomplete data (per protocol 
analysis). 
2.3.4 Number needed to treat 
The number needed to treat (NNT) has been advocated as a clinically 
meaningful outcome for use in clinical trials (Cook and Sackett, 1995; 
Laupacis et al. 1988). Outcomes were presented as NNT figures in addition to 
change scores for knee pain at 24 months. For the purposes of this study, a 
clinically meaningful outcome was defined as being at least a 50% 
improvement in knee pain in a single individual. The number needed to treat is 
calculated by taking the inverse of the attributable risk, and confidence 
intervals are calculated by taking the inverse of confidence intervals for the 
attributable risk (Altman, 1998; Kahn and Sempos, 1989). 
2.4 Statistical analysis 
A significance level of 5% was employed throughout the study and confidence 
intervals were reported at the 95% level. 
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2.4.1 Primary outcome 
Between group comparisons were based on change scores (baseline score was 
subtracted from the post-treatment score), rather than absolute values. This 
approach meant that variance within the dataset was minimised by adjusting for 
any (non-significant) baseline differences between the 6 treatment groups. A 
negative change score thus represented a post-treatment improvement in knee 
paIn. 
The primary outcome measure was the change in knee pain observed at 24 
months. Between group comparisons (for the 6 treatment groups) were 
performed using one-way ANOV A. Individual p values were reported using 
Tukey's Honestly Significant Difference (THSD) and used the no intervention 
control group as the comparator. Factorial comparisons were performed using 
the independent samples t-test. Effect sizes were reported in addition to p 
values thus providing an indication of the degree of variance within the dataset 
(Matthews and Altman, 1996). Effect size calculations were performed using 
the following formula: 
Equation 2 Effect size calculation 
~ ~ intervention group - ~ ~ control group 
s.d. of ~ ~ scores for whole population. 
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An effect size of 0.2 is generally considered to be small, 0.5 as medium and 0.8 
as large (van Baar et al. 1998b). 
The possible interaction of exercise and telephone support was explored using 
a factorial ANOV A model. 
2.4.2 Secondary outcomes 
Baseline characteristics were presented in a descriptive manner. Body mass 
index (BMI) was calculated using the following equation: 
Equation 3 Calculation of body mass index 
Weight (kg) / height (m)2 
All other secondary outcomes (WOMAC stiffness and physical function, SF-36 
physical function, HADS anxiety and depression and voluntary muscle 
strength) were analysed by factor. Change from baseline was used throughout, 
and p values (independent samples t-tests) and effect sizes were calculated for 
each measure. 
Muscle strength measurements (MVC) are reported in Newtons (KgF x 9.8). 
Analysis of muscle strength data presented methodological difficulties since 
the unit of measurement was that of the leg rather than the person. The 
difficulty of "two knees, one person" has been identified by others (Sutton et 
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al. 1997; Zhang et al. 1996). For the purposes of this study analysis was 
based on the left leg only. 
2.4.3 Exploratory analysis 
Further exploration of the factors associated with improved knee pain was 
conducted using multiple regression techniques. In order to combine data from 
each assessment period, a summary statistic based on the area under the curve 
(AUC) was calculated (Matthews et al. 1990). (Equation 4). 
Equation 4 Area under the curve calculation for WOMAC pain scores. 
((pain at 6 months - pain at baseline) / 2) + ((pain at12 months - pain at 6 
months) / 2) + ((pain at 18 months - pain at 12 months) / 2) + ((pain at 24 
months - pain at 18 months) / 2) 
Exploratory analysis was based on per protocol data and included only those 
subjects with data for the entire period. Three models were developed; one for 
the entire study population, one for those subjects allocated to the exercise 
programme and one for those subjects not allocated to the exercise 
intervention. 
Each regression model was developed in two stages. Variables were initially 
entered using a backward selection model (entry criteria of 10%). A second 
stepwise model was then conducted in which significant \ariables from the first 
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model were entered, plus factors of a-priori interest (treatment factor - exercise, 
telephone or dolomite and radiographic status). For the stepwise model, entry 
was set at the 5% level and exclusion at 10%. Assumptions were checked at 
each stage. 
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2.5 RESULTS 
2.5.1 Postal questionnaire 
The postal survey was sent to 4541 patients from practice A and 4755 patients 
from practice B. Questionnaires were returned from 6035 individuals giving an 
overall return rate of 65%. Analysing the returned questionnaires, 1932 were 
from subjects who met the criteria for knee pain, giving an overall prevalence 
rate for knee pain in the community of 32% (21 % of the total population). 
Gender-specific prevalence rates were 35% among females and 28% among 
males (p = <0.01). 
All remaining data from the recruitment questionnaire has been used to inform 
a separate body of work and has not been reported in this thesis. 
2.5.2 Recruitment for intervention study 
Recruitment of volunteers for the intervention study took place from January 
1996 to January 1997. Patient flow during recruitment is shown (Figure 9). 
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Figure 9 Summary of study recruitment. 
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2.5.2.1 Comparison of recruited and non-recruited subjects 
The age distribution of study volunteers was different from that of the knee 
pain positive non-volunteers. The largest difference was in the over 75 years 
age group, who were far less likely to have been recruited than younger age 
groups. Recruitment of over 75 year olds was 20%, compared to 40% of under 
55s and 48% of those aged between 55 and 75. Proportionally more knee pain 
positive women than men were recruited (43% versus 37%), and recruitment 
was higher among married subjects (45%) than unmarried (31 %). 
History of both back pain and hip pain were greater among recruited compared 
to non-recruited patients. Smoking rates were similar between the two groups. 
Non-recruited subjects were more likely to report diagnosis of more than one 
co-morbid condition (5% versus 2.6%) from the following list: heart disease, 
stroke, lung disease, cancer and diabetes. 
2.5.2.2 Baseline characteristics of subjects entering the trial 
Baseline characteristics of subjects entering the intervention trial are 
summarised (Table 15). In line with previous community studies, the majority 
(64%) were women, the average age was 62 years and 29% had a body mass 
index (BMI) of> 30 kg/m2 . Radiographic evidence of knee OA ( ~ G r a d e e II in 
either the tibiofemoral or the patellofemoral compartments) was present in 330 
individuals (-+7%). Isolated patellofemoral OA was present in 58 (8 .37r) of the 
study population and represents the number of cases that would ha\'c been 
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missed in prevalence studies based solely on radiographic evidence of 
tibiofemoral OA. 
Table 15 Baseline characteristics of study population. 
Total Non- Significant 
Patient characteristics population % completers % difference 
n=786 0=186 
Practice A 317 40% 90 48 % # 
Practice B 469 60% 96 52% 
Female 500 64% 126 68 % 
Male 286 36% 60 32% 
Age: # 
45 to 54 years 189 24% 42 23 % 
55 to 64 years 279 36% 55 30% 
65 to 74 years 243 31 % 47 25 % 
75+ years 75 10% 42 23% 
BMI 
Underweight <20 kg/m2 8 1% 2 1% 
Normal 20 to 24.9 188 24% 41 22% 
kg/m2 
Overweight 25 to 29.9 357 45 % 86 46% 
kg/m2 
Obese> 30 kg/m2 231 29 % 55 30% 
Radiographic changes (n = 700) (n = 143) 
< Grade II 370 53 % 68 48% 
Grade II 330 47 % 75 53 % 
Comorbidity 
No comorbidity 615 78 % 140 75 % 
> 1 comorbid condition 171 22% 46 25 % 
Baseline WOMAC pain # 
o to 4 202 26% 34 18% 
5 to 7 212 27% 48 26% 
8 to 10 225 29% 61 33% 
11+ 147 19% 43 23% 
Mu cle trength (N) n =467 n - 95 
LMVC < 100 66 14% 19 20% 
LM 100 to 199.9 179 38% 35 37 C'ft 
LM 200 to 299 .9 133 29% --+ 25 % 
LM >300 9 19% 17 1 % 
I 
2 
# ignili ant dilTeren between n n- mpleter and total tud) p pulal10n X p- 00 
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Randomisation was successful and no significant baseline differences were 
observed between the 6 treatment groups at baseline (Table 16). 
Patient flow throughout the intervention study is shown (Figure 10). Study 
attrition was relatively low; 599 (76%) of volunteers completed the study and 
returned for final assessment at 24 months. Subjects who dropped out earlier in 
the study were contacted by post at 24 months and asked to complete a final 
assessment questionnaire. This resulted in the return of a further 83 
questionnaires. Differences between completers and non-completers are 
tabulated (Table 15). Subjects who dropped out of the study were more likely 
to be aged> 75 years; have higher baseline pain scores; come from practice A; 
and be randomised to one of the exercise groups. 
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Table 16 Randomisation to treatment group (demographic details and key 
outcome measures). 
Exercise Exercise, Exercise Telephone Dolomite Nothing 
& telephone 
telephone & 
dolomite 
n 121 114 235 160 78 78 
Age 45-54 26 (22%) 19(17%) years 66 (28%) 41 (26%) 20 (26%) 17 (22%) 
Age 55-64 45 (37%) 48 (42%) years 71 (30%) 56 (35%) 28 (36%) 31 (40%) 
Age 65-74 37(31%) 36 (32%) 78 (33%) 50 (31 %) 20 (26%) 22 (28%) years 
Age '?75 
years 
13 (11 %) 11 (10%) 20 (9%) 13 (8%) 10 (13%) 8 (10%) 
Female 74 (61 %) 71 (62%) 150 (64%) 105 (66%) 49 (65 %) 51 (65 %) 
BMI 36 (30%) 38 (33%) 69 (29%) 46 (28%) 20 (26%) 22 (28%) 
'?30kg/m2 
Bilateral 89 (74%) 79 (69%) 161 (69%) 102 (64%) 50 (64%) 48 (62%) 
pam 
Mean 
WOMAC 6.96 7.82 6.93 7.43 7.49 7.04 
pam 
Muscle 13 (18%) 11 (17%) 20 (14%) 10(11%) 5 (11 %) 7 (14%) 
strength 
n = 74 n= 64 <lOON n = 141 n = 94 n=45 
n = 49 
Structural 61 (54%) 43 (43%) 88 (42%) 80 (57%) 30 (42%) 34 (57%) 
change 
n=112 n=101 n=207 n=141 n=72 n=73 >grade 2 
1 5 
.. 
o 
0) 
Figure 10 Progress of volunteers through the trial. 
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(88%) (82%) (83%) (93%) (91 %) 
~ ~
Subjects who dropped out during the trial were sent a final assessment questionnaire - this added a further 83 (11 %) to the total at 24 months. 
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2.5.3 Primary outcome - self-reported knee pain at 24 months 
2.5.3.1 Analysis by treatment group 
A significant between group difference was observed in the change in 
WOMAC pain scores at 24 months (ANOVA, p = <0.01). This represented a 
significant reduction in pain for group 1 (exercise and telephone) compared to 
group 6 (no intervention). The remaining two exercise groups (groups 2 and 3) 
showed a similar, statistically non-significant trend (Table 17). 
Table 17 Baseline and change in WOMAC pain scores at 24 months by 
treatment group (ITT analysis). 
Baseline Mean fl from 95% c.r. for % fl Sig pain baseline mean fl p* 
Exercise & Telephone 
Group 1 6.96 -1.61 -2.22, -1.01 -23 0.02 (n=119) 
Ex, Tel & Dolomite 
Group 2 7.82 -1.21 -1.86, -0.55 -15 0.19 (n=114) 
Exercise 
Group 3 6.93 -1.13 -1.58 , -0.69 -16 0.13 
(n=234) 
Telephone 
Group 4 7.43 -0.45 -1.0, 0.1 -6 0.96 
(n=160) 
Dolomite 
Group 5 7.49 -0.87 -1.55 , -0.19 -1 2 0.67 
(n=78) 
No intervention 
Group 6 7.04 -0.06 -0.71, 0.59 -0.1 N/A 
(n=78) 
* Significance reported compared to group 6. Tukey's Honestly Significant Difference (THSD). 
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For comparison with previous studies , outcomes at 6 months are also shown 
(Table 18). The decrease in pain in the no intervention control group (group 6) 
meant that between group comparisons were non-significant, with the 
exception of the telephone support group (group 4), which showed a significant 
. " lncrease In patn. 
Table 18 Baseline and change in WOMAC pain scores at 6 months by 
treatment group (lIT analysis). 
Baseline Mean /j. from 95% c.r. Sia % il 0 pain baseline for mean il p* 
Exercise & Telephone 
Group 1 6.96 -0.97 -1.50, -0.44 -14 1.00 (n=119) 
Ex, Tel & Dolomite 
Group 2 7.82 -1.25 -1.84, -0.67 -16 0.99 (n=114) 
Exercise 
Group 3 6.93 -0.72 -1 .08 , -0.37 -10 0.98 (n=234) 
Telephone 
Group 4 7.43 0.16 -0.28 , 0.60 2 0.03 
(n=160) 
Dolomite 
Group 5 7.49 -0.56 -1.16, 0.03 -13 0.92 
(n=78) 
No intervention 
Group 6 7.04 -1.01 -1.62, -0.41 -14 N/A 
(n=78) 
* Significance reported compared to group 6. Tukey's HSD. 
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Change in pain scores throughout the trial are shown graphically (Figure 11). 
The three exercise groups generally showed a consistent downward trend in 
reported knee pain throughout the period. Overall, the telephone group (group 
4) showed the least improvement over time, with pain scores remaining 
relatively stable at all time points. The no intervention control group (group 6) 
showed a marked improvement at 6 months, although this effect had 
diminished to baseline levels by 24 months. 
Figure 11 Mean change in WOMAC pain scores by treatment group (ITT 
analysis). 
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2.5.3.2 Number needed to treat 
The mean reduction in pain for each of the exercise groups was approximately 
1 to 1.5 points on the WOMAC pain scale. However, the clinical importance 
of such a finding is unclear. In order to address this issue, findings were 
presented on a "number needed to treat" (NNT) basis (Cook and Sackett, 1 9 9 5 ~ ~
Laupacis et al. 1988). For the purposes of this analysis, a clinically significant 
improvement was defined as a reduction in pain of > 50%. In producing the 
NNT statistic, each group was compared with the no intervention control 
group. 
In order to achieve a > 50% reduction in pain over group 6, it was necessary to 
treat between 8 and 13 people in the exercise groups. The telephone and 
dolomite groups achieved similar outcomes based on the treatment of 26 and 
20 people respectively. The number reporting a significant worsening of pain 
was relatively constant across all treatment groups (Table 19). 
Results presented in Table 19 represent analysis on an intent-to-treat basis. 
The NNT based solely on subjects who completed the exercise programme was 
between 6 and 8. 
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Table 19 Number needed to treat in order to achieve a ~ ~ 50% reduction in pain 
at 24 months (ITT analysis). 
Better by No change Worse by Attributable NNT ~ 5 0 % % ~ 5 0 % % risk (95% C.L) 
Ex & Tel 36 (30%) 74 (60%) 11 (9%) 0.13 7.7 
Group 1 (4.2, 11.2) (n=121) 
Ex, Tel & Dol 12.7 
Group 2 28 (25%) 73 (64%) 13 (11%) 0.08 (9.5, 15 .9) (n=114) 
Exercise 65 (28%) 138 (58%) 32 (14%) 0.11 9.1 
Group 3 (5.8, 12.4) (n=235) 
Telephone 33 (21 %) 102 (64%) 25 (16%) 0.04 25 .5 
Group 4 (22.7,28.3) 
(n=160) 
Dolomite 17 (22%) 52 (67%) 9 (12%) 0.05 19.6 
Group 5 (16.5,22.7) 
(\1=78) 
No intervention 
Group 6 13 (17%) 51 (65%) 14 (18%) NA NA 
(n=78) 
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2.5.3.3 Analysis by factor 
The number of treatment options within this trial meant that analysis of 
individual groups was limited by lack of power. Nevertheless, the factorial 
nature of the trial design allowed exploration of individual treatment factors. A 
highly significant difference was observed between exercise and non-exercise 
groups (Figure 12). Similar comparisons for the telephone and dolomite 
groups revealed no such differences (Table 20). 
Figure 12 Mean change in WOMAC pain - exercise v non-exercise (lIT 
analysis) 
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Table 20 Summary o/WOMAC changes in pain scores by treatment/actor at 
24 months (lIT analysis) 
Baseline Mean 11 from 95% C.I. % Sig. Effect 
pam baseline for mean!l 11 p* sIze 
Exercise 7.15 (n = 467) -1.27 -1.59, -0.96 -18 0.001 0.25 
Non-exercise 7.35 -0.46 (n = 316) -0.82, -0.1 -6 
Telephone 7.40 -1.02 -1.37, -0.68 -14 0.52 0.04 (n = 393) 
Non-telephone 7.06 -0.87 -1.19 , -0.54 -12 (n = 390) 
Dolomite 7.68 -1.07 (n = 192) -1.54, -0.60 -14 0.55 0.04 
Non-dolomite 7.08 (n = 591) -0.92 -1.18, -0.63 -13 
* Independent samples t-test. 
2.5.3.4 Interaction of factors 
The possible interaction of exercise and telephone support was explored using 
a factorial ANOV A model. The addition of telephone support to the exercise 
programme did not result in significant improvement over the exercise only 
group (Table 21). 
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Table 21 Impact of the interaction offactors on WOMAC pain scores (lIT 
analysis). 
Baseline Mean tJ. Mean tJ. Meant::. Mean tJ. 
n pain 6mths 12 mths 18 mths 24 mths* 
Exercise with 233 7.39 Telephone -1.11 -0.94 -1.10 -lA1 
Exercise without 234 6.93 -0.72 Telephone -0.93 -1.08 -1.13 
*Factorial ANOV A P = 0.54 
2.5.3.5 Handling of missing values 
Primary analysis has been conducted on an intent-to-treat basis . Analysis of 
this kind requires assumptions to be made in relation to missing data. Study 
attrition meant that data for WOMAC pain scores at 24 months were missing 
for 103 (13%) individuals. In order to explore the impact of these data on 
study conclusions, analysis was repeated using two alternative strategies. 
i) Missing values imputed with baseline WOMAC pain scores. 
ii) Per protocol analysis - complete data only. 
In both cases, study conclusions were largely unaffected (Table 22). 
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Table 22 Alternative handling of missing data - WOMAC pain at 24 months. 
Baseline Mean 95% c.I. for % ~ ~ Sig. Effect 
pain ~ ~ m e a n ~ ~ p* Size 
ITT ANALYSIS 
Exercise 
7.15 Cn = 467) -1.27 -1.59, -0.96 -18 0.001 0.25 
Non-exercise 7.35 Cn = 316) -0.46 -0.82, -0.1 -6 
RETURN TO BASELINE 
Exercise 7.15 Cn = 467) -1.16 -1.46, -0.87 -16 0.002 0.22 
Non-exercise 7.35 -0.45 Cn = 316) -0.80, -1.07 -6 
PER PROTOCOL 
Exercise 6.99 -1.42 Cn = 392) -1.77 , -1.07 -20 0.001 0.27 
Non-exercise 7.28 -0.5 -0.88, -0.12 Cn = 288) -7 
* Independent samples t-test. 
2.5.4 Secondary outcomes 
A number of secondary outcomes were incorporated into the trial. For the sake 
of clarity, these have all been reported by factor rather than by treatment group. 
2.5.4.1 Knee specific stiffness and physicalfunction (WOMAC) 
The two remaining domains of the WOMAC scale addressed the impact of the 
interventions on physical function and stiffness. The exercise groups showed a 
significant improvement in both of these domains over the non-exerci e group 
at 24 month (Table 23). No uch impro ement were obser ed for either th 
tel ph ne r the dol mit gr up . 
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Table 23 Change in WOMAC physical function and stiffness at 24 months -
(ITT analysis). 
Baseline Mean 1:1 95% C.l. %1:1 Sig. Effect 
for mean 1:1 p* size 
PHYSICAL FUNCTION 
Exercise 23.15 (n = 466) -2.59 -3 .6, -1.6 -11 <0.001 0.25 
Non-exercise 22.97 -0.02 (n = 316) -1.2,1.1 -1 
Telephone 23.42 -1.43 (n = 394) -2.51, -0.35 -6 0.75 -0.02 
Non-telephone 22.73 -1.63 -2.68, -0.68 -7 (n = 388) 
Dolomite 24.16 -1.45 -3 .0,0.06 -6 0.88 -0.01 (n = 192) 
Non-dolomite 22.73 -1.59 -2.43, -0.74 -7 (n = 590) 
STIFFNESS 
Exercise 3.42 -0.41 -0.6, -0.3 -12 0.01 0.18 (n = 470) 
Non-exercise 3.46 (n = 316) -0.13 
-0.3,0.04 -4 
Telephone 3.46 -0.27 (n = 395) 
-0.43 , -0.12 -8 0.65 -0.04 
Non-telephone 3.42 -0.33 -0.48, -0.17 -10 (n = 391) 
Dolomite 3.66 -0.19 -0.40, 0.02 -5 0.28 -0.09 (n = 192) 
Non-dolomite 
(n - 594) 3.37 
-0.33 -0.46, -0.21 -10 
* Independent samples t-test 
Analysis at 6 months revealed similar results to those achieved at 24 months. 
Once again, no improvements were observed for either the telephone or the 
dolomite gr up . 
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2.5.4.2 Muscle strength 
Subjects in the exercise groups showed a significant increase in isometric 
muscle strength (MVC), compared to the non-exercise groups throughout the 
trial (Figure 13 - per protocol analysis; Table 24- ITT analysis). The greatest 
impact was observed at 6 months, when subjects allocated to the exercise 
intervention showed an increase in muscle strength of 5.3%. By contrast, those 
allocated to the non-exercise groups showed a reduction in muscle strength of 
5.4%. 
Figure 13 Change in muscle strength: per protocol analysis (practice B only). 
30 
20 
w 
en 10 
,.... 
..!.. 
..:!;. 
U 0 
> 
::.i! 
c: 
~ ~ -10 
c: 
ca 
s: 
(.) 
~ ~ -20 
CII 
::.i! 
-30 
"'-T-- ------1- --------1- --------f 
-40 L - - - - - - - - - - c - - - - - - . - - - - ~ - - - - - - 2 = - : - 4 4-mo--::nth-s-----, 
6 months 12 months 18 months Baseline 
Time period 
117 
~ E x 9 r c i s e e
.. • - Non-exercise 
CHAPTER 2: INTERVENTIO STUDY 
Table 24 Change in MVC at 24 and 6 months - practice B only (ITT analysis) 
Baseline Mean 95% C.I. for % ~ ~ Sig. Effect 
MVC ~ ~ m e a n ~ ~ p* SIze 
(Newtons) 
24 MONTHS 
Exercise 212.2 (n=280) 4.8 -2.2, 11.9 2.3 <0.001 0.30 
Non-
exerCIse 215.5 -13.6 -22.8, -4.3 -6.3 
(n=189) 
6 MONTHS 
Exercise 212.2 (n=280) 11.2 5.4, l7.0 5.3 <0.001 0.44 
Non-
exercise 215.5 -11.6 -18.9, -4.2 -5.4 
(n=189) 
* Independent samples t-test 
Due to a calibration error during the recording of baseline MVCs for Practice A 
(n=317), all change scores were analysed based on data from Practice B alone 
(n = 469). Nevertheless, subjects were randomised to treatment groups in 
permuted blocks throughout the recruitment period. Any shift in calibration 
would therefore have affected all groups equally. As a result, it has been 
possible to repeat the analysis based on absolute scores for all subjects. 
Analysis in this way continued to show a significant effect (independent t-test; 
p = 0.02). 
In order to explore the possible impact of a change in muscle strength on self-
reported pain status the data were examined by degree of change in mu cle 
trength. Table 25 illu trate the ignificant difference in pain core etv n 
th ubj t who gained mu cle trength and th e \\ ho 1 t mu Ie tr nbth . 
1 1 
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This relationship showed a dose-response effect; the largest reductions in pain 
were seen amongst subjects with the greatest improvement in muscle strength. 
Table 25 Impact of change in MVC scores on WOMAC pain scores at 24 
months (all groups - practice B). 
~ M V C C Pain at f::... pain* 95% c.r. %f::... % f::... over Effect 
baseline for mean f::... control Slze 
;::: 10% 
reduction 6.72 -0.19 'I' -0.7,0.3 -2.8 
(n = 160) 
No 
substantial 6.80 -0.94 -1.4,0.5 -13.8 -11 0.22 
change 
(n=170) 
;::: 10% 
mcrease 7.29 -1.36 -2.0, -0.7 -18.7 -16 0.34 
(n - 136) 
* One-way ANOYA, p = 0.01. 
'I' Used as comparison group for effect size calculation. 
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2.5.4.3 Exercise adherence 
Treatment adherence decreased over the 2-year study period as shown 
diagrammatically (Figure 14). 
Figure 14 Adherence with interventions at 6 and 24 months. 
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The most common reasons for non-completion of the exercise programme were 
related health problems involving back, hips and ankles (24%) and lack of time 
or motivation (23%) (Table 26). 
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Table 26 Summary of reasons for non-completion of the exercise programme. 
Reason for non-completion 
Related health problems 57 (24%) 
Lack of time / motivation 53 (23%) 
Unrelated health / death 42 (18%) 
Knees worse / no better 25 (11 %) 
Personal circumstances 24 (10%) 
Knees better 6 (3%) 
Other 28 (12%) 
The degree to which adherence with the exercise programme relates to changes 
in WOMAC pain scores may help to explain the possible mechanism of 
change. Pain scores were examined by sub-group based on categories of low, 
medium and high adherence. Subjects who dropped out of the exercise 
programme prior to 24 months were included in the low adherence group; as 
were subjects who accepted treatment but failed to provide data relating to 
exercise activity (Table 27). 
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Table 27 Impact of exercise adherence on WOMAC pain scores at 24 months. 
Adherence Pain ~ ~ pain· 95% c.l. for % ~ ~ % ~ ~ over Effect 
at 24 mths Base1ine m e a n ~ ~ control SIZe 
(non-exercise#) 
Low 7.24 
n= 307 -1.01 -1.39, -0.62 -14% -8 0.16 
Medium 7.59 
n= 32 -1.63 -3.00, -0.25 -21% -15 0.34 
High 6.82 -1.83 -2.40, -1.26 -27% -21 0.42 
n = 128 
# % ~ ~ in WOMAC pain for non-exercise control group = -6% . 
• One-way ANOV A, P = 0.05 
Two aspects are of particular relevance. Firstly, the number of subjects who 
maintained at least medium levels of exercise throughout the trial was 160 
(34% of those randomised to the exercise programme). Secondly, a dose-
response effect was observed. Greater reductions in pain were seen with 
increasing levels of exercise adherence. The effect size ranged from 0.16 for 
subjects in the low adherence group, to 0.42 for those in the high adherence 
group. 
Of secondary interest was the impact of exercise adherence on subsequent 
changes in muscle strength. Both the medium and the high adherence groups 
showed a significant improvement in muscle strength over the low adherence 
group (based on data from Practice B only) (Table 28). 
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Table 28 Impact of exercise adherence on change in muscle strength 
(Newtons) at 24 months - practice B only. 
LMVC L1 95% c.r. for %6 % L1 over Effect 
Baseline LMVC· mean L1 control SlZe 
(non exercise#2 
Low 213.1 
-5.86 
-14.2,2.5 
-2.8 3.5 0.12 
n = 173 
Medium 226.2 25.31 
-12.5,63.1 11.2 17.5 0.62 
n = 15 
High 20804 21.61 8.8, 3404 lOA 16.7 0.56 
n= 92 
# % 6 in LMVC for non-exercise control groups = -6.3% . 
• One-way ANOVA, p = 0.01. 
2.5.4.4 SF-36 
A higher score on the SF-36 physical function score represents improved health 
status. This measure changed less than the WOMAC and although modest 
improvements were observed between exercise and non-exercise groups at 6 
months, the effect was not sustained at 24 months (Table 29). No change was 
observed in either the telephone or the dolomite groups. 
Table 29 Change in SF-36 physical function at 24 and 6 months (ITT analysis) 
24 MONTHS 
Exercise 
(n=457) 
Non-exercise 
(n=309) 
6 MONTHS 
Exercise 
(11=457) 
Non- reI e 
(n- 309) 
Baseline 
PF 
56.68 
55.51 
56.68 
5 .51 
Mean L1 95% c.r. % L1 
for mean L1 
-0.65 -2 .0,0.8 -1 
-1.62 -3 .3 0 .04 -3 
2.S8 lA , 3.8 4.6 
0.74 -0 .7 2.2 1 
Sig. 
p* 
0.38 
o.OS 
Effect 
SIZe 
0.04 
0.08 
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2.5.4.5 Anxiety and depression 
Levels of anxiety or depression were not significantly altered by any of the 
study interventions. The mean scores for all subjects at baseline were 7.0 for 
anxiety and 4.7 for depression. For the purposes of screening, a level of> 7 
would indicate a potential clinical condition for each of these subscales 
(Zigmond and Snaith, 1983). In this population, 321 (41 %) were rated as 
possibly anxious at baseline and 151 (19%) depressed. A summary of the 
results is presented (Table 30, Table 31). 
Table 30 Mean baseline and change in anxiety scores by factor at 24 months 
(ITT data). 
Exercise 
(n = 468) 
Non-exercise 
(n = 315) 
Telephone 
(n = 393) 
Non-telephone 
(n = 390) 
Dolomite 
(n = 191) 
Non-dolomite 
(n 592) 
Baseline 
anxiety 
6.91 
7.11 
6.79 
7.20 
7.33 
6.89 
* Independent samples t-test. 
M e a n ~ ~ 95% c.I. % ~ ~ Sig*. 
for mean ~ ~ p 
-0.46 -0.7, -0.2 -6.7% 0.51 
-0.33 -0.6, -0.02 -4.6% 
-0.30 -0.6, -0.03 -4.3% 0.23 
-0.53 -0.8, -0.3 -7.5% 
-0.58 -1.0, -0.2 -7.9% 0.31 
-0.40 -0.6, -0.1 -5.8% 
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Table 31 Mean baseline and change in depression scores by factor at 24 
months (ITT analysis). 
Exercise 
Cn = 468) 
Non-exercise 
Cn =315) 
Telephone 
Cn = 393) 
Non-telephone 
Cn = 390) 
Dolomite 
Cn = 191) 
Non-dolomite 
Cn = 592) 
Baseline 
depression 
4.65 
4.74 
4.59 
4.78 
4.89 
4.62 
* Independent samples t-test. 
Mean !::J. from 
baseline 
-0.05 
-0.16 
-0.02 
-0.18 
-0.02 
-0.l7 
2.5.4.6 Patient satisfaction 
95% C.l. for %!::J. Sig*. 
mean !::J. p 
-0.3,0.2 -1.1 % 0.5 
-0.4,0.1 -3.4% 
-0.3,0.2 -0.4% 0.4 
-0.4,0.05 -3.8% 
-0.3,0.2 -0.4% 0.3 
-0.4,0.06 -3.7 % 
Upon completion of the trial, participants were asked to complete a short 
questionnaire outlining their experience of participation in the study. A total of 
641 (82%) questionnaires were returned (people who had previously dropped 
out of the study were invited to return the questionnaire by post). 
The majority (62%) felt that they had benefited from participation in the trial. 
The most frequently reported benefit resulted from the study treatments 
themselves (228 responses), although improved knowledge and support v a 
also an important factor (161 re pon e ). More exerciser 
r p rted per nal ben fit f1' m participation (Table 3_ . 
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Adverse events resulting from participation in the study were reported by 95 
(15%) subjects. Of these, 36 were related to events experienced during the 6-
monthly assessments, 52 were related to the exercise programme and 7 were 
for miscellaneous reasons. Although largely minor (e.g. exercise band dug into 
ankle), the importance of exercise related adverse events should not be ignored 
and may be important in explaining poor treatment adherence. 
Table 32 Self-reported beneficial and adverse events resulting from 
participation in the study. 
Exercise Non-exercise Total 
n = 371 n=270 n = 641 
BENEFIT 
Yes 257 (69%) 141 (52%) 398 (62%) 
No 109 (29%) 128 (47%) 237 (37%) 
Missing 5 (1 %) 1 «1 %) 6 (1%) 
ADVERSE EVENT 
Yes 73 (20%) 22 (8%) 95 (15%) 
No 298 (80%) 247 (92%) 545 (85%) 
Missing 0(0%) 1 « 1 %) 1 «1 %) 
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2.5.5 Multivariate analysis 
WOMAC pain scores obtained at 6-monthly intervals were combined to 
produce a single dependent variable (AUC) for each subject. A negative AUC 
score represents a reduction in knee pain and therefore improved health 
outcome. This change score was examined for the possible effects of a number 
of independent factors including: 
Baseline characteristics 
Age, sex, BMI, radiographic status (> Grade II or normal), 
clinical signs (fibromyalgia, joint hypermobility, concurrent hip 
pain, concurrent back pain), self-reported comorbidity (absent or 
present), bilateral knee pain (absent or present), WOMAC knee 
pain scores, HADS anxiety and depression scores. 
Factors relating to trial participation 
Recruitment centre, intervention type, voluntary muscle strength 
at 24 months, change from baseline at 24 months for anxiety 
and depression. 
Continuous variables were recoded as categorical variables in order to aid 
interpretation of results. Age, baseline knee pain and MVC at 24 months were 
entered based on quartile groupings. BMI was classified as 
underweight/normaL overweight or obese. Baseline anxiety and depression 
127 
CHAPTER 2: INTERVE:\TION STUDY 
were entered as binary variables reflecting the presence or absence of clinically 
meaningful cases (based on HAD scores of >7) (Zigmond and Snaith, 1983). 
Change in anxiety and depression were coded as being better than, the same as, 
or worse than baseline values. Full criteria for creating the model are outlined 
in the statistical methods section of this chapter (section 2.4.3). Entry into the 
final stepwise model was set at the 5% level and exclusion at 10%. Only actual 
data were used (not imputed values) and all necessary assumptions were met. 
Since muscle strength measurements were affected by the calibration error at 
practice A, baseline MVC and change in MVC scores were not included in the 
model. Nevertheless, it was possible to include actual MVC readings at 24 
months as these were unaffected by the error. 
Eight variables were found to be significant predictors of response (R 2 = 27%, 
adjusted R2 = 26%) (Table 33). The most important of these were high 
baseline pain scores and low MVC readings at 24 months. Those with the 
worst pain at baseline showed the greatest improvement in knee pain, (although 
this may reflect regression to the mean). Individuals with low MVC scores at 
24 months were less likely to report an improvement in pain. Even after 
adjusting for these variables, allocation to the exercise intervention remained a 
significant factor. In addition, radiographic OA, obesity, clinical anxiety at 
baseline, worsening anxiety during the period of the study and bilateral knee 
pain were all associated \vith poorer outcomes. 
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Table 33 Results of multivariate analysis for change in WOMAC scores 
throughout the 24-month period (dependent variable: Area Under the Curve) 
B coefficient S.E. c.r. for B P R2 
Baseline 
WOMAC pain 
-11.7 1.06 -13.8 , -9 .6 <0.001 8.60/0 
>10 
MVC at 24 mths 
4.3 0-140N 0.9 2.5,6.1 <0.001 4.7 0/0 
Exercise 
-2.8 0.7 -4.2, -1.5 <0.001 2.9% 
Baseline 
WOMAC pain -6.9 1.1 -8.9, -4.8 <0.001 2.9% 
7-9.9 
2 Grade II OA 1.3 0.4 0.6,2.0 <0.001 2.0% 
Anxiety worse 2.9 0.7 1.5 , 4.4 <0.001 1.50/0 
Baseline anxiety 2.5 0.7 1.0,3.9 0.001 1.2% 
Obesity 2.3 0.8 0.8 ,3.8 0.003 1.2% 
Baseline 
WOMAC pain -3 .1 1.0 -5.1 , -1.2 0.002 1.2% 
4-6.9 
Bilateral knee 1.8 0.7 0.4,3.2 0.01 0.80/0 
Eam 
Residual s.d. = 0.99 
Total R2= 27 % 
Two further models were constructed in order to assess the importance of each 
of these variables in explaining health outcomes for the exercise and non-
exercise groups independently. For the 'exercise model', treatment adherence 
was included as an independent variable. In both models, results were broadly 
similar to those obtained for the whole population. However, the importance of 
structural change was no longer significant for the exercise group, whil t both 
structural change and elf-reported back pain proved to be significant factor 
for the non-exerci e group. Treatment adherence failed to reach ignifi an In 
due t it clo e a ociation with mu cl tr noth. 
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2.6 DISCUSSION 
2.6.1 Main findings 
This study demonstrates that exercise therapy can produce a moderate and 
significant reduction in self-reported knee pain amongst older, community 
dwelling adults over a 24-month period. Compared to the non-exercise control 
groups, exercise therapy resulted in an average reduction in knee pain of 12%. 
This effect was incremental to benefits resulting from normal care and is thus 
of considerable clinical relevance. 
Improvements in pain were achieved by six months and sustained throughout 
the study period. Exercise therapy may therefore be considered a realistic 
treatment option, capable of providing long-term improvements in knee pain. 
Adherence with the programme was moderate. In those that adhered to the 
programme however, the exercises were well tolerated. The main reasons for 
non-adherence involved either related health problems (back, hips and ankles) 
or lack of time or motivation. 
The number needed to treat statistic (NNT) provides a direct measure of the 
clinical importance of the findings. An improvement of >50% in reported knee 
pain was chosen as a clinically meaningful outcome in order to facilitate 
comparison with other studies. For example, a meta-analysis of the efficacy of 
topical NSAIDs suggested the NNT in order to achieve a ~ 5 0 ( ; r r improvement 
in pain after 2 wccks of treatment was .3.1 (Moore et al. 1998). The ;\:'\T in the 
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current study was higher (mean = 10), but exercise therapy was delivered as an 
adjunct to normal care and outcomes were maintained over 2 years. Varying 
the trial period for outcome data can have a marked impact on efficacy 
findings. Two studies to examine the efficacy of intra-articular hyaluronic acid 
suggested that the NNT to achieve a >20% improvement in knee pain was 40.2 
if outcomes were assessed at 1 year, whereas outcomes assessed at 35 days 
produced a NNT figure of 7.2 (Pendleton et al. 2000). 
The introduction of telephone support and the placebo health food product 
contributed little to the observed improvements in knee pain. This finding 
supports the belief that exercise therapy can provide benefits beyond the 
potential psychosocial effects intrinsic to the delivery of the programme. The 
lack of an interaction between exercise and telephone in the two combined 
treatment groups also suggested that little could be added by the concurrent 
provision of social support. Nevertheless, the telephone intervention was 
specifically structured in order to avoid discussion of the exercise programme 
and may therefore have minimised any possible interaction. A more proactive 
intervention could potentially have resulted in improved exercise adherence 
(with its associated improvements in knee pain). 
Results of the multivariate analysis supported the conclusion that exercise 
therapy was an important factor in the control of knee pain. Both allocation to 
an exercise group and muscle strength at 2-1- months were significant factors in 
the final model. Other modifiable factors included obesity and Je\cls of 
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anxiety. Obesity has consistently been reported as a putative risk factor for 
knee OA (Felson et al. 1997; Felson, 1995; Cooper et al. 1994) and 
encouragement to reduce weight should ideally be included as a first line 
treatment (ACR subcommittee on osteoarthritis guidelines, 2000; Pendleton et 
al. 2000). The importance of anxiety in explaining self-reported knee pain 
points to the continued importance of psychosocial factors in pain management 
and may help to inform our understanding of the possible impact of educational 
support programmes. 
The importance of concurrent back pain in the 'non-exercise model' may 
reflect the difficulty of developing condition specific outcome measures. Back 
pain has previously been identified as an important factor in determining 
WOMAC scores (pain, stiffness and physical function), along with other non-
articular factors such as fatigue and depression (Wolfe, 1999). 
2.6.2 Secondary outcomes 
In addition to improvements in self-reported knee pain, the exercise 
programme produced significant improvements in knee stiffness and knee-
specific physical function. These effects were relatively small, but again 
represented improvements beyond existing levels of care. More generic 
measures of health status (SF-36, HADS and EuroQol) did not show a 
sianificant effect. Given the nature of the trial interventions it was to be 
b 
expected that knee-specific improvements might not have been reflected in 
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wider measures of quality-of-life. Other authors have reported similar 
limitations in using generic outcome measures (Fransen and Edmonds, 1999: 
Wolfe and Hawley, 1997; Bellamy, 1995). In particular, the presence of 
comorbidity could have exerted a dominant effect, which would have masked 
the limited knee-specific benefits (Xuan et al. 1999). 
2.6.3 Comparison with other studies 
This was a pragmatic study, the implications of which are important when 
seeking to make comparisons with other study findings. In general, it was 
anticipated that effect sizes achieved by the trial would be smaller than those 
reported in previous studies. Several factors contributed to this effect: i) 
analysis was on an intent-to-treat basis; ii) limited exclusion criteria were 
employed (resulting in high levels of comorbidity and relatively low baseline 
values for knee pain); iii) practical interventions were used, with limited input 
from health professionals; iv) effects were reported as incremental to normal 
care, and v) a relatively long-term period of follow-up was undertaken. 
One study to have employed a similar design to that of the current trial was the 
Fitness Arthritis and Seniors Trial (FAST) (Ettinger et al. 1997). These 
investigators reported a 12% improvement in knee pain for subjects allocated 
to exercise therapy (compared to health education), which equates to an effect 
size of 0.5. Adherence with the exercise programme was roughly comparable 
to rates observed in the current trial. Outcomes were examined over an 18-
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month period and analysis was conducted on an intent-to-treat basis. 
Treatment arms included exercise therapy (aerobic and quadriceps 
strengthening arms) and a health education control group. One difficulty with 
the trial was that health education was used as the control group. As a result it 
was not possible to quantify the health benefits of the education programme 
compared to no intervention. Interpretation of the incremental benefits of 
exercise therapy (compared to existing levels of care) was therefore difficult to 
establish. In addition, the exercise programme was delivered in a relatively 
intensive manner; involving a combination of both group therapy and 
individual home exercise. As such, it was intended as an exploratory trial to 
examine the benefits of exercise therapy in an optimal research environment. 
Analysis of a less intensive home-based exercise programme was explored in a 
pragmatic study of 6-month duration (O'Reilly et al. 1999). This study 
randomised 191 adults aged 40-80 years with self-reported knee pain, to either 
home-based exercise or no intervention. The exercise programme was 
delivered as four home visits by the research therapist and consisted of 
quadriceps strengthening and aerobic exercises. At 6 months a 16% reduction 
in self-reported knee pain was reported for the exercise participants compared 
to the no intervention control group. However, the lack of a social support 
control group meant that it was not possible to quantify the psychosocial 
aspects of contact with the therapist. 
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An influential study to have examined the impact of aerobic exercise was a 
study by Kovar et al, (1992). This study examined 102 OA patients who were 
randomised to receive either supervised walking or no intervention. Outcomes 
were examined at 8 weeks and were thus of relatively short-tenn duration. The 
investigators reported an effect size of 0.6 for a reduction in knee pain. A 
recent follow-up to this study (Sullivan et al. 1998) examined outcomes at one 
year, post-treatment. It was found that continued adherence with the walking 
programme was low and that any significant improvements in pain status 
resulting from the intervention were subsequently lost. This reinforces the key 
importance of improving exercise adherence if benefits are to be sustained. 
The fact that the current study showed sustained improvements throughout the 
24-month period of the trial suggests that the continued follow-up of patients at 
6-monthly intervals may be an appropriate way to encourage continued 
participation. 
A meta-analysis comparing patient education with NSAID use in both OA and 
RA patients (Superio-Cabuslay et al. 1996) was conducted in order to examine 
the incremental benefits of patient education. The average effect size for 
improvements arising from patient education was 0.17. However, there was a 
significant difference between education programmes that sought to affect 
behavioural change and those providing infonnation and social support alone. 
This effect was also reported by Maisiak et al. (1996), who found that a 
combination of symptom monitoring and social support was less etlecti\'e than 
a treatment aimed at increasing patient in\'oi\'cment and encouraging 
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behavioural change. The findings of the present study support this hypothesis 
in that the limited social support available through the telephone intervention 
was not sufficient to produce any improvement in health status. 
2.6.4 Caveats 
Every effort was made to reduce the methodological problems associated with 
some of the earlier trials into the efficacy of exercise therapy. Nevertheless, 
certain limitations need to be recognised. The trial sought to achieve both 
internal and external validity through its pragmatic design. However, the 
generalisability of the study findings was compromised by the significant 
differences between the pain positive subjects recruited into the trial and those 
not recruited. This means that extrapolation beyond the study population 
should be conducted with care. 
Similarly, adherence was identified as being important in explaining the study 
findings. It is conceivable that adherence within the trial was higher than may 
be observed upon wider implementation. Subjects were aware that they were 
involved in a trial and that they would be contacted at regular intervals. The 
impact of a possible reduction in adherence should not therefore be dismissed. 
Throughout the trial, primary analysis was based on intent-to-treat principles. 
Whilst this was intended to deal with missing data in as pessimistic a manner 
as possible. the technique does not a\'oid bias completely. It is possible that 
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short-term improvements seen at 6 months were simply carried forward to later 
time points for those subjects who dropped out of the study prior to 24 months. 
This could have artificially inflated improvements in pain at later assessments. 
However, sensitivity analysis (per protocol and return to baseline for missing 
values) suggested no such bias. 
Blind assessment of treatment outcomes was a key feature of the trial design. 
Whilst every effort was made to ensure that this was maintained, the nature of 
the trial meant that this was not always possible. The regular contact between 
assessment metrologists and study volunteers meant that some degree of 
disclosure was inevitable. Nevertheless, the primary outcome was based on 
self-completion questionnaires and should not therefore have been influenced 
by any knowledge on the part of the research metrologist. 
A more fundamental problem for the study was the fact that lack of power 
limited the ability to perform between-group analysis. Whilst factorial 
comparison of exercise and non-exercise groups was helpful, this limited the 
ability to distinguish between the various non-exercise interventions 
(telephone, dolomite and no intervention). 
Finally, an important aspect of any exercise therapy is to establish that the 
programme does not aggravate existing symptoms. Evidence from the trial 
suggested a largely positive effect. However, it should be recognised that a 
dramatic worsening of knee pain may have resulted in premature drop out. As 
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a result, no evidence would have been gathered concerning these individuals. 
Nevertheless, complete data were available for 87% of subjects at 24 months 
and sensitivity analysis relating to the handling of missing data revealed no 
evidence of bias. Results of the patient satisfaction survey suggested possible 
adverse events in 20% of those subjects allocated to the exercise programme 
(compared to 8% for non-exercise participants). Whilst the majority of these 
events related to incidents of minor importance (e.g. the exercise band was 
uncomfortable around the ankle), their impact on possible treatment adherence 
should not be ignored. Evidence of radiographic progression of disease activity 
was not possible to assess in this study since subjects were not X-rayed at 24 
months. The FAST study reported no evidence of change in radiographic 
status resulting from exercise therapy of this kind (Ettinger et al. 1997). 
138 
CHAPTER 3: COST OF KNEE PAIN 
3 Cost of knee pain 
3.1 Aims and objectives 
Health costs incurred during the 6-month period prior to participation in the 
intervention study were assessed for all subjects. These data provided baseline 
values for the subsequent cost-effectiveness study and represented a period in 
time prior to contact with the study team. Two main objectives were 
addressed: 
1. To explore the economic impact of knee pain in the community (including 
medical and personal costs). 
2. To identify the factors most closely associated with high primary care costs. 
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3.2 Method 
3.2.1 Study perspective 
This cost-of-illness study reflects the costs incurred by study volunteers for the 
6-month period prior to entry into the trial. A societal perspective was adopted, 
although the principle emphasis was on direct costs to the NBS. Comparison 
with a control group was not possible within the study design. As a result, the 
reported data are intended to provide an indication of the relative contribution 
of individual costs only. 
3.2.2 Subjects 
Subjects for the economic evaluation were taken from the intervention trial. 
They were categorised by diagnosis (OA or RA) on the a-priori assumption that 
the medical and personal costs incurred by RA subjects would be considerably 
higher than those incurred by OA subjects (Lanes et al. 1997). In the absence 
of a positive diagnosis of RA (or other connective tissue disorder) in the OP 
notes, subjects were classified as OA (regardless of radiographic status). RA 
patients were included in the economic analysis since the principle concern of 
the study was that of self-reported knee pain. Costs are reported both with and 
without these patients for comparative purposes. 
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3.2.3 Clarification of terminology 
The terminology of economic evaluation lacks standardisation. In particular, 
disagreement over the appropriate use of several key terms has resulted in the 
same concepts being labelled differently by different authors (Pettiti , 1994). In 
order to avoid such confusion, a list of the key terms used in the following two 
chapters are documented in Table 34. 
Table 34 Definition of key terms used in the current study and alternative 
definitions used by other authors (adapted from Petitti, 1994) 
Term used by current study Definition 
Direct cost of treatment provision / The cost of delivering the treatment under 
intervention costs investigation (including labour and materials) 
Personal costs of treatment provision Costs incurred by patients as a result of the 
treatment under investigation. 
Medical costs Costs incurred by the health provider for normal 
treatment provision (including +ve and -ve 
consequences of direct treatment provision) 
Personal medical costs Costs incurred by patients in accessing normal 
health care provision. 
Indirect co ts The cost of lost productivity due to ill health and / 
or treatment provision (including the concept of 
costs associated with alternative use of time). 
Additional co t / intangible co t The cost of pain and disability caused by knee 
pail1. 
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3.2.4 Costs included in the cost analysis 
Having identified the major resource use implications of knee pain (adopting a 
societal perspective), the main cost drivers were chosen for further analysis. 
Items that were felt to be of minor importance, or were difficult to accurately 
quantify or cost, were documented in a qualitative manner. 
Costs included in the final analysis were: 
a) Medical costs - OP consultation costs, OP prescribed drugs and 
secondary care costs. 
b) Personal medical costs - prescription charges, travel costs and OTC 
drugs. 
Results are presented for primary care costs (OP costs + OP prescribed drug 
costs), total medical costs (primary care costs + secondary care costs) and 
societal costs (total medical costs + personal medical costs). The implications 
of excluding other costs from the main analysis were explored using sensitivity 
analysis. 
3.2.5 Definition of costs 
All costs are reported in pounds sterling at 1996 prices. 
3.2.5.1 Medical costs 
Details of service-use provision (GP costs, OP prescribed drug costs and 
secondary care costs) were obtained from an examination of patients' OP notes. 
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Obtaining frequency data from GP notes rather than through patient 
questionnaires has two main advantages: 
• It reduces recall error. This may be particularly true of elderly, community 
dwelling adults with a chronic condition (Linet et al. 1989). 
• It allows the collection of data for all subjects regardless of study attrition. 
Details of related services (e.g. physiotherapy, chiropody and other primary 
care services) were recorded where possible, although reliable data were rarely 
available. 
In an attempt to attribute resource use, data in all categories were recorded 
according to four criteria: 
i) Exclusively related to knee pain. 
ii) Partially related to knee pain: 
a) Only part of the consultation time involved talking about knees. 
b) Consultations involving the lower back, hips, ankles or feet. 
iii) Side-effects of arthritis drugs e.g. gastrointestinal problems caused by 
NSAID use. 
iv) Not related to knee pain. 
3.2.5.1.1 GP Costs 
These were based on frequency of GP consultations, treatments (injections or 
n1inor surgical operations), investigations (blood/urine tests, ECG recordings), 
radiographs and don1iciliary Yisits. Unit costs were obtained from PSSRU 
(Netten and Dennett, 1996) and from the local hospital finance department. 
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3.2.5.1.2 GP Prescribed Drugs 
Details of prescribed drugs were abstracted from GP notes and recorded 
according to the British National Formulary (BNF) classification scheme. The 
cost of individual drugs was based on average unit prices quoted in the 
September 1996 edition of the BNF. Drugs of particular relevance to arthritic 
conditions were identified by a consultant rheumatologist as outlined in Table 
35, and were documented individually. Dispensing costs were excluded from 
analysis since it was unclear from previous studies whether they had been 
included or not. The impact of excluding such costs was explored in sensitivity 
analysis. 
Table 35 Arthritis related drugs. 
Drug Type 
Oral NSAIDs - normal 
- slow release 
Topical NSAIDs 
Analgesics 
Gastro-intestinal drugs 
Other related drugs: 
• Steroids 
• Tri-cyclic anti-depressants ~ ~ 50 mg 
• Quinine (if quoted by patient) 
BNFCode 
10.1.1 
10.3.2 
4.7.1 or 4.7.2 
1.3 .1, 1.3.5 or 1.3.4 
10.1.2 
4.3.1 
10.2.2 
It was not always possible to establish why particular drugs had been 
pI' cribed from GP ca not alone. Judg ments were therefor ba d on 
r tr p cti dat 011 ct d thr ugh pati nt qu tiormair ( pp ndi ' 3 . 
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3.2.5.1.3 Secondary care costs 
Hospital costs were based on local figures from the finance department at 
Queen's Medical Centre, Nottingham. Outpatient and daycase costs were 
based on average rheumatology visits. Inpatient costs used the main cost 
drivers of number of days in hospital, and the number of days in intensive care. 
This was felt to best reflect actual resource use as figures produced for 
individual procedures by the hospital finance department did not take into 
account the often high levels of variance between individual patients. This was 
of particular relevance to the current study since arthritis is associated with 
high cost conditions such as obesity, diabetes and heart disease (Gabriel et al. 
1999; Gabriel et al. 1997a). 
The use of private medical facilities was documented separately. Total medical 
costs are reported both with and without these private costs. The personal cost 
of private health insurance was difficult to ascertain from questionnaire 
responses as monthly premiums were usually unknown or paid for by an 
employer. 
Abstraction fOnTIS employed for case note abstraction are available in 
Appendix 10. 
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3.2.5.2 Personal medical costs 
Three categories of costs were identified as relating to personal medical costs: 
a) prescription charges; b) over-the-counter (OTC) drugs and c) travel costs 
incurred whilst travelling to and from the health provider (GP surgery or 
hospital). Prescription and OTC drug costs were assessed using patient 
questionnaires (assessed retrospectively for the preceding 6 months). 
(Appendix 3). In order to avoid double counting of prescription costs (since 
they are a transfer payment), details have been documented in the personal 
costs section, but were not included in the total societal costs. 
3.2.5.2.1 Prescription charges 
Prescription charges were calculated at £5.50 per prescription issued. 
Exemption from prescription charges was assessed through the patient 
questionnaire. However, the relevant question was worded in the negative; 
"Are you exempt from prescription charges? ", and the resulting responses 
revealed clear confusion. As a result, prescription status was estimated for all 
periods based on a volunteer's age and employment status. All those under the 
age of 60 who were not registered as unemployed were assumed to pay 
prescription charges. Subjects who received more than 7 prescriptions in the 6 
months prior to randomisation, were assumed to have purchased a prepayment 
certificate. As a result, a ceiling of £40 per person was imposed on prescription 
costs incurred during each 6-n10nth period. It is hoped that the resulting data 
arc a reflection of the actual personal costs incurred. 
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3.2.5.2.2 Over-the-counter (OTC) drugs 
Items bought over-the-counter for the relief of knee pain were identified by 
subjects using the patient questionnaire. Drugs of interest were identified as 
being: NSAIDs, analgesics, rubs or gels and health food products (e.g. cod liver 
oil). Since much of the patient derived information was difficult to interpret, 
standard quantities (based on GP prescription data) were assumed for each 
identified purchase. Costs were based on prices quoted in the OTC directory 
1995/6. (Table 36). 
Table 36 Summary of quantity and price of aTe drugs. 
Drug Price based on Quantity Cost 
(6 months) 
NSAIDs Ibuprofen 56 per month £15 
200 mg 
Analgesics Paracetamol 50 per month £18 
500mg 
Rubs / gels Movelat One tube £6.99 
100g 
Health foods Cod liver oil I per day £10 
500 mg 
3.2.5.2.3 Travel costs 
Cost incurred by patients for travel to and from the health provider (GP or 
hospital) were calculated based on average distances traveled. The staff travel 
rate for the local hospital of 37p per mile was used (mileage was estimated at 
two ll1il s [74p] p r doctor's isit and ten miles [£3.70p] per hospital isit) . 
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Travel costs incurred by the friends and family of knee pain patients were not 
considered as part of this analysis. 
3.2.5.3 Costs not included in the economic analysis 
Details of other resource use were collected using patient questionnaires and 
included the following: 
• Equipment purchased - an assessment of those items purchased by patients 
or outside agencies. 
• Assistance from social services - provision of aids, meals-an-wheels, 
home-help. 
• Eligibility for financial assistance - disability living allowance etc. 
• Use of alternative health care - osteopathy, aromatherapy etc. 
These data were not included in the formal economic analysis as the 
information related to services and equipment used for the relief of knee-
related symptoms only (rather than total costs) and was collected over a 
different time period (12 months). 
Medical costs relating to the professions allied to medicine (PAMs), such as 
physiotherapy, occupational therapy and chiropody were documented from GP 
notes. It has not been possible to provide accurate cost data for these 
professions since the number of sessions provided per treatment block was 
unclear. 
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Costs associated with lost productivity (indirect costs) were documented in a 
qualitative manner. The financial impact of excluding these costs was explored 
in sensitivity analysis. 
Intangible costs (loss of leisure time, pain and disability) associated with knee 
pain were difficult to capture and cost in a meaningful way. Nevertheless, the 
need for informal care from family and friends was documented and provided 
some indication of the possible impact of knee pain on daily function. It was 
not felt appropriate to attach a monetary value to this care, and the need for 
help was documented in a descriptive manner only. 
3.2.6 Unit costs 
Unit cost and frequency of resource use are documented in Table 38 and Table 
42 of the results section. Alternative costs may be applied as required 
3.2.7 Data manipulation 
3.2.7.1 General data management 
All data were entered onto a customised database (Microsoft® Access 97), and 
analysis was conducted using SPSS for windows version 8.0 (SPSS Inc., 
Chicago, IL). Unit cost and total cost data are presented throughout; from 
which unit resource use can be calculated. It has been possible to calculate 
annual equivalent rates from the 6-month data, since recruitment \\as achieved 
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over a 12-month period. Any seasonal variation should therefore have been 
captured. The total costs and arithmetic mean are presented as being the most 
informative summary measures for policy decision-makers (Thompson and 
Barber, 2000; Barber and Thompson, 1998). Nevertheless, the median 
provides an indication of the degree of skew in the dataset and has been 
included for interest. 
Primary care costs are reported in addition to total medical costs since the 
majority of knee pain sufferers are managed in the community. It was 
therefore of some interest to be able to isolate primary care costs. 
The identification of costs specifically related to knee pain proved to be 
problematic. Attempts were made to classify all data as being either knee 
costs, partially knee related costs, costs resulting from NSAID related side 
effects, or unrelated costs. However, the specific joint of involvement or 
reason for a particular prescription were not always clear and it is possible that 
some degree of overlap or misclassification has occurred. Nevertheless, for the 
main analysis, total knee costs were defined as being: 
Knee costs + 20% of partially knee related costs + 20% of NSAID-related side 
effect costs. 
The decision to allocate 200(, of the partially related costs and 20% of the side 
effect costs to the total cost of knee pain was taken after an examination of the 
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data capture forms and through discussion with consultant rheumatologists. 
Whilst it is hoped that this provides a best estimate as to the probable cost of 
knee related care, the probable impact of varying this percentage has been 
explored in sensitivity analysis. 
3.2.7.2 Key assumptions 
This cost-of-illness study is based solely on those items specifically outlined in 
earlier sections. It is not an exhaustive study of all possible cost implications. 
Rather, it is a pragmatic attempt to document some of the major cost drivers in 
relation to the medical management of knee pain in the community. 
Whilst every effort was made to identify a broadly representative sample 
population, it should be recognised that all subjects were enrolled in the 
subsequent 2-year intervention programme. As a result, it is possible that 
generalisation of the observed health costs to a wider population may be 
problematic (Cronan et al. 1997b). 
Finally, the majority of data collection was achieved through an examination of 
OP case notes. It is possible that unit resource use data have been 
underestimated as a result of inaccurate / inconsistent documentation or 
limitations in communication between primary and secondary care. It has not 
been possible to ascertain the degree of any such bias. 
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3.2.7.3 Regression analysis 
Economic data provides a unique challenge for data analysis as it is usually 
highly skewed and frequently includes large numbers of patients who have 
incurred zero costs. In order to explore the data through regression analysis it 
was necessary to construct two-stages of analysis (Lipscomb et al. 1998): 
i) Logistic regression model - to compare the characteristics of those 
patients who incurred costs with those who did not. 
ii) Linear regression model - excluding those patients who incurred 
zero costs. This analysis assessed the factors most closely 
associated with high medical costs. 
Secondary care costs were excluded from analysis since the predominance of 
low frequency, but high cost events would have reduced the predictive ability 
of the model. 
The dependent variable for the logistic regression was defined by whether or 
not primary care costs were incurred during the six-month baseline period. 
Odds ratios (OR), confidence intervals (Cl) and significance levels have been 
reported. The odds ratio (OR) is calculated as the exponential of the B-
coefficient. An OR of greater than 1 represents increased risk, whilst an OR of 
less than 1 suggests a protective effect. Continuous variables were re-classified 
as categorical variables in order to aid interpretation. 
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Subjects who incurred no costs during the six-month baseline period were 
excluded from further analysis. Linear regression was then conducted using 
the log of the baseline primary care costs for the remaining subjects. Log 
transformation of the data was performed prior to inclusion in the model in 
order to meet the assumption of normality. 
Both models were conducted in two stages. Variables were initially entered 
using a backward selection model (entry criteria of 10%). A second stepwise 
model was then conducted in which significant variables from the first model 
were entered, plus factors of a-priori interest (radiographic status and BMI). I For the stepwise model, entry was set at the 5% level and exclusion at 100/0. 
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3.3 Results 
3.3.1 Subject characteristics 
Subjects for the economic evaluation were taken from the intervention trial 
(n = 759). Case notes were unavailable for 27 subjects (patients had either died 
or left the surgery), and these subjects were excluded from further analysis. 
The demographic characteristics of the study population have been reported 
elsewhere (Table 15). Additional characteristics of relevance to the economic 
evaluation are summarised (Table 37). 
Table 37 Summary of baseline patient characteristics. 
Patient characteristics In study Excluded 
n(%) n(%) 
OA 729 (96) 27 (100) 
RA 30 (4) 0 (0) 
Prescription exempt 467 (61.5) 17 (63) 
Private health insurance 88 (11 ) 2 (7) 
Retired 440 (58) 16 (59) 
Work full-time 139 (18) 4 (15) 
Work part-time 100 (13) 3 (11 ) 
Unemployed 49 (7) 3 (11 ) 
Not employed 28 (4) 1 (4) 
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3.3.2 Medical costs 
3.3.2.1 Total medical costs 
The total medical costs incurred by the study population for the baseline 6-
month period was £191,697 (x = £253). Costs were highly skewed with the 
majority of patients (55%) incurring costs of less than £100 (Figure 15). Of 
these, 85 (11 % of total population) incurred no medical costs for this period. 
Of the 'high' service users (those who incurred costs of greater than £400), 36 
incurred costs of over £1,000, with a range from £1,000 to £4,752 (with the 
exception of a single outlier of £25,366). 
Figure 15 Total baseline costs to the health provider (6-month period). 
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The relative contribution of secondary care, GP prescribed drugs and GP 
consultation costs were £113,258 (59%); £56,906 (30%) and £21,533 (11 %) 
respectively. Whilst secondary care costs represented the largest overall 
expenditure, this amount was incurred by 29% of the population and 69% of 
the total was accounted for by just 28 patients. 
Total knee costs for secondary care, GP prescribed drugs and GP consultations 
were £5,285 (38%), £6,684 (48%) and £1,992 (14%) respectively. Knee 
related costs were consistently higher for patients with RA (x =£44.36) than for 
patients with OA (x = £17.33). 
3.3.2.2 GP costs 
GP consultation costs were relatively modest compared to secondary acre and 
GP prescribed drug costs. In all categories, the major cost driver was GP 
consultation time. The impact of investigations, treatments and radiographs 
contributed just 14% (£2,953) to total GP consultation costs (Table 38). The 
mean cost per person was £28.37 (£56.74 annual equivalent) for total GP costs 
and £2.63 (£5.25 annual equivalent) for total knee costs. 
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Table 38 Direct medical costs incurred during baseline 6 month period (knee 
costs = knee costs + 20% related costs + 200/0 side effect costs; totals rounded 
to nearest pound). 
Total cost (£) Total knee cost (£) Knee cost excl. 
(n =759) (n =759) RA patients (£) (n = 729) 
GP COSTS 
Consultations @ £1 0 16,660 1,564 
Telephone contact @ £5 l30 4 
Investigations / treatments @ £5 2310 160 
X-rays @ £9 per joint 513 144 
D o m i c i l l i a r ~ ~ visits @ £30 1,920 120 
TOTAL 21,533 1,992 1,779 
Mean (s.d.) 28.37 (30.6) 2.63 (8. 5) 2.44 (8.4) 
Median 20.00 0.00 0.00 
ANNUAL EQUIVALENT 43,066 3,984 3,558 
Mean (s.d) 56.74 (61.2) 5.25 (17.0) 4.88 (16.7) 
HOSPITAL COSTS 
Inpatient 1 st day @ £500 28,500 1,600 
Inpatient subsequent days @ £300 59,700 2,160 
Days in ICU @ £1,000 0 0 
Daycase surgery @ £480 5,280 96 
Outpatient new refenal @ £100 7,100 520 
Outpatient follow-up @ £40 11 ,800 808 
A&E @£42 798 101 
TOTAL 113,258 5,285 5,041 
Mean (s.d.) 149.22 (976.9) 6.96 (9 1.0) 6.91 (92.9) 
Median 0.00 0.00 0.00 
ANNUAL EQUIVALENT 226,516 10,570 10,082 
Mean ( .d) 298.44 l3.93 (182.1) l3.83 (185.7) 
(1,953.7) 
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Table 38 (Continued) 
Total cost Total Knee cost Knee cost excl. 
(£) (£) RA patients (£) 
PRESCRIBED DRUGS 
ARTHRITIS DRUGS 
NSAIDs 6,218 .74 4,240.47 
Topical rubs / gels 885.88 608.97 
Analgesics 2,126.09 1,290.16 
Gastrointestinal drugs 6,847.19 316.77 
Other arthritis related drugs 625.06 227.79 
TOTAL ARTHRITIS DRUGS 16,703 6,684 5,810 
Mean (s .d.) 22.01 (50.2) 8.81 (23.5) 7.97 (2 1.1 ) 
ANNUAL EQUIVALENT 33,406 13,368 11,620 
Mean {s.d.} 44.02 {100.4} 17.62 {47.1) 15.95 {42 .2) 
TOTAL UNRELATED DRUGS 40,203 
Mean {s.d.} 52.97 {105.0) 
TOTAL DRUGS 56,906 
Mean (s.d.) 74.98 (123 .9) 
ANNUAL EQUIVALENT 113,812 
Mean {s.d.} 149.97 (247.8} 
TOTAL PRESCRIPTIONS 7,637 1,187 1,023 
ISSUED (6 months) 
Mean £ f!er f!rescrif!tion 7.45 5.63 5.68 
TOTAL DIRECT MEDICAL 191,697 13,961 * 12,630 
COSTS 
Mean (s .d.) 252.57 18.39 (94.7) 17.33 (95.8) 
(1 ,023.7) 
Median 80 0 0 
ANNUAL EQUIVALENT 383,394 27,922 25,260 
Mean {s.d.) 505 .1 {2,047.4) 36.79 (189.4) 34.65 (191.6) 
TOTAL PRIMARY CARE 78,439 8,676* 7,589 
COSTS 
Mean ( .d.) 103.35 (136.2) 11.43 (25.6) 10.41 (23 .2) 
Median 64.24 0 0 
ANNUAL EQUIV LENT 156878 17,352 15,179 
Mean { .d.) 206.70 {272.3) 22.86 {51.2) 2082(46.4) 
ent 7% of total medical costs and 11 % of primary care co ts . 
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3.3.2.3 GP prescribed drugs 
The cost of GP prescribed drugs was 212 times the cost of GP consultations at 
£56,906. Arthritis related drugs contributed 29% to this total, with knee 
prescriptions alone being £6,684 (12%). The mean cost per person was £75 for 
all drugs, £22 for arthritis-related drugs and £9 for drugs taken specifically 
because of knee pain. Full details are tabulated (Table 38). On average, 10 
prescriptions were issued per person (x cost per prescription to NHS £7.45), 1.6 
of which were issued for knee pain (x cost per prescription £5.63). The relative 
contribution of each of the arthritis related drugs is shown (Figure 16). The 
importance ofNSAIDs and gastrointestinal drugs to treat the side effects of 
NSAIDs in the treatment of arthritis is of particular note. 
Figure 16 Contribution of drug type to total arthritis drug costs (6-month 
period). 
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The majority of prescriptions were issued to patients who were exempt from 
prescription charges. This meant that reimbursement through prescription 
charges contributed just 11 % to the total cost (Table 39). 
Table 39 Total drug costs in relation to prescription charges paid (6-month 
period). 
Knee related drugs 
Total drugs 
Drug cost to NBS 
(£) 
6,684 
56,906 
3.3.2.4 Secondary care costs 
Prescription 
charges paid (£) 
1,044 
6,128 
% of total cost 
reimbursed 
15.6% 
10.8% 
The impact of secondary care on total medical costs was high (59% of total 
cost). The majority of this amount was incurred as inpatient stays (£88,200). 
The mean cost per person was £149 (s.d. £977). Full details are tabulated 
(Table 38). 
Secondary care costs for knee related care were relatively low (£5,285). Three 
operations (arthroscopies) accounted for 76% of this amount. However, a 
single knee replacement operation (costing £5,000) would effectively double 
the b er ed co t. Since having had a total knee replacement (TKR) was an 
x Iu i n litelia for entry to the trial, this data may under-represent the true 
t f kn te arthri ti . 
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3.3.3 Other medical costs 
Details of professions allied to medicine (P AMs) were documented where 
possible (Table 40). Great variability existed in the quality of the data and 
figures should be used as a guide only. 
Table 40 Number of PAMs sessions instigated through primary care (6-month 
period). 
Physiothera py Private Chiropody Psychiatrist Dietician 
physiotherapy 
Knee related 3 0 0 0 0 
Partially knee 9 4 2 0 0 
related 
Other 12 8 0 10 1 
Total 24 12 2 10 1 
In addition to physiotherapy provided in primary care, 4 courses of hospital-
based physiotherapy were prescribed (l for a knee complaint and 3 for back 
and hip complaints). 
3.3.4 Personal costs 
The personal costs incurred by patients in accessing medical care (prescription 
payments and travel costs) are summarised in (Table 41). The cost of items 
b ught ver-the-counter (OTC) has been documented separately since data for 
th it m wer collected for knee related purchases only (Table 42). 
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Table 41 Personal medical costs excluding aTe costs (6-month period) 
Prescriptions Prescriptions Travel- Travel- Mean Total 
n=759 (exempt) (non-exempt) GP Hospital (s.d) 
n=467 n=292 visits visits 
Knee costs Units 848 339 156 31 
Units 
incurring 
° 
217 N/A N/A 
cost # 
Cost £0 £1,194 £116 £115 £1.88 £1,424 
(5.3) 
Total costs Units 5,458 2,179 1,666 453 
Units 
mcurnng 
° 
1,114 N/A N/A 
cost # 
Cost £0 £6,128 £1,233 £1,676 £11.90 £9 ,037 
(16.0) 
# Individuals who incurred more than 7 prescriptions within the 6-month period were assumed 
to have purchased a pre-payment certificate. 
3.3.4.1 Prescription charges 
Prescription charges reflect the costs incurred by 38.5% of subjects (the 
remainder being exempt from charges). Nevertheless, these charges 
contributed significantly to the total personal costs incurred. This was 
particularly so for total knee costs, where prescription charges accounted for 
84% of the total personal costs and may reflect the importance of drug therapy 
for the treatment of OA. 
3.3.4.2 Travel costs 
Travel costs incurred by patients were generally low (£3.83 per person for total 
and £0.30 for kne cost). The e figure repre ent direct tra el co t and 
d n t in lude an timation of the opportunity co t of time pent tra elling. 
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3.3.4.3 aTe drug costs 
Drugs bought over-the-counter (OTC) represent a considerable cost to the 
indi vidual. The cost of purchases made in this way was almost 3 times greater 
than the combined cost of travel and prescription charges (£3,996 : £1,424). 
The most frequently recorded purchases were for health food products (most 
commonly cod-liver oil), analgesics and topical preparations. 
Table 42 aTe drugs bought for knee-related care (6-month period). 
Drug type Units Cost (£) 
Analgesics @ £15 89 1,602 
Rubs I Gels @ £6.99 85 594 
Health foods @£18 123 1,230 
NSAIDs @ £15 38 570 
Other @ N/K 6 N/K 
TOTAL 341 3,996 
Mean per person 0.45 5.25 
3.3.5 Other costs 
Other costs were collected retrospectively for a 12-month period. They refer to 
total knee costs only. Summary details are presented in Table 43. 
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Table 43 Other knee costs incurred over 12 months. 
Support from social 
services 
n = 641 
Adaptive aids 
Meals on wheels 
Home help 
Social security 
payment 
n=641 
Disability allowance 
Mobility allowance 
Attendance allowance 
Carers allowance 
Incapacity allowance 
Other 
3.3.6 Indirect costs 
N umber receiving 
support 
n (%) 
15 (2.3) 
2 (0.3) 
4 (0.6) 
Number claiming 
allowance 
N (%) 
27 (4.2) 
28 (4.4) 
9 (2.0) 
6 (0.9) 
22 (3.4) 
5 (0.8) 
Alternative health 
care 
Osteopath / 
Chiropractor 
Homeopathy / 
Aromatherapy 
Toning tables 
Number of 
sessions 
n 
7 
91 
192 
Of the 239 in paid employment, 18 (7.5%) reported having taken time offwork 
due to knee pain. In total 303 days (x = 17 days) of sick leave were reported. 
The cost implications of time lost from work due to knee pain have been 
included in the sensitivity analysis. 
In an attempt to capture the disease morbidity associated with knee pain, the 
ne d for infom1al care from friends and relatives was also documented (Table 
44). Very few people paid for help with activities of daily Ii ing. 
N rth 1 s, consid rub I n d \ as identified particularly in relation to 
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shopping, heavy domestic duties and bathing. Members of the immediate 
family generally provided assistance with these activities. 
Table 44 The need for assistance with activities of daily living (due partly or 
fully to knee pain). 
Type of activity Requires help Receives help Source of help Help paid 
n =587 (% of need met) Live in Live out 
Shopping 97 93 (96) 62 30 8 
Cooking 14 14 (100) 10 4 2 
Light domestic duties 12 11 (92) 9 2 2 
Heavy domestic duties 178 143 (80) 93 46 19 
Bathing 93 34 (37) 31 2 0 
Showering 15 13 (87) 11 1 0 
Dressing 29 21 (72) 21 0 0 
Getting in / out of bed 14 11 (79) 8 1 
Walking 45 21 (47) 13 3 3 
Getting in / out of a car 72 52 (72) 21 26 0 
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3.3.7 Summary of total costs 
Summaries of primary care costs, direct medical costs and societal costs for the 
study cohort are tabulated (Table 45). 
Table 45 Summary of primary care costs, direct medical costs and societal 
costs (6-month and annual equivalent data, figures rounded to nearest whole 
pound). 
PRIMARY CARE COSTS 
Total 
Mean (s.d.) 
Median 
ANNUAL EQUIVALENT 
Total 
Mean (s.d) 
TOTAL MEDICAL COSTS 
Total 
Mean (s.d .) 
Median 
ANNUAL EQUIVALENT 
Total 
Mean (s.d) 
SOCIETAL COSTS 
Total 
Mean (s.d.) 
Median 
ANNUAL EQUIVALENT 
Total 
Mean ( .d) 
Total costs (£) 
n=759 
78,439 
103 (36.2) 
64 
156,878 
207 (272.3) 
191,697 
253 (1,023.7) 
80 
383,394 
505 (2,047.4) 
198,602 
262 (1027.3) 
98 
397.204 
523 (2,054.7) 
Knee costs (£) 
n=759 
8,676 (11 %)* 
11 (25 .6) 
o 
17,352 
23 (51.2) 
13 ,961 (7%)* 
18 (94.7) 
o 
27,922 
37 (189.4) 
18,187 (9%)* 
24 (96.5) 
10 
36,374 
48 (192.9) 
* Figure in brackets represent knee costs as a % of the total cost for each category. 
stimated societal cost for UK population aged ~ 4 5 5 years = £218 - £350 million (assuming 
pre alence of21 - 35%). 
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3.3.8 Sensitivity analysis 
Several assumptions underlie the economic analysis presented thus far. Their 
possible impact was explored through sensitivity analysis (Table 46). 
Firstly, the impact of those variables excluded from the formal analysis should 
be noted. It was not possible to accurately document visits to the practice 
nurse. However, data obtained from OP notes suggested that between 20-50% 
of patients attended for a nurse visit during the study period. Data relating to 
services provided by PAMs (physiotherapy, chiropody, psychiatry and dietary 
advice) was equally limited. Nevertheless, the frequency data collected during 
the trial provides an indication of the possible cost implications. These figures 
should be treated with great caution as it was difficult to tell whether or not an 
entire course of treatment had been prescribed, or a 'one-off' consultation. 
Sensitivity analysis has been conducted assuming either extreme (i.e. each 
physiotherapy session was a single session versus a block of 15 sessions) 
(Netten and Dennett, 1996). Multi-way analysis including both nurse and 
PAM consultations suggested that total direct medical costs would be increased 
by between £1,487 (0.8%) and £6,522 (3.4%). The impact on knee costs was 
between £67 (0.5%) and £963 (6.9%). 
For this analysis, local hospital unit costs were applied. Units of resource use 
were rep0l1ed so that local values could be applied as necessary. Ho\\c\er, it is 
interesting to note that national figures taken from the CIPFA 199)/96 database 
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suggest that total hospital costs could be up to 26% lower (£83,683) and knee 
costs 22% lower (£4,110). The majority of this discrepancy arose from 
differences in the cost of inpatient stays. 
A total of 303 days were documented as being lost from work as a result of 
knee related illness. These costs were excluded from the main economic 
analysis but represent a substantial economic burden (based on GDP capita per 
head of £45 per day).(Moffett et al. 1999). The inclusion of indirect costs 
increased the societal cost of knee pain from £18,187 to £31,822 for the 6-
month study period. 
Dispensing costs were not included in the main analysis as it is unclear from 
previous studies whether such costs have been included or not. The impact of 
including dispensing costs is outlined (Table 46). Additional resource 
implications stem from the use of BNF prices for the costing of drugs. Prices 
quoted in the BNF do not accurately reflect the cost of drugs to the dispensing 
pharmacist. The Department of Health generally assumes that a discount of 
approximately 11 % has been negotiated with the drug companies (personal 
communication). The combined effect of including dispensing costs, but 
discounting the total drug cost by 11 %, resulted in little overall change in the 
estimated cost of prescribed drugs. 
The possible impact of using subjects recruited into the subsequent RCT is 
more difficult to quantify. Other investigators have explored the cost 
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implications of studying elderly volunteers with osteoarthritis (Cronan et al. 
1997b). These investigators found that non-volunteers were more likely to 
have a comorbid condition (particularly cancer), but that the overall number of 
health contacts for non-volunteers was lower than that for volunteers. 
However, the average cost of each contact was greater for the non-volunteer 
group. Overall, this resulted in roughly comparable total health costs between 
the two groups and further sensitivity analysis was not therefore felt to be 
necessary for the current data. 
The identification of knee-specific costs was also problematic. For OP and 
hospital consultations it was not always clear if knee-related issues had been 
discussed. The previous analysis assumed that 20% of related costs (those for 
which knee pain formed only part of the consultation or in which other arthritis 
related locomotor conditions were involved) could be attributable to knee pain. 
This figure was based on an examination of the reason for service-use 
documented during data collection. Nevertheless, the figure was somewhat 
arbitrary and could have impacted on estimates of the overall knee costs. 
Results have therefore been presented assuming that 0 to 50% of the related 
costs were attributable to knee pain. 
Finally, gastrointestinal drugs contributed 41 % (£6,847) to the total cost of 
arthritis related drugs. This amount was almost entirely categorised as being 
unrelated to the knee pain, as only 3 individuals reported taking 01 medicines 
as a result of their knee pain at a total cost of £317. It is cOflL'ci\'able that many 
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more patients were prescribed GI drugs as a result ofGI complication 
stemming from the use ofNSAIDs for the treatment of knee pain and knee 
drug costs may therefore be underestimated. Sensitivity analysis assessed the 
impact of re-categorising up to 50% of GI drugs as knee-related drug costs. 
Multi-way analysis exploring the possible impact of both of these issues 
suggests that direct medical costs for the knee could be reduced by £ 1,645 or 
increased by £6,349. 
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Table 46 Sensitivity analysis (figures in brackets represent change in costs). 
Total cost Knee cost 
Min. Max. Min. Max. 
Inclusion of nurse visits @ £6 20 % attended 50 % attended N/A N/A 
192,608 193,974 
Total direct medical cost 
( +911 ) (+2,277) 
Inclusion of PAMs Per session Per block Per session Per block 
192,273 195,942 14,028 14,924 
Total direct medical costs 
(+576) (+4,245) (+67) (+963) 
Multi-way analysis 193,184 198,219 14,028 14,924 
(Nurse + PAMS) (+1,487) (+6,522) (+67) (+963) 
Definition of knee costs N/A N/A 0 % 50 % (% of related costs included) 
12,316 16,429 
Total direct medical costs 
(-1 ,645) (+2,468) 
Definition of knee costs N/A N/A 20 % 50 % (% of GI drugs included) 
13,961 17,842 
Total direct medical costs 
(+0) (+3 ,881) 
Multi-way analysis 12,316 20,310 
N/A N/A 
(definition of knee costs) (-1,645) (+6,349) 
Di pensing costs included £0.00 £0.90 £0.00 £0.90 
191 ,697 198,570 13,961 15,029 
Total direct medical costs 
(+0) (+6,873) (+0) (+ 1,068) 
Drug tariff discount applied -11 % 0% -11 % 0 % 
185,437 191,697 13,226 13,961 
Total direct medical costs 
( -6,260) (+0) (-735) (+0) 
Multi-way analysis 185,437 198,570 13,226 15,029 
(drug cost) (-6,260) (+6,873) (-735) (+1,068) 
Inclu ion of indirect co t N/A 303 days N/A 303 days @£45 per day. 
ictal 0 l 212.237 31 .822 
(+ 13,635) (+13 ,635) 
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3.3.9 Regression analysis 
Total primary care costs were included as the dependent variable in a two-stage 
model exploring the possible impact of a range of independent variables. 
Factors included in the model were as follows: 
Demographic characteristics: 
Age, sex, BMI and recruiting practice. 
Health status measures 
Clinical diagnosis (OAlRA), self-reported comorbidity (comorbidity 
absent or present), clinical signs [fibromyalgia, bilateral knee pain, 
concurrent hip pain, concurrent back pain (absent or present)], 
WOMAC knee pain, radiographic status (> Grade II or normal), anxiety 
and depression. 
Age, BMI, knee pain scores, anxiety and depression were entered as categorical 
variables in order to aid interpretation. Age and knee pain were entered based 
on quartile groupings. BMI was classified as underweight/normal, overweight 
or obese. Anxiety and depression were entered as binary variables reflecting 
the presence or absence of clinically meaningful cases (based on HAD scores 
of ~ 7 ) ) (Zigmond and Snaith, 1983). In all cases, the reference group was that 
which would be expected to incur the lowest costs. Sufficient numbers (>100 
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cases) were available for each of the groups. It was not possible to include 
muscle strength scores in the final model because data relating to subjects 
recruited from practice A were subject to a calibration error during the 
collection of baseline readings. 
Full criteria for developing the models are outlined in the statistical methods 
section of this chapter. Two models were fitted, firstly a logistic regression 
analysis. This compared the characteristics of individuals who incurred 
primary care costs (n = 674) with those who did not (n = 85). Individuals who 
incurred primary care costs were then entered into a further linear regression 
model, which identified the factors most closely associated with high primary 
care costs. In order to adjust for the highly skewed distribution of the dataset, 
log transformation of the data was performed prior to inclusion in this model. 
All necessary assumptions were then met. 
3.3.9.1 Logistic regression 
The final logistic regression model included 672 cases (87 were excluded due 
to missing data). Three variables were found to be significant risk factors for 
incurring primary care costs: comorbidity (OR = 12.7), WOMAC pain scores 
of > 10 (OR = 3.2) and HADS anxiety scores of >7 (OR = 2.3). Full details are 
tabulated (Table 47). BMI and radiographic status were not included in the 
final model (p = 0.4 and p = 0.3 respectively). 
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Table 47 Results of logistic regression - risk facto rs for incurring primary care 
costs. 
OR 95% C.I Sig. (p) 
Comorbidity 12.67 3.1 , 52.5 <0.001 
WOMAC pain ~ 1 0 0 3.18 1.3,7.4 0.007 
Clincally relevant 2.26 1.3 , 4.0 0.005 
anxiety (HAD ~ 7 ) )
3.3.9.2 Linear regression 
In the linear regression model seven variables showed an association with 
primary care costs (R2 = 20%, adjusted R2 = 19%). The most important factors 
were a) WOMAC pain score of greater than or equal to 10; b) at least one 
comorbid condition; c) self-reported back pain and d) clinically relevant 
depression. All factors demonstrated a positive relationship. 
Knee pain was an important factor in dictating primary care costs. By contrast, 
radiographic evidence of structural change and BMI were not included in the 
final model (p = 0.5 and p = 0.3 respectively). Nevertheless, it is possible that 
tructural change may better predict secondary care costs (particularly the need 
for invasive procedures such as arthroscopy or knee replacement surgery). 
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Table 48 Results of linear regression - primary care costs (6-month period) 
B S.E. 95% C.l. for B P R2 
coefficient 
WOMAC pain 2:10 0.42 0.08 0.26,0.59 <0.001 7.1% 
Comorbidity 0.51 0.08 0.36,0.67 <0.001 6.0% 
Back pain 0.22 0.07 0.08 , 0.35 0.002 2.2% 
Clinical depression 0.28 0.09 0.11 , 0.45 0.002 1.6% (HAD 2:7) 
RIA 0.41 0.16 0.11,0.72 0.01 1.1 % 
Practice B 0.16 0.07 0.03 , 0.30 0.02 0.8% 
WOMAC pain 7 - 0.19 0.09 0.03 , 0.36 0.02 0.7% 9.9 
Female 0.15 0.07 -0.29, -0.01 0.03 0.7% 
Residual s.d. = 1.01 
Total R2 for model = 20.3% 
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3.4 Discussion 
3.4.1 Main findings 
The cost of knee pain has been assessed in this cost-of-illness study. It 
provides UK data in relation to both the total costs incurred by patients with 
knee pain and knee-specific costs. This study is unique in that previous data 
have come largely from the USA and have looked at the cost of arthritis in 
general. Knee costs were found to be modest (x = £37 per annum for health 
service costs, x = £48 for societal costs). Knee costs represented 
approximately 100/0 of the total medical costs in the study sample. As is 
common with cost data, results were highly skewed and a small percentage of 
the population incurred extremely high costs. One individual incurred costs of 
over £25,000 for the 6-month study period. Nevertheless, a large number of 
those examined incurred no cost at all. Despite the relatively modest knee 
costs, the high prevalence of knee pain in the community ensures a substantial 
economic burden. Assuming a prevalence rate of between 21 % and 32% for 
this population, the estimated total cost of knee pain in the UK for people aged 
45 years and over at 1996 prices would be between £218 million and £350 
mil1ion (excluding indirect costs). 
The in1portance of secondary care and prescribed drug costs in dictating health-
related costs for OA has been reported elsewhere (Lanes et al. 1997). The 
CUlTent study confin11ed the importance of these aspects of care. In this 
population, drug costs \ n ~ r c c substantial, and were incurred by almost all 
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individuals (84%). By contrast, secondary care costs were incurred by few 
(29%), but were generally at very high cost. 
Of the prescribed drugs identified, slow release NSAIDs and GI drugs were 
commonly prescribed. These were very expensive; the total cost of these two 
categories alone accounted for 78% of the total arthritis related drugs bill. 
Recent guidelines recommend the first-line treatment for the management of 
knee OA as being simple analgesics e.g. paracetamol and topical preparations, 
coupled with simple advice on weight loss and exercise therapy (ACR 
subcommittee on osteoarthritis guidelines, 2000; Pendleton et al. 2000). 
NSAIDs are reserved as second-line treatments because of their known 
association with GI complications, particularly amongst elderly patients. It is 
also of note that very few of the study population received formal 
physiotherapy for their knee pain or advice on exercise therapy. However, it is 
possible that simple advice by the GP may have been given but not recorded in 
the GP notes. 
Personal costs included in the study were relatively high, particularly for the 
purchase of OTC preparations: most ;}otably health food products. As is 
common with many chronic conditions, alternative means of coping with the 
condition are an imp0I1ant source of perceived patient need (Woolf and 
Doherty, ~ O O O ) . .
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Given that the majority of those recruited to the study were either retired or 
unemployed, it was anticipated that the indirect cost of lost productivity would 
be relatively modest. However, indirect costs were considerable (£13,635) and 
increased the estimated knee related costs by 70%. The importance of indirect 
costs for individuals with osteoarthritis has been identified previously (Gabriel 
et al. 1997b; Gabriel et al. 1995; Badley, 1995b). 
Finally, the intangible costs associated with knee pain should not be ignored. 
Considerable disability and the need for informal care were identified. These 
aspects of the condition are extremely difficult to cost in a meaningful way, but 
impact on the daily lives of virtually all sufferers. 
3.4.1.1 Regression analysis 
Despite relatively high secondary care costs, the predominance of high cost but 
low frequency events meant that further analysis was limited. Regression 
analysis therefore concentrated on an exploration of the factors associated with 
high primary care costs. 
Logistic regression analysis compared individuals who incurred primary care 
costs with those who did not and identified comorbidity, knee pain and anxiety 
as being significant risk factors for incurring medical costs. Interestingly, age, 
BMI and radiographic evidence of change were not significant factors in the 
model. 
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Similar results were observed with the second model (linear regression), which 
examined factors relevant to the magnitude of primary care costs. This model 
was able to explain 20% of the observed variance. The importance of pain 
intensity and comorbidity were confirmed, as was psychological distress 
(depression). Pain severity has been reported by other investigators as being 
important in dictating primary care costs (Andersson et al. 1999; Gabriel et al. 
1997b), as has depression (Andersson et al. 1999). Once again, obesity and 
radiographic status were not significant factors within the model. The 
importance of pain rather than radiographic status in explaining primary care 
costs, supports the importance of studying symptoms (knee pain) rather than 
clinical signs (radiographic change). 
3.4.2 Comparison with other studies 
Costs reported in this study are generally low in comparison with other cost-of-
illness studies for OA. However, direct comparison is difficult due to the 
varied methodologies used. A summary of studies that have examined costs 
specific to OA is presented Table 49. 
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Table 49 Summary oJprevious cost-oj-illness studies Jar GA. (Costs reported in 1996 £ sterling equivalent values). 
Source Costs examined Method of data collection Subjects Main findings Comment 
Lanes et al. (1997) Direct medical costs Individual utilisation data Age ~ ~ 30 yrs with 8,128 (81 %) received care High service utilisation but 
relating to arthritis only obtained from the Fallon confirmed diagnosis of for OA during study. very select population 
USA (incl. side-effects of Community Health Plan . OA and ~ ~ 1 health (deliberately targeting high 
arthritis drugs). contact in previous year Av. cost: £408 per year. service users) . 
Included: Duration: 1 year. for OA. 2 0 care = 46%. Distribution of costs 
Consultations, screening Medication = 32% between 2 0 care, 
and treatment procedures, n = 1O,1Ol. 3.3 visits per person (incl. 1.2 medication and J 0 care, 
medications, surgery, visits to physical therapist. similar to current study. 
emergency room visits . Greater use of physical 
therapy observed (may be 
USA v UK). 
Gabriel et al. (1995) Direct medical, indirect Individual utilisation data Aged ~ 3 5 5 yrs, with a OA: 84% received medical Specification of costs 
medical and non-medical from Rochester Epidemiology diagnosis of OA care during 1987 . included unclear. 
USA - total costs (not OA Project, Olmsted County between 1975-87. Controls: 82% received care. 
specific). Health Care Utilisation and n = 7,889. Av. cost: £2,362, £1,840 Not able to isolate medical 
Expenditure Database + postal Controls: residents aged respecti vel y. costs specific to OA - total 
Costing year not specified survey. ~ 3 5 5 yrs without Postal response rate = 50%. costs on ly. 
(assumed to be 1987). diagnosis of OA. Indirect & non-medical costs: 
Duration : 1 year. n = 25,893. £ 110,517, £88,675 
Postal survey = random respecti vel y. 
sample of 200 from each Excl. wage losses: £326, £66 
cohort. respectively. 
Gabriel et aJ . (l997a) Direct medical costs. Individual utilisation data Diagnosed 1975-87, A v. direct medical cost: Same cohort as 1995 paper 
from Rochester Epidemiology aged ~ 3 5 5 yrs . OA: £3,068 , 
USA Compared OA, RA and Project, Olmsted County RA: £4,395 Incremental costs specific 
controls with no arthritis Health Care Utilisation and OA: n = 6,742 NA: £1 ,605 to OA identi fied through 
(NA). Expenditure Database. RA: n = 397 OA patients sig. greater costs comparison of population 
NA: n = 25,904 than NA in arthritis re lated based cohorts. 
Logistic regression used for care, but also virtual ly al l Identification of individual 
comparison of groups. other body systems. costs specific to OA not 
possible. 
--- ----
Table 49 (continued) 
----_ ._--
Source Costs examined Method of data collection Subjects Main findings Comment 
I Gabriel et al. (1997b) Indirect and non-medical Postal survey. Response rate: % incuning these costs: Poor response rate 
costs Random sample of above OA: 116 OA: 39% 
USA population (200 per group). RA: 123 RA: 66% 
Included: NA: 94 NA: 17% 
Use of non-medical Logistic regression modelling Predictors of costs: 
practitioners, travel, home Functinal status, pain and 
health care, medical presence of arthritis 
equipment, days off work, 
change in occupation due 
to ill heal th 
Liang et al . (1984) Direct and indirect cost of Random sample of patients 303 contacted, 184 Isolation of OA costs not Prospecti vely collected 
OA care registered at Boston Multi- volunteered possible as all data reported diary data, but led to 
USA purpose Arthritis Centre who 148 returned at least 1 as aggregate (OA and RA methodological problems 
1979 US$ had visited ~ ~ once in last 5 yrs diary (49 of which were combined) and small OA sample size 
for arthritis care OA patients) 
~ ~
Q) 
~ ~
Direct costs: Complete data for whole yr I 
Medication, outpatient Included OA and RA patients not possible, costs 
visits, inpatients stays, presented per month 
surgery, rehab, assistive 
devices, domestic help. Highly selected population 
Indirect costs: 
Days ofrestricted act'y, 
days confined to bed, days 
off work 
Kramer et al . ( 1983) Limited to physician National Health Interview RA: 258 For OA patients: Community sample but 
visits, hospitalisation and Survey 1976 OA: 152 A v. visits to GP = 3.5/yr still reliant on physician 
USA restricted activity days diagnosis 
Inclusion criteria: 32% had been hopsitalised at 
Specific diagnosis of some time. Limited sample and costs 
OA or RA 17% had had surgery. examined 
39% reported limited in 
activities of daily living. No attempt made to cost 
these items 
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The relatively low costs observed in the current study could be for several 
reasons. Firstly, the dataset relates to the UK system of health-care. To date, 
studies examining the cost implications of arthritis have come largely from the 
USA. Given the very different system of health care provision in the USA, it is 
important to collect UK data around which policy decisions can be made. A 
study by Drummond et al. (1995) identified this need when they demonstrated 
that the cost-effectiveness of using different NSAIDs varied according to the 
country in which treatment was provided. This difference was largely 
explained by differences in the cost of laboratory tests and hospitalisation. 
Given that almost 40% of the direct medical cost associated with the treatment 
of knee pain was for hospital care, findings could vary considerably between 
countries. 
Clearly another major difference in identifying knee pain costs is the nature of 
the study population. Previous studies have considered OA costs (all joints) 
rather than knee-specific costs, have included only those cases with a previous 
diagnosis of OA (rather than self-reported knee pain) and frequently required 
evidence of recent health resource use prior to entry (Lanes et al. 1997; Liang 
et a1. 1984). Whilst studies of this kind are informative, they do not estimate 
the true burden of symptomatic OA (both diagnosed and undiagnosed) in the 
community. It is also possible that knee-related costs are genuinely modest in 
compalison with other joints of involvement. Back pain, for example, is 
associated with considerable morbidity and is common in younger males. 
Indirect costs alone represent a considerable societal burden. It has been 
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suggested that indirect costs may account for 93% of the total cost of back pain 
(van Tulder et al. 1995). 
Patients who had had a total knee replacement (TKR) at baseline were 
excluded from this study. This may have resulted in an underestimation of the 
true cost of knee OA. Nevertheless, the degree of such bias is likely to be 
small given the current under-utilisation of knee replacement surgery in this 
country. Rates are reported as being 0.5-0.7 per 1000 in those aged over 65 
years. By contrast, TKR is far more common in the USA where rates of >2 per 
1000 have been reported (Dieppe et al. 1999). 
Finally, the type of costs considered and the method of applying unit costs vary 
from study to study. The importance of examining unit resource use rather 
than average figures for individual procedures was emphasised in this study. 
Within this population, 3 patients received arthroscopies during the 6-month 
period of study. Of these patients, 2 incurred costs of £800 each (one for a 
bilateral operation) and one incurred £2,000. The average cost of an 
arthroscopy as quoted by the local hospital was £480. Clearly these patients 
revealed wide variation in actual resource use and were more likely to 
experience complications resulting in higher medical costs. 
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3.4.3 Strengths and weaknesses of the study 
A major strength of this study was the fact that data were collected 
prospectively through an examination of GP records. This process was 
extremely time-consuming but provided unique resource use data for the 
sample population. In this way estimates were relatively free of recall bias and 
the impact of study attrition. 
Nevertheless, a fundamental concern relating to the study stems from the fact 
that data were collected within the structure of a randomised controlled trial 
(RCT). This meant that the study population consisted of volunteers with self-
reported knee pain who were enrolled in a 2-year RCT. As a result, the 
characteristics of this population may well be different from the wider knee 
pain population and may have reduced the external validity of our findings. 
Unfortunately, lack of time and resources meant that an examination of the GP 
notes of non-volunteers was not possible. Previous authors have suggested that 
non-volunteers may differ from volunteers in that they have fewer overall 
health-related contacts, but that those contacts that do occur tend to be at a 
higher cost. In addition, non-volunteers are more likely than volunteers to 
suffer from serious life-threatening conditions such as cancer (Cronan et al. 
1997b). 
The method of data collection used by this study also meant that the sample 
size was considerably smaller than is possible from wide-scale population 
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surveys (Kramer et al. 1983) or from the examination of well-maintained 
computerised records (Lanes et al. 1997; Gabriel et al. 1997a). Given the 
variability of economic data, it is possible that a fully representative sample 
was not achieved and that very different cost estimates may be obtained from a 
larger sample population. 
The difficulty of ascribing knee-related costs from an examination of medical 
notes was also problematic. Value judgements were sometimes required and 
the extent to which the data reflects the true cost of knee pain may be subject to 
bias. Nevertheless, this represents an ambitious attempt to identify the direct 
medical costs specific to an individual joint of involvement and the impact of 
classification errors of this type was explored through sensitivity analysis. 
It may be possible that the use of patient questionnaires would have alleviated 
some of the difficulties of identifying knee-specific costs. However, patients 
may find it equally difficult to isolate costs relevant to a single joint of 
involvement in the presence of generalised OA. It is possible that reliance on 
patient derived data may therefore have introduced greater variability than the 
methods used (whereby value judgements were limited to 2 individuals). In 
addition, patient questionnaires pose their own difficulties, most notably the 
quantification of recall bias (particularly amongst elderly populations) and the 
need for cx.cessi \'c complexity and length. 
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Finally, whilst the regression analysis conducted as part of this study provides 
an interesting insight into some of the factors relating to high medical costs in 
these patients, it should be recognised that any model is limited by the factors 
included therein. This study sought to explore factors of a-priori interest and 
was not intended to be an exhaustive investigation of all relevant factors. It is 
possible that other factors may be more important in dictating overall costs, 
such as social class, coping style or the belief in the efficacy of conventional 
medicine in treating knee pain (Dieppe et al. 1999). 
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CHAPTER 4: ECONOMIC EVALUATION OF TRIAL INTERVENTIONS 
4 Economic Evaluation of trial interventions 
4.1 Aims and objectives 
This economic analysis was conducted alongside the main RCT (reported in 
Chapter 2). It is unique in that it provides prospectively collected resource use 
data over a period of two years. It had two primary objectives: 
1. To perform a cost-effectiveness analysis based on outcome measures 
obtained from the intervention study. 
2. To perform a cost-utility analysis in which outcomes were measured in 
Quality-Adjusted Life-Years. 
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4.2 Method 
4.2.1 Study perspective 
Analysis was conducted alongside the RCT to assess whether the provision of a 
community-based exercise programme was cost-effective in relieving the 
symptoms and disability of knee pain. Exercise therapy was compared with 
telephone support, a placebo health food product and no intervention. The 
study adopted a societal perspective; costs and benefits were examined for both 
the health care provider and for individuals suffering from knee pain. 
4.2.2 Subjects 
Subjects for the economic evaluation were taken from the intervention trial and 
had self-reported knee pain at baseline. Randomisation was successful and no 
significant differences were observed between the groups at baseline in 
demographic or key outcome measures (Table 16). 
4.2.3 Materials 
Frequency data for resource use were collected through an examination of GP 
case notes and from patient questionnaires over the 2-year intervention period 
and for 6 months prior to randomisation (Figure 17). 
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Data abstraction from GP case notes was performed blind to treatment group 
and informed consent was obtained from patients prior to the accessing of 
notes. 
Effectiveness data were based on self-completion questionnaires and were 
collected during assessments at six-monthly intervals throughout the trial (see 
Chapter 2). Units of effectiveness for the economic analysis were based on 
WOMAC pain scores achieved at 24 months. In order to provide clinically 
meaningful cost-effectiveness ratios, pain scores were also presented using the 
number needed to treat statistic (NNT) (Cook and Sackett, 1995; Laupacis et al. 
1988). 
Utility measures for the cost-utility analysis were obtained using the EuroQol 
EQ-5D (EuroQol Group, 1990). Scores were calculated using Tariff Al as 
supplied by the EuroQol group (Table 50). This tariff is based on the time 
trade-off (TTO) method of valuing health states. Quality-adjusted life-years 
(QAL Ys) were calculated by multiplying the resulting utility scores by the 
number of life years remaining for each subject (using survival data from 
interim life tables produced by Trent Regional Health Authority for the years 
1993-95). 
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Table 50 Calculation of EQ-5D utility scores. 
EuroQol dimension 
Mobility 
Self-care 
Usual activity 
Pain / discomfort 
Anxiety / depression 
Full health = 1 
Example: health state 1 1 2 2 3 
Utility score: 
Level 2 
0.069 
0.104 
0.036 
0.123 
0.071 
Constant for any 
dysfunctional state: 
subtract 0.081 
Level 3 
0.314 
0.214 
0.094 
0.386 
0.236 
Any dimension scoring 3: 
subtract 0.269 
l(full health) - O.081(constant) - 0.036 (usual activity) - 0.123 (pain) - 0.236 (anxiety) -0.269 
(constant for level 3) = 0.255 
4.2.4 Costs included in the cost analysis 
Three Inain categories of costs were included in the economic analysis: 
1. Direct treatment costs - costs incurred by the treatment programmes. 
2. Medical costs - secondary and primary care. 
3. Costs to patients / family - costs associated with accessing health services 
(e.g. travel costs, prescriptions and OTC drugs) 
Other costs (e.g. p rsonal costs of treatment provision and indirect costs) were 
'amin d in a qualitati I11ann r. 
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4.2.5 Definition of costs 
All costs are reported in £ sterling at 1996 prices. 
4.2.5.1 Direct cost of treatment provision 
Treatment costs were based on frequency data collected during the trial and 
excluded research costs. This was a pragmatic study, the aim of which was to 
deliver realistic treatment programmes with a minimum of input from health 
professionals. 
Treatment sessions were approximately 45 minutes (including travel time) for 
the exercise groups and 2 minutes per call (8 minutes for 1 st calls) for the 
telephone support groups. Exercise participants were given an instruction 
booklet and a rubber exercise band (ClinibandTM). Depending on subsequent 
muscle strength readings, stronger bands were issued at later visits and 
damaged bands were replaced. 
Exercisers were visited in their own homes and received 7 visits over the two-
year period (4 times in the first two months and then once at 6, 12 and 18 
months). Subjects in the social support group received monthly calls 
throughout the two-year period. Allowance was made for the consequences of 
study attrition in subsequent analysis (actual exercise yisits, x = 5.--1-; telephone 
calls, x = 15.2). 
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Overheads were included in the hourly labour rate to produce a total hourly rate 
(including salary, salary on-costs, indirect overheads and capital overheads) 
(Netten and Dennett, 1996). This resulted in an under-representation of 
overheads for the telephone support programme since limited client-contact 
time was involved per person. Nevertheless, the degree of bias was small and 
should have been compensated for by the fact that telephone calls (normally 
included in overheads) were costed separately for the telephone intervention. 
For ease of comparison, personnel time for both exercise therapy and telephone 
support were based on physiotherapist pay-scales. Alternative costs (based on 
different personnel pay scales) were considered in sensitivity analysis. 
For the purposes of this study, labour costs were classified as variable costs. 
This meant that the marginal cost of treating one additional patient was 
represented by the ongoing treatment cost per person (i.e. total cost minus start-
up cost). Start-up costs were low for all treatment groups and would be 
reduced substantially further should a standard exercise programme be 
developed and disseminated nationwide. Costs incurred in the second year of 
the intervention programme were discounted by 5% in order to aid comparison 
with other studies. The impact of applying alternative discount rates (0% to 
10%) was explored in sensitivity analysis. 
The cost of delivering the placebo health food product was assumed to be its 
purchase price only, since its inclusion was for research purposes. 
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4.2.5.2 Personal costs of treatmen t provision 
Personal costs to the individual (loss of leisure time and adverse side effects of 
the exercise programme) were collected through patient questionnaires and 
have been documented in a qualitative manner. It was not felt appropriate to 
attach a monetary figure to these aspects of the programme. 
4.2.5.3 Medical costs 
The impact of study treatments on the degree to which subjects accessed 
medical services was explored through an examination of patients' GP notes. 
The protocol for the examination of notes has already been reported 
(Chapter 3). 
4.2.5.4 Personal medical costs 
Personal costs incurred by patients resulting from the need to access medical 
services were documented. Three types of costs were examined: 
i) prescription charges; ii) over-the-counter (OTC) drugs and iii) travel costs 
incurred whilst travelling to and from the health provider. Further discussion 
of these costs can be found in Chapter 3. 
4.2.5.5 Indirect Costs 
Costs associated with lost productivity were not of direct financial relevance to 
the current study because only 20/0 of the study popUlation had taken time off 
\\'ork due to knee pain at baseline. Given the small numbers in\'oh'Cd, any 
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possible change in work capacity would have been negligible. Nevertheless, 
change in work status has been described in a qualitative manner. 
4.2.6 U nit costs 
Unit cost and frequency of resource use are documented in Table 51 and 
Table 56 of the results section. Alternative costs may be applied as required. 
4.2.7 Data management 
4.2.7.1 General data management 
All data were entered onto a customised database (Microsoft® Access 97) and 
unit costs were applied in SPSS for Windows version 8.0 (SPSS Inc., Chicago, 
IL). Costs for each 6-month period were calculated separately, resulting in five 
individual cost periods as follows. 
Baseline costs: 
Period 1 costs: 
Period 2 costs: 
Period 3 costs: 
Period 4 costs: 
-6 months to 0 months 
o months to 6 months 
6 months to 12 months 
12 months to 18 months 
18 months to 24 months 
Data relating to the first 18 months were collected by two researchers alongside 
the intervention study. Due to time and financial constraints, data relating to 
the final 12-month period were collected as part of a separately funded project 
by 3 di ffcrent researchers. In order to ensure consistent results, training \\'as 
proyided along \\'ith regular monitoring sessions. Any bias that may have been 
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introduced by this process would have been equally distributed between the 
treatment groups. 
4.2.7.2 Total costs versus change in costs 
Costs included in the economic analysis represent total costs over the 2-year 
intervention period. Total costs were chosen rather than change in costs for 
two main reasons: 
a) It allowed the inclusion of all study data. Baseline costs were collected for 
a 6-month period only and change in cost calculations would therefore have 
been possible for two periods of six months only (period 2 and period 5). 
b) Total costs are potentially more informative to health policy decision-
makers. 
4.2.7.3 Handling of missing values 
The identification of medical resource use was not influenced by study attrition 
as details were collected through an examination of GP notes. However, data 
for the final 12-month period were unavailable for 101 (13%) individuals 
because either informed consent was not obtained in order to re-examine case 
notes, or the patients' notes were no longer available. Missing values for these 
individuals were carried forward from the previous period corresponding to the 
san1C tin1e of year (Rutten-van Molken et al. 1995; Rutten-van Molken et al. 
1994). This lneant that data for period 4 were obtained by carrying forward 
values from period 2. Likewisc, data for period 5 were taken from period 3. 
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Individuals without data for the final 12-month period were evenly distributed 
between the treatment groups and should not have impacted on subsequent 
between group comparisons. 
4.2.7.4 Handling of uncertainty 
Sensitivity analysis has been used to examine the implications of uncertainty 
surrounding frequency of resource use, unit costs and patient outcomes (Briggs 
and Sculper, 1995). In addition, confidence intervals provide an indication of 
the variability of patient-specific data for both costs and benefits. Confidence 
intervals have been reported using standard parametric tests. This was felt to 
be appropriate as recent authors have suggested that simple parametric 
techniques are more robust in handling skewed cost data than had previously 
been recognised (Thompson and Barber, 2000; Lord et al. 1999). 
Nevertheless, results were confirmed using non-parametric bootstrapping 
techniques for the final incremental cost-effectiveness analysis. 
4.2.8 Statistical analysis 
A significance level of 50/0 was employed throughout the study and confidence 
intervals were reported at the 95% level. An indication of clinical significance 
was addressed by using the NNT statistic as the measure of treatment efficacy 
(Cook and Sackett, 1 9 9 5 ~ ~ Laupacis et al. 1988). The NNT represents the 
number of patients who need to be treated in order to achieve a ~ ~ 500/0 
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improvement in self-reported knee pain at 24 months. For patient-specific 
outcome data, the change in WOMAC pain score was used. 
4.2.8.1 Power 
As is common with studies of this type, power calculations were performed 
using the primary outcome measure for the intervention study (reported in 
Chapter 2). However, cost data provide unique difficulties for statistical 
analysis, being highly variable, usually demonstrating a skewed distribution 
and having a large number of individuals with zero cost. Retrospective power 
calculations based on direct medical costs observed at 12 months suggested 
that the current study had only 34% power to detect an effect size of 0.12 in 
primary care costs (26% power for total medical costs) (nQuery Advisor 3.0). 
Whilst conclusions relating to the economic evaluation of this trial should be 
made with caution in the light of this low power (Briggs, 2000), these data 
represent an ambitious attempt to document the economic impact of exercise 
therapy. 
As the study had insufficient power to detect between group cost differences, 
the presentation of data for individual costs (direct intervention costs, medical 
costs and personal costs) was limited to descriptive statistics. Analysis of 
between group differences was presented for the combined cost and outcome 
data (lCERs) using non-parametric bootstrapping techniques to produce a 
distribution on the C/E plane and an 'acceptability curve' (Lothgren and 
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Zethraeus, 2000; Briggs and Fenn, 1998). It is hoped that the presentation of 
results in this way will provide meaningful and readily interpretable data for 
health policy decision-makers. 
4.2.8.2 Incremental cost-effectiveness analysis 
Incremental cost-effectiveness ratio (lCER) calculations were perfonned using 
the equations outlined overleaf. Two effectiveness measures were used; the 
first provides patient-specific data (change in WOMAC pain), the other 
provides a clinically relevant summary statistic based on group comparisons 
(NNT). The number needed to treat is based on a comparison of the 
intervention group and the no intervention control group. As such, it is already 
incremental in nature. Equally, the treatment costs incurred by the no 
intervention group were zero. Incremental treatment costs thus reflect the costs 
incurred by each group during the period of the trial. 
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Equation 5 Cost-effectiveness formulae for change in WOMAC pain (C=cost,· 
E=eJficacy; CIE = cost effectiveness ratio). 
C/E == C Intervention - C Control 
E Intervention - E Control 
Equation 6 Cost-effectiveness formulae for NNT (C=cost,· E=eJficacy,· CIE = 
cost effectiveness ratio,· NNT=number needed to treat,· 
NNT = liE Intervention _ E ControU. 
C/E== NNT X (C Intervention - C Control) 
4.2.8.3 Interpretation of leERs 
Ratio statistics such as those represented by incremental cost-effectiveness 
ratios (lCERs) present difficulties for standard methods of dealing with 
uncertainty (Briggs and Fenn, 1998). Various suggestions have been made in 
the health economics literature as to the most appropriate method to be used 
(Tanlbour et al. 1998; Briggs and Fenn, 1998; Chaudhary and Steams, 1996; 
van Hout et al. 1994; O'Brien et al. 1994). One of the simpler and more 
robust nlethods to have been discussed is the non-parametric bootstrap 
(Lothgren and Zethraeus, 2000; Efron and Tibshirani, 1993). This computcr-
i n t e n s i n ~ ~ technique in\'olvcs the repeated re-sampling of the original dataset 
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and does not require assumptions of normality (Johnston et al. 1999). 
Bootstrap estimates have been used in the current study to produce an 
'acceptability curve'. The resulting probability curve gives an estimate of the 
precision of the cost-effectiveness ratios and the probability that the ratio of 
costs and benefits falls within acceptable cost limits (Briggs and Fenn, 1998; 
van Hout et al. 1994). 
Non-parametric bootstrap techniques require patient-specific outcome data for 
both costs and benefits. As such, ratios have been presented using the change 
in WOMAC pain score rather than the NNT (which is a summary statistic). 
Since this change score results in a negative value for an improvement in knee 
pain, the resulting C/E plane is slightly different to that commonly reported in 
the literature (Figure 6). Using change scores as the measure of effectiveness, 
it is quadrant IV that represents an improvement in health outcome at some 
additional cost. This is usually represented by quadrant I on the C/E plane. 
Points presented on the resulting C/E plane are the result of the re-iterative 
process of the bootstrap technique; each point representing a new bootstrap 
sample. 
Bootstrapping is a 3-stage process. Firstly, a sample of patient-specific costs 
and outconle data is taken (with replacement) from the existing dataset. Mean 
cost and effecti\'cness estinlates are then calculated for the resulting sample. 
This process is repeatcd for each of the compared interYentions. Finally, the 
leER is calculated V'l cost I ~ ~ effect). Repeating this process many times 
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(usually> 1,000 times) produces a series of bootstrap estimates, which are an 
empirical estimate of the sampling distribution of the lCER statistic (Briggs 
and Fenn, 1998). From this data, it is possible to present confidence intervals 
for the lCER distribution (Briggs et al. 1997; Chaudhary and Stearns, 1996). 
However, it has been argued that a two-sided confidence interval is 
inappropriate for economic analysis when the appropriate hypothesis is one-
sided (i.e. what is the probability that the new intervention is not cost-
effective?) (Briggs and Fenn, 1998). The presentation of data as an 
'acceptability curve' resolves this issue and has the added advantage of 
quantifying the probability that an intervention is cost-effective across a range 
of potential ceiling values (Lothgren and Zethraeus, 2000). This intuitive 
manner of presenting cost data does not require the researcher to make 
assumptions on behalf of the health decision-maker, as the probability that an 
intervention is cost-effective is presented for a range of ceiling values, and the 
range of costs and benefits presented in the curve is dictated by the original 
dataset from which the bootstrap samples are drawn. 
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4.3 Results 
4.3.1 Cost of treatment provision 
4.3.1.1 Direct treatment costs 
Costs to the health provider for the two-year intervention period were £112 for 
the exercise programme, £61 for telephone support and £7 for the dolomite 
control group. Full details are tabulated (Table 51). For exercise therapy, the 
majority of costs were incurred during the first 6 months of treatment provision 
(representing 4 treatment visits). Subsequent periods incurred comparable 
costs to those of the telephone intervention. 
4.3.1.2 Personal costs 
Personal costs incurred as a result of direct treatment provision were limited to 
the opportunity costs of time spent in therapy for all treatment groups. For the 
exercise groups this was up to 20 minutes per day (depending on treatment 
adherence) and for the telephone support groups approximately 2 minutes per 
month. All necessary equipment was provided for the exercise programme and 
treatments were delivered to subjects in their own homes. It has not been 
possible to attach a monetary figure to the opportunity cost of time spent 
exercising (particularly as many volunteers reported exercising whilst 
perfom1ing other activities). Details have been documented in a qualitative 
manner only (Table 52). 
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Table 51 Summary of 2-year treatment costs by treatment type. 
Unit cost Year 1 Year 2* Total 
£ Units £ Units £ £/person 
EXERCISE 
Start-up costs 
Initial training 18 / hour 2 days 260.00 
Dev't of programme 18 / hour 1 month 2,730.00 
Start-up cost / person 6.35 
Ongoing costs / 
person 
Personnel - treatment 18/ hour 3hr 22 min 58.05 49 .5 min 14.10 
Personnel - admin 18/ hour Ihr 10 min 21.00 17 min 4.85 
Travel 0.37 / mile 8.6 miles 3.18 2.2 miles 0.77 
Equipment 
Booklet 0.30 each 1 booklet 0.30 o booklets 
Exercise band 1.76/ m 2.1m 3.70 O.lm 0.17 
Total £ / person 92.58 19.89 112.47 
TELEPHONE 
Start-up costs 
Initial training 18 / hour 1 day 130.00 
Start-up cost / person 0.33 
Ongoing costs / 
person 
Personnel - phone 18 / hour 20.4 min 6.12 16 min 4.56 
contact 
Personn I - admin 18 / hour Ihr 27 min 26.10 1 hr 20 22.80 
mm 
Telephone charges 0.04 / min 20.5 0.82 16 min 0.60 
Total £ / person 33.37 27.96 61.33 
PLA EBO-
DOLOMITE 
Tablet co t 1.69 / bottle 2 bottles 3.38 2 bottles 3.20 
Total £ / per on 3.38 3.20 6.58 
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Table 52 Personal time costs incurred by subjects in the exercise programme. 
Time taken per n < 10 minutes 10 -20 minutes > 20 minutes 
seSSIOn {%2 (%2 {%2 
1 st 6 months 317 57 (18) 145 (46) 115 (36) 
2nd 6 months 235 51 (22) 114 (48) 70 (30) 
3rd 6 months 207 46 (22) 92 (44) 69 (33) 
Days per week n 5 to 7 days 3 to 4 days < 3 days (%2 (%2 {%2 
1st 6 months 334 237 (71) 43 (13) 54 (16) 
2nd 6 months 266 181 (68) 29 (II) 56 (21) 
3rd 6 months 227 161(71) 24 (11) 42 (18) 
From an examination of patients' GP notes, adverse effects relating to the 
exercise programme were noted in 9 consultations during the 1 st year (positive 
effects being reported during one visit). 
4.3.2 Medical costs 
4.3.2.1 Baseline medical costs 
Baseline medical costs were documented in Chapter 3. Costs by treatment 
group at baseline are documented in Table 53. As is common with cost data, 
relatively high variation exists between the treatment groups. This is 
paliicularly so for hospital costs. Mean hospital costs in the exercise only 
group wer high because a single outlier incurred costs of £24 400. Hospital 
costs incurr d by the no intervention group were low compared to the other 
group (x = £ .5). 
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Table 53 Baseline medical costs by treatment group. 
GP COSTS 
Group Mean (s.d.) Median 1st quartile 3rd quartile Max 
{£} {i) {£} {£} {£} 
Ex & Tel (n = 117) 23 .56 (26.5) 20.00 0.00 39.00 130 
Ex, Tel & Dol (n = 109) 30.17 (31.8) 20.00 10.00 50.00 170 
Exercise (n = 226) 30.20 (33.7) 20.00 10.00 41.25 178 
Telephone (n = 154) 28.58 (30.5) 22.50 0.00 40.00 180 
Dolomite (n = 77) 27.38 (28.0) 20.00 10.00 35.00 140 
Nothing Cn = 762 28 .36 (27.8} 20.00 10.00 40 .00 130 
PRESCRIBED DRUG COSTS 
Group Mean (s.d.) Median lst quartile 3rd quartile Max 
{£} {£} {£} {£} {i) 
Ex & Tel (n = 117) 70.60 (107 .0) 26.01 4.32 109.53 604 
Ex, Tel & Dol (n = 109) 83 .21 (128 .2) 38.72 4.86 105.41 750 
Exercise (n = 226) 74.43 (120 .7) 30.28 4.33 101.51 95 1 
Telephone (n = 154) 78.42 (150.3) 29.06 5.07 75 .84 1,200 
Dolomite (n = 77) 69.89 (99.6) 34.43 9.04 66.15 513 
Nothing Cn = 762 69.70 ( 1 1 1 . 0 ~ ~ 24.52 5.20 75 .35 752 
HOSPIT AL COSTS 
Group Mean (s.d.) Median 1st quartile 3rd quartile Max 
{i) {i) {i) {£} {£} 
Ex & Tel (n = 117) 125 .9 (510.3) 0 0 188.40 3,960 
Ex, Tel & Dol (n = 109) 148 .5 (393.8) 0 0 560.00 2,340 
Exercise (n = 226) 235 .0 (1,682) 0 0 146.00 24,400 
Telephone (n = 154) 99.01 (345 .5) 0 0 140.00 2,340 
Dolomite (n = 77) 114.1 (323 .5) 0 0 256 .00 1,800 
Nothing ~ n n = 762 68.50 (369.6) 0 0 80.00 3,100 
TOTAL MEDICAL COSTS 
Group Mean (s.d.) Median lst quartile 3rd quartile Max 
{£} {£} {£} {£} {£} 
& Tel (n = 117) 220.0 (577 .3) 74.56 14.13 173.04 4,619 
, Tel r Dol (n = 109) 261.9 (459.0) 110.64 29.44 196.01 2,645 
E, erci e (n = 226) 339.6 (1,744) 79.16 26.64 212 .77 25,366 
T 1cphone (n = 154) 206 .0 (390 .7) 75.62 21 .79 194.69 2.393 
I mite (n = 77) 211. (356.7) 7 .77 35.46 193 .20 1,856 
thing {n = 7 ) 166.6 {407 .6) 74.0- 21.59 150.36 3,331 
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4.3.2.2 Medical and societal costs incurred during the trial 
Total primary care costs were almost £342,000 for the 24-month treatment 
period, with a mean cost of £450 per person. The inclusion of hospital costs 
resulted in an almost three-fold increase to just over £960,000 (x = £1 ,266). 
Summary details are tabulated (Table 54). Costs incurred during year 2 were 
discounted by 5%. 
Table 54 Summary of medical and societal costs incurred during the trial 
period. 
n = 759 Year 1 Year 2* 24 Months 
PRIMARY CARE COSTS 
(GP + GP prescribed drugs) 
Total 168,750 173,108 341 ,85 8 
Mean (s.d.) 222 (278) 228 (280) 450 (548) 
Median 135 137 274 
TOTAL MEDICAL COSTS 
(Primary + secondary care costs) 
Total 480,896 479,724 960,619 
Mean (s .d.) 634 (2,004) 632 (1,889) 1,266 (3,688) 
Medi an 206 2 16 478 
OCIETAL COSTS 
(Total medical costs + personal costs) 
To tal 503 ,51 4 50 1,511 1,005 ,025 
Mean ( .d. 663 (2,01 1) 661 ( I 95) 1,324 (3 699) 
Med ian _30 242 554 
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4.3.2.3 Impact of study interventions on medical costs 
Between group differences in medical costs at 24 months are presented in 
(Table 55). In addition to mean costs, median and maximum values are 
presented for interest. The extremely high maximum values for hospital costs 
in the 'exercise only' and the 'dolomite' groups reflect the cost of treating two 
individuals who required intermittent inpatient care throughout the 24-month 
period. 
Table 55 Medical costs by treatment group over 24 months. 
GP COSTS (£) 
Group Mean Mean 95% CI Median Max (s.d.) difference* 
Ex & Tel (n = 117) 107 (80) -14 -58 ,29 88 384 
Ex, Tel & Dol (n = 109) 126(134) 5 -39,49 88 816 
Exercise (n = 226) 118(110) -3 -42,36 89 712 
Telephone (n = 154) 112 (96) -9 -50,32 86 519 
Dolomite (n = 77) 105 (75) -1 6 -64,3 1 78 274 
Nothing (n = 76) 121 (98) 93 435 
GP PRESCRIBED DRUG COSTS (£) 
Group Mean Mean 95%CI Median Max 
(s.d.) difference* 
Ex & Tel (n = 117) 297 (400) -76 -286, 134 158 2,872 
Ex, Tel & Dol (n = 109) 372 (569) -1 -214 ,212 206 3,777 
E ercise (n = 226) 331 (431) -42 -231,146 169 2,513 
Telephone (n = 154) 341 (589) -32 -232, 167 124 4,194 
Dolomite (n = 77) 307 (384) -66 -296, 164 163 1,68 1 
Nothing (n = 76) 373(612) 156 3,415 
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Table 55 (continued). 
SECONDARY CARE COSTS (£) 
Group Mean Mean 95% CI Median Max 
(s.d.) difference* 
Ex & Tel (n = 117) 827 (1,972) 238 -1,254,730 40 9,900 
Ex, Tel & Dol (n = 109) 896 (2,020) 307 -1,207,820 82 13,098 
Exercise (n = 226) 737 (2,899) 148 -1,195,491 78 39,238 
Phone (n = 154) 557 (1,260) -32 -1,452, 1,388 40 7,644 
Dolomite (n = 77) 1,653 (9, 165) 1,064 -574,2,70 1 78 80,223 
Nothing ~ n n = 762 589 (11 562 100 5,040 
PRIMARY CARE COSTS (£) 
Group Mean Mean 95%CI Median Max 
{s.d.} difference* 
Ex & Tel (n = 117) 404 (446) -90 -321, 140 287 3,241 
Ex, Tel & Dol (n = 109) 498 (653) 4 -230,238 332 4,121 
Exercise (n = 226) 449 (480) -45 -253, 162 262 2,744 
Phone (n = 154) 452 (628) -42 -261, 178 265 4,276 
Dolomite (n = 77) 41 2 (4 14) -82 -335, 171 263 1,749 
Nothing {n = 762 494 (660) 265 3,522 
TOT AL MEDICAL COSTS (£) 
Group Mean Mean 95%CI Median Max 
{s.d.} difference* 
Ex & Tel (n = 11 7) 1,23 1 (2,208) 147 -1,401,1,696 478 13,071 
Ex, Tel & Dol (n = 109) 1,394 (2,387) 310 -1,261, 1,881 470 14,200 
Exercise (n = 226) 1,186 (3,101) 103 -1 ,29 1, 1,496 494 41,738 
Phone (n = 154) 1,009 (1,499) -74 -1 ,547,1,400 433 7,754 
Do lom ite (n = 77) 2,065 (9, 154) 982 -718,2,682 501 80,377 
Nothing ~ n n = 762 1,083 (1,5832 527 8,312 
... Mean difference calculated using no in tervention control group as comparator. 
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4.3.2.3.1 Analysis by factor 
Between group comparisons were repeated by factor (exercise, telephone and 
dolomite), with similar results (Figure 18). 
Figure 18 Mean societal costs by treatment type (exercise, telephone and 
dolomite) 
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A breakdown of unit of resource use and total costs are tabulated for the 
exercise and non-exercise groups (Table 56). Subjects in the exercise groups 
incurred marginally lower costs than those in the non-exercise groups: -£3 for 
total prin1ary care costs, -£45 for total medical costs and -£50 for societal costs. 
Since these differences were minilnal and had extremely wide confidence 
lnt rvals cost-effectiveness analysis was based on direct costs of treatment 
pr ision only. Medical costs were subsequently included in a secondary 
an 1 sis to produce an ace ptability curve' based on re-sampl d bootstrap data 
L thor nand Z thr u, _000· 11 Hout t al. 1 4). 
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Table 56 Frequency a/resource use and total medical costs over the 24-month 
study period - exercise versus non-exercise (costs in year 2 discounted by 5%). 
Unit cost Unit Total cost (£) Unit Total cost (£) 
£ resource Exercise resource Non-exercise 
use n =452 use n=307 
GP COSTS 
Consultations 10 4,084 39,825 2,681 26,137 
Telephone contact 5 53 258 28 137 
Investigations / 5 1,275 6,209 916 4,449 
treatments 
X-rays 9 per joint 157 1,373 112 977 
Domicilliar;r visits 30 179 5,243 96 2,802 
TOTAL 52,908 34,503 
Mean (s.d.) 117 (110) 112 (92) 
Median 89 88 
SECONDARY CARE COSTS 
Inpatient I st day 500 149 277,830 84 203 ,310 
Inpatient subsequent 300 
days 
Days in ICU 1,000 1,000 2 1,950 
Daycase surgery 480 56 26,160 30 13 ,968 
Outpatient new 100 224 21,845 163 15,880 
referral 
Outpatient follow-up 40 813 31,680 550 21 ,408 
A&E 42 58 2,402 33 1,350 
TOTAL 360,917 257,866 
Mean (s.d.) 799 (2,485) 840 (4,712) 
Median 77 78 
GP PRESCRIBED DRUGS 
NSAlDs x (s.d.) 15,558 (34.42) 10,401 (33.88) 
Topical rubs / gels X (s.d.) 2,695 (5.96) 2,120 (6.91) 
nalgc ics X (s.d.) 5,591 (12.37) 3,414 (11.12) 
a trointestinal drugs 20,324 (44.97) 14,804 (48.22) 
x ( .d.) 
Othcr al1hritis relat d 987 (2.18) 761 (1,4 ) 
drug X ~ ~ .d.2 
TOTAL ARTHRITI DR G 45,154 31 500 
I\lean { .d.} 100 {I 2} 103 {22_) 
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Table 56 (continued). 
Total cost (£) Total cost (£) 
Exercise Non-exercise 
TOTAL UNRELATED DRUGS 104,855 72,938 
Mean (s.d.) 232 (376) 238 (460) 
TOTAL DRUGS 150,010 104,439 
Mean {s.d.} 332 {461} 340 (550} 
TOTAL PRIMARY CARE COSTS 202,917 138,941 
Mean (s.d.) 449 (519) 453 (598) 
Median 285 265 
TOT AL MEDICAL COSTS 563,830 396,790 
Mean (s.d.) 1247 (2,725) 1,293 (4,770) 
Median 480 477 
TOTAL SOC lET AL COSTS 589,270 415,755 
(Medical + personal costs) 
Mean (s.d.) 1,304 (2,744) 1,354 (4,773) 
Median 532 568 
4.3.3 Indirect costs 
Only 18 (2.3%) subjects reported having taken time off work due to knee pain 
at baseline. By 24 months this figure had fallen to 8 (1.2%) and was evenly 
distributed between the 6 treatment groups. It is most likely that any reduction 
reflected a change in work status and the consequences of study attrition rather 
than the direct consequences of treatment provision and indirect costs were not 
therefore included in the cost-effectiveness analysis. 
4.3.4 Incremental cost-effectiveness analysis 
Th prin1ary co t- fD cti n ss m asure was based on costs and outcomes 
hi at ~ 4 4 months . T\ incr n1ental ratios are presented . The first is 
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based on the cost of achieving a one-point reduction on the WOMAC pain 
scale and the second is based on the NNT statistic (Table 57). Costs incurred 
by the combined intervention groups reflect the provision of multiple 
treatments. As a result, the cost of providing the exercise programme in 
isolation is best estimated from the exercise only group; amounting to £108 per 
unit change on the WOMAC pain scale or £1,024 per patient showing a ~ 5 5 % %
improvement. The provision of dolomite tablets was consistently the most 
cost-effective form of treatment, costing just £129 to achieve at least a 50% 
reduction in pain (a reflection of the extremely low costs incurred by this 
intervention, rather than superior efficacy). 
Table 57 Incremental cost-effectiveness ratios based on WOMAC pain and 
NNT scores at 24 months, figures rounded to nearest whole pound). 
Group 1 
Exercise & 
Telephone (n= 121) 
Group 2 
Ex, Tel & 
Dolomite (n= 114) 
Group 3 
K ercis (n=235) 
r up 4 
T 1 phon (n=160) 
roup 5 
Dolomit (n=78) 
roup 6 
N int rv ntion 
(11=7 ) 
Direct L\ 
treatment WOMAC 
cost (£) pam 
173 .80 1.49 
180.38 1.07 
112.48 1.04 
61.33 0.45 
6.58 0.75 
f fA 
CIE ratio * 
WOMAC 
pain (£) 
117 
169 
108 
136 
9 
NfA 
NNT 
~ 5 5 % %
7.7 
12.7 
9.1 
25.5 
19.6 
fA 
* 0 t f n hieving a one point impro\ ment on the \ OM C pain score. 
CIE ratio# 
NNT (£) 
1,338 
2,291 
1,024 
1,564 
129 
NfA 
# t of hic\ ing Ilni all meantngfullmprovement 10 at lea tone mdJ\,idual compared with the no 
lntcr\'cntl n ontr I group. 
o 1 ~ ( C « \ W W
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4.3.5 Acceptability curve 
Point estimates for the lCER presented thus far are based on direct intervention 
costs only. In order to assess the importance of medical and personal costs and 
to provide an indication of the variability of the dataset, all costs were included 
in a subsequent bootstrap analysis. This analysis is based on a comparison of 
WOMAC change in pain scores for the exercise only group (group 3) 
compared with the no intervention control group (group 6). A negative effect 
score represents a reduction in knee pain, and therefore an improvement 
overall. Estimates of incremental cost-effectiveness resulting from the 
bootstrap analysis are presented on the C/E plane below (Figure 19). 
Figure 19 Cost-effectiveness plane (showing bootstrapped ICERs) 
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Clearly, the majority of the new ICER estimates fall within quadrant IV 
(79611 000). These represent estimates whereby the intervention produces 
additional health benefits, but these are achieved at a greater cost. The number 
of points in each of the four quadrants is used to calculate the' acceptability 
curve' (Figure 20). This curve intersects with the y-axis at 0.2, suggesting that 
there is a 20% chance that the programme could deliver a one-point 
improvement in knee pain at no additional cost. However, with an investment 
of approximately £500 per unit of effect, the probability of a successful 
outcome is increased to 800/0. 
Figure 20 Acceptability curve (exercise only compared with no intervention 
control). Based on total societal costs and change in WOMAC pain. 
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4.3.6 Sensitivity analysis 
Sensitivity analysis was performed in order to test a range of assumptions 
relating to both the costs and consequences of the study treatments. ICERs are 
presented based on the NNT as the unit of outcome. 
4.3.6.1 Sensitivity analysis - costs 
For the sake of clarity, cost comparisons were based on comparison of the 
exercise only group (Group 3) with the no intervention control group 
(Group 6). 
Personnel costs represented the single most important factor in determining 
direct treatment costs. Cost-effectiveness estimates were based on 
physiotherapy pay-scales. This could have led to a potential over-estimation of 
the actual implementation costs if physiotherapy assistants implemented the 
programme. The use of physiotherapy assistants would reduce the 2-year 
implementation costs from £113 per person to £71. 
A further source of uncertainty is the potential impact of the treatment 
interventions on subsequent medical costs. Sensitivity analysis was used to 
explore the impact of a change in primary care costs. Results of the current 
study were limited by lack of power and confidence intervals for the mean 
di ffcrence in costs show wide \'ariation ranging from a saving of £253 to an 
additional cost of {162. 
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4.3.6.2 Sensitivity analysis - benefits 
Participation in the current study was the result of active recruitment following 
completion of a postal questionnaire. Upon wide-scale implementation, the 
programme would be delivered to knee pain sufferers who presented to their 
GP. In order to explore the possible impact of this, results relating to 
individuals who consulted their GP for knee pain in the 6 months prior to 
participation in the study where analysed separately (n = 217). Comparison of 
exercise and non-exercise groups for those attending surgery showed a large 
difference in effect size (0.51 versus 0.10). This meant that the NNT for the 
self-referred group was 6.1 with a corresponding C/E ratio of £686. 
A factor with the potential to impact both costs and benefits is that of treatment 
adherence. As reported in Chapter 2, effect sizes for those volunteers who 
adhered well to the programme were considerably higher than for those who 
did not (0.42 versus 0.16). Direct treatment costs were higher for those 
completing the programme because all 7 treatment visits were delivered. 
Nevertheless, the additional cost of these visits was compensated for by 
improved outcomes (NNT = 6). In the absence of data relating to the number 
oftreatnlent visits received by the low adherence group, sensitivity analysis 
assunled that an average of three out of the 7 treatment visits were delivered. 
This would result in a cost per person for the low adherence group of 
approximately £77 and a C/E of £ 1 ,632. 
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Finally, baseline pain was found to be a strong predictor of improvements in 
knee pain at 24 months. The potential impact of baseline pain levels on 
subsequent C/E ratios was explored using 3 categories of pain (tertiles). Those 
individuals who scored 5 or less for WOMAC pain at baseline (range 0 - 20) 
were less likely to report improved outcomes at 24 months (NNT = 19). By 
contrast, those with baseline pain scores greater than 9, were more likely to 
benefit from the exercise programme (NNT = 8.6). 
Whilst these effects have been reported separately, it should be recognised that 
their effects are not mutually exclusive. Rather, they may be seen as possible 
indicators of symptomatic knee pain. It is possible that an individual with 
severe pain would be more likely to consult their GP for treatment and may 
also be more likely to adhere to the exercise regime once implemented. 
Given that a total knee replacement operation costs approximately £5,000, it 
would appear that the exercise programme provides a cost-effective addition to 
the n1edical management of knee pain. Variation of the above parameters 
largely resulted in modest changes to C/E ratios. The largest change was 
elicited by a possible change in primary care costs based on the upper 95% CI 
(resulting in increased costs of £ 162 per person). Even this extreme case 
resulted in a C/E ratio of just £2,500. Threshold analysis suggested that the 
di reel costs for provision of the exercise progran1me would have to increase to 
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£550 per person or the NNT increase to 44.5 in order produce CIE ratios 
comparable to the direct cost of surgery. 
Table 58 Sensitivity analysis. 
Source of 
uncertainty 
Min. value Max. value Value used Min. CIE 
ratio 
(£/person) 
Max. CIE 
ratio 
(£/person) 
Uncertainty in 
costs* 
Personnel costs 
!:1 primary care costs 
Discount rate: 
Costs 
Uncertainty in 
benefits+ 
Self referred 
patients (n = 217) 
Treatment 
adherence 
Basel ine pain 
Physio. 
Assistant 
(£ 1 0. 5 Olhr) 
Lower c.r.# 
(-£253) 
0% 
NNT = 6.1 
Low 
adherence 
NNT = 21.3 
Cost/person 
£76.64 
WOMAC 
pain <5 
NNT= 19 
# Upper c.r. 
(£162) 
10% 
High 
adherence 
NNT=6 
Cost/person 
£142.21 
WOMAC 
pain >9 
NNT= 8.6 
Physio. 
(£18.00/hr) 
Not used 
5% 
All subjects 
NNT= 12.6 
Actual 
adherence 
NNT = 12.6 
Cost/person 
£112.48 
All subjects 
NNT = 12.6 
£ 647 
(£ 71.14) 
-£ 1,279 
(-£140.52 ) 
£ 1,033.03 
(£ 113.52) 
£686 
(112.48) 
£1,632 
(£76.64) 
£2,137 
(£112.48) 
* IE ratios for costs based on comparison of group 3 (exercise) versus group 6 (no intervention) 
IE = £ 1,024) . Effectiveness based on NNT for ~ ~ 50% improvement at 24 months (9.1 people). 
# 95 % .r. for mean difference in primary care costs . 
+ IE ratios for benefits based on a comparison of combined exercise and non-exercise groups. 
£ 2,498 
(£ 274.48) 
£ 1,014.01 
(£ 111.43) 
£853.26 
(£142.21) 
£967 
(£112.48) 
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4.3.7 Cost-utility analysis 
No differences were observed between the exercise and the non-exercise 
groups in quality-adjusted life-years (QAL Ys) at either 6 or 24 months (Table 
59). QAL Y scores for the two groups were so similar that cost-utility analysis 
was not performed and the resulting analysis becomes one of cost-
minimisation. The exercise therapy was provided at an additional cost of £113 
per person treated (direct treatment costs) and was therefore less cost efficient 
than normal care in producing improvements in quality-of-life. 
Table 59 Change in QALYat 6 and 24 months (exercise versus non-exercise). 
QALYs Baseline Mean Ll Mean 95% C.I. 
QALY difference mean 
difference 
6 months 
Exercise 12.93 0.75 -0.17 -0.72,0.38 (n = 452) 
Non-exercise 12.56 0.92 (n = 307 ) 
24 months 
Exercise 12.93 0.61 -0.09 -0.83,0.63 (n = 452) 
Non-exercise 12.56 0.70 (n = 307 ) 
The above QAL Y scores were derived from 5 domains, each with a range from 
1 to 3. As anticipated baseline scores revealed difficulties with pain, mobility 
and acti iti s of daily. Hower, between group comparisons re ealed no 
di ffl r n in chano scores b tv een the x rcise and non-e ercise group at 24 
111 nth Ii r an f th 5 don1ain (T ble O. 
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Table 60 EQ-5D domains at 24 months - exercise versus non-exercise 
Baseline Mean 11 from Mean 950/0 CI mean 
mean (s.d) baseline difference difference 
Mobility 
Exercise 1.63 (0 .5) -0.05 -0.04 -0.11 , 0.05 
Non-exercise 1.61 (0.5) -0.01 
Self-care 
Exercise 1.12 (0.3) 0.04 0.03 -0.02, 0.08 
Non-exercise 1.12 (0 .3) 0.01 
Usual activities 
Exercise 1.59 (0.5) -0.09 -0.08 -0.15 , 0.02 -
Non-exercise 1.60 (0 .5) -0.01 
Pain 
Exercise 2.05 (0.3) -0.10 0.01 -0.07, 0.09 
Non-exercise 2.09 (0.4) -0.11 
Depression 
Exercise 1.38 (0 .5) -0.02 0.02 -0.05 , 0.1 
Non-exercise 1.39 (0.5) -0.04 
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4.4 Discussion 
4.4.1 Main findings 
The direct cost of the 2-year exercise programme was £112 per person. The 
majority of this amount was incurred during the initia16-month training phase 
of the programme. Subsequent visits were principally designed to encourage 
continued participation and to ensure that the exercises were performed 
correctly. The relative benefits of a home-visit every six months versus 
monthly telephone contact are difficult to assess from this trial. However, it is 
conceivable that both could have fulfilled a similar role. Data from the trial 
suggested that similar resource use was intrinsic to both modes of treatment 
provision in later months. 
The direct treatment cost of the 2-year telephone intervention was roughly half 
that of the exercise programme. The very low cost of this intervention has led 
to claims of cost-effectiveness by other researchers (Weinberger et al. 1993). 
However, efficacy data from the current trial failed to show a significant 
improvement in health status. Similarly, the benefits observed from the use of 
the placebo health food product were non-significant and the cost-effectiveness 
ratio should therefore be treated with caution. The apparent cost-effectiveness 
of this product is the result of its very low cost (£6.58 for 2 years) rather than 
any significant clinical improven1ent in knee pain. 
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Whilst a monetary value was not attached to the opportunity cost of time spent 
exercising, the importance of the individual burden incurred by exercise 
therapy should not be ignored. The majority of subjects reported spending 10 
to 20 minutes on the exercises, an average of 5 to 7 times per week. Lack of 
time or motivation was cited as a major reason for failure to continue with the 
exercise programme and it is therefore an important factor in determining the 
efficacy of the programme. Of those subjects who continued to exercise 
throughout the 24-month period, the majority reported having built the exercise 
programme into their daily routine. This included performing the exercises 
alongside existing routines (e.g. after bathing), or whilst performing other 
activities (e.g. watching television). 
Provision of the study interventions did not result in a change in either total 
medical costs or primary care costs during the period of the study. However, 
the wide variability of the economic data and low power of the study meant 
that findings were difficult to interpret. 
Of possibly greater significance is the importance of personnel costs in 
detennining the overall cost of the programme. It is not within the remit of this 
study to make policy decisions regarding the wider implementation of exercise 
therapy. Nevertheless, it is noteworthy that this programme was implemented 
quickly and safely as a home-based exercise programme by non-specialist staff. 
\Vhilst better eligibility screening by a trained physiotherapist may result in 
improved outcomes, implementation and subsequent follo\y-up could be 
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conducted by physiotherapy assistants or district nurses. This may be 
especially true for follow-up visits, when the primary focus would be on 
general advice and encouragement. It is equally true that treatment sessions 
could be delivered from GP surgeries or hospitals, rather than as home visits. 
In effect this would transfer the time and expense of travel from the health 
provider to the patient. Whether or not this would impact on treatment 
adherence is impossible to tell from the current study. 
The cost implications of continued treatment adherence are of interest. The 
degree to which patients adhere to the programme has implications for both 
costs and consequences. In sensitivity analysis, the additional costs incurred by 
a fully compliant population were compensated for by the fact that the NNT 
was correspondingly lower (NNT = 6 versus 9). However, given the intensive 
nature of exercise therapy, improved adherence with the programme is unlikely 
to be achieved with ease. 
Presentation of the patient-specific cost-effectiveness data as an 'acceptability 
curve' allows policy decision-makers to assess their willingness to implement 
the programme assuming a variety of ceiling limits. Data from the trial 
suggested that there was an 80% probability that the exercise programme 
would be cost-effective (compared to normal care), with an investment of £500 
per unit of effect. Gi yen the high prevalence of self-reported knee pain in the 
community, this could represent a substantial burden. Further work may be 
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necessary in order to assess those patients most likely to benefit from the 
programme. 
4.4.2 Comparison with other studies 
Economic evaluation of exercise therapy is still relatively rare. None of the 
efficacy studies discussed to date included concurrent economic analysis. Full 
economic evaluation includes consideration of all costs and consequences 
resulting from a given intervention. However, given the paucity of data in 
relation to exercise therapy for knee OA, comparison of current findings with 
average published treatment costs is possibly more informative. The 2-year 
exercise programme implemented by this study incurred direct treatment costs 
of £112 per person (1996 £ sterling). A course of hospital-based physiotherapy 
typically cost £150 per person in the same year (Netten and Dennett, 1996). 
Whilst little has been reported on the relative efficacy of hospital physiotherapy 
compared to home-based exercise, two studies have reported that the observed 
improvements were comparable (Green et al. 1993; Chamberlain et al. 1982). 
More importantly, the exercise programme assessed in the current study 
represented treatment costs over a 2-year period. By comparison, hospital 
physiotherapy is generally short-term in nature, with very little long-term 
follow-up. As previously discussed, adherence with an exercise programme 
generally dinlinishes once regular contact is withdrawn (Sullivan et al. 1998; 
Chamberlain et al. 1982). As a result, the direct costs of the current 
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intervention (which resulted in continued exercise adherence in approximately 
40% of subjects) is low compared to hospital care. 
One study to have reported a change in medical costs resulting from exercise 
therapy compared individual home exercise and group exercise therapy for the 
treatment of ankylosing spondylitis (Bakker et al. 1994). Medical costs were 
reduced for both treatment groups over the 9-month treatment period, 
(individual exercise by 35% and group therapy by 44%). However, baseline 
costs were based on self-completion questionnaires requiring recall of medical 
resource use during the preceding year. Any assessment of baseline costs may 
therefore have been subject to recall bias. Since the study included no control 
group, it was not possible to quantify this effect. In addition, cost-effectiveness 
analysis was based only on those subjects who completed a 'cost diary' 
throughout the 9-month period. This represented 77% of the initial sample and 
may have introduced further bias. 
The cost-effectiveness of social support has been more widely addressed. 
Weinberger et a1. (1993) presented cost-effectiveness data relating to the 
provision of regular telephone support to patients with osteoarthritis. This 
study reported telephone support to be highly cost-effective, although no 
change in medical costs was observed. It is noteworthy that the direct 
treatment costs for the study were extremely low (S 14.88 per patient per year). 
This \\'as lowcr than figures reported by the current study; largely because of 
the dramatically diffcrent personnel costs ($6 per hour versus f 18 per hour). 
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Direct comparison is difficult as the costing year was not explicitly stated in the 
Weinberger study. 
A further study to examine the impact of social support on health care resource 
use reported reduced medical costs compared to a no-intervention control 
group (Cronan et al. 1997a). This significant result represented a remarkable 
increase in health care costs for the control group of almost 100% in year one 
and of 1120/0 in year 2 (n =86). These dramatic increases were explained by 
differences in the number of days in hospital between the control and the 
intervention groups (the mean number of days for the control group increased 
from 0.05 to 1.15, whilst the mean for the experimental group increased from 
0.23 to 0.55). Caution should be used in interpreting such cost data, since they 
are based on very high cost but low frequency events. In addition, it is 
important to note that social support consisted of weekly group meetings 
designed to promote empathy and the sharing of coping techniques. This was 
clearly very different to the social support provided through the telephone 
intervention of the current study. 
A more widely investigated programme is that of the Arthritis Self-
Management Programme (ASMP). This is a broad cognitive-behavioural 
progran1me that seeks to effect behavioural change. Several studies have 
reported this progran1n1e to be cost-effective (Kruger et al. 1998; Barlow et al. 
1997: Lorig et al. 1993b). It is reported to reduce health care c o s t s ~ ~ with 
possible reductions in physician visits by as much as 40° 0 (Lorig et al. 1993b). 
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However, these studies usually report relatively high service use at baseline 
(average of 8 to 9 GP visits per year for patients with OA). This is higher than 
rates found in the current study, where the average number of GP visits for the 
6-month baseline period was 2.2 (arthritis related visits accounted for only 0.5 
visits per person). Whilst different study populations could partially account 
for such differences, it is also likely that the conflicting results reflect the very 
different health care system available in the USA. 
The potential impact of the ASMP in a UK population was examined by 
Barlow et a1. (1998). This study reported similar baseline resource use to that 
observed in the Lorig investigation (GP visits over the baseline 4-month period 
were 2.7 per person - equivalent to 8.1 visits per year). However, almost 50% 
of the UK sample had a GP diagnosis ofRA; for whom medical costs are 
known to be high. In addition, short-term reductions in GP consultations were 
observed at 6 months, but these were not maintained at 12 months. The 
investigators pointed to the impact of free health care at point of delivery to 
explain the possible disparity between American and UK findings. 
A second UK based study examined the cost-effectiveness of a nurse-led 
education programn1e for the treatment of knee OA, delivered as 4 group 
sessions at local GP surgeries (Lord et a1. 1999). Outcomes were assessed at 
12 months and revealed no significant differences between the intervention and 
control groups in health outcomes. The incremental cost of delivering the 
education prograI11me was £ ~ 3 9 9 per person (1996 £ sterling) and no difference 
228 
CHAPTER 4: ECONOMIC EVALUATION OF TRIAL INTERVENTIO?,\S 
---------------------------------------------------------------------' 
was observed between the intervention and control group in health service 
resource use. The investigators concluded that their education programme was 
not a cost-effective use of health care resources. 
4.4.3 Strengths and weaknesses of the study 
This economic analysis was conducted alongside a large-scale RCT and was 
able to address important issues relating to the implementation of future 
community-based interventions. Drummond, (1995) identified the 
fundamental criterion for the inclusion of economic analysis alongside a 
clinical trial as being the quality of the trial itself. He suggested that: 
"the strongest candidates for concurrent economic analysis are 
those trials with random allocation of participants to experimental 
and control groups, with blinded assessment of outcomes on an 
intent-to-treat basis and with sufficient sample size to detect the 
predetermined clinically important differences at the conventional 
levels of statistical significance" (Drummond, 1995), p 1403. 
Whilst the current study was able to fulfil these criteria, the level of power 
required for the clinical outcome was insufficient for the detection of 
differences in cost data. Similar difficulties have been reported previously 
(Gray et al. 1997), although it is possible that the resources required in order 
achieve adequate po\ver for economic evaluation will always be beyond the 
scope of a ReT. 
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The demographics of the study population were also important. Baltussen et al. 
(1996) pointed to the potential difficulties of extrapolating clinical findings 
from young study populations, and the possible impact of this on cost-
effectiveness ratios. The age distribution of subjects within the current study 
reflected the age distribution of those most commonly affected by knee OA and 
should therefore have been representative of the target population. 
In July 1994 the second Conference on Outcome Measures in RA Clinical 
Trials (OMERACT) accepted that rheumatology was falling behind other 
disciplines in the use of quality-of-life and utility scales (Tugwell, 1996). They 
recommended the adoption of utility scales as a matter of urgency in all aspects 
of rheumatological research. Quality-of-life was measured within the current 
study, although the EuroQol EQ-5D proved an insensitive tool within this 
context. Other researchers have reported similar difficulties when using the 
EuroQol for patients with knee OA (Fransen and Edmonds, 1999). 
Whilst every effort was made to follow the available guidelines for the 
implementation of economic evaluation (Jefferson et al. 1996), some degree of 
bias and uncertainty necessarily remains. One of the strengths of the current 
trial was that details of health care costs were obtained from medical notes, 
rather than through self-completion questionnaires. This meant that 
interpretation of results was not limited by missing data and recall bias. 
H o w c \ ' l . ~ r r errors rna\' havc been incorporated into the dataset as a result of 
, -
illegible GP hand\\Titing, poor communication bet\\'ccn secondary and primary 
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care and recorder error. Nevertheless, researchers were blind to treatment 
group during case note abstraction. Any uncertainty should therefore have 
effected all treatment groups equally. 
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5 Summary and conclusion 
5.1 Main findings 
This thesis describes a series of inter-related studies designed to examine: 
i) the prevalence of knee pain in a community-based sample; ii) the efficacy of 
providing a home-based exercise programme to a sub-sample of this 
population; iii) the estimated cost of knee pain, and iv) the cost-effectiveness of 
providing the exercise therapy. Prevalence was assessed using a postal 
questionnaire, which was sent to all patient aged 2::45 years from two 
participating general practices in the Nottingham area. Treatment interventions 
were assessed through a pragmatic, factorial, randomised controlled trial of 
two-year duration. Cost data were collected prospectively alongside the 
clinical trial and analysis assumed a societal perspective. 
The postal questionnaire was returned by 650/0 of the study population. The 
prevalence of self-reported knee pain in the community based on returned 
questionnaires was 32% (21 % of the total population). These rates are similar 
to those observed by others (O'Reilly et al. 1998; McAlindon et al. 1992). 
The intervention study was unique in that it was a large pragmatic study, 
designed to cxan1ine the long-term impact of a simple home-exercise 
programn1e in the con1n1unity. Primary outcomes were assessed at 2.+ months 
and atteIl1pts \\'cre n1ade to contro I for the psychosocial aspects of treatn1ent 
provision and placebo effects. 
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Results of the intervention study showed modest improvements in self-reported 
knee pain, physical function and knee stiffness at 24 months for volunteers 
allocated to the exercise intervention. These effects were incremental to 
normal care. The telephone support and dolomite control groups did not show 
significant improvements at 24 months. Assessment of treatment adherence 
suggested that 400/0 of those allocated to the exercise programme continued to 
perform the exercises after 2 years. Adherence at this rate was achieved by 
providing a single review visit every 6 months (following the initial training 
period of 4 visits). This represented considerably less input from health 
professionals than had been used in previous studies reporting similar levels of 
treatment adherence (van Baar et al. 1998b; Ettinger et al. 1997). Volunteers 
most likely to continue with the programme were those who had built the 
exercises into their existing daily routine. Regression analysis suggested that 
volunteers with high baseline pain scores and those allocated to the exercise 
programme were most likely to show improvements in knee pain at 24 months. 
Low muscle strength, obesity, anxiety, bilateral pain and radiographic OA were 
all associated with poorer outcomes. 
The cost-of-illness study suggested that costs to the health provider for the 
treatment of knee pain in the con1munity were modest (mean £37 per annum). 
Knee costs were approxin1ately 10% of the total direct medical costs. 
Howc\,er, exact figures were di fficult to ascertain as the isolation of knee-
spccific costs \\'JS often problematic. It is of note that only 29% of the study 
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sample consulted their GP for knee-related care during the 6-month study 
period. Despite a predominantly retired study p o p u l a t i o n ~ ~ indirect costs were 
high. Sensitivity analysis suggested that the inclusion of indirect costs resulted 
in a 75% increase from £ 3 8 ~ ~762 per annum to £66,032 per annum in societal 
costs attributed to knee pain. 
Economic analysis of the trial interventions was conducted prospectively 
alongside the RCT. Direct intervention costs for the exercise programme were 
£ 113 per person for the 24-month treatment period. No differences were 
observed between the treatment groups in medical or societal costs. Cost-
effectiveness analysis based on direct treatment costs suggested that the 
incremental cost-effectiveness of achieving a 250% improvement in a single 
individual at 24 months was £ I ~ O I 2 . . An indication of the variability of the 
patient-specific cost data (including direct treatment cost, medical costs and 
personal costs) was presented as an acceptability curve. This suggested that 
exercise therapy had an 80% probability of being cost-effective if the health 
provider and patient were prepared to pay £500 per unit of effect on the 
WOMAC pain scale. Given the high prevalence of knee pain in the 
community, this could represent a substantial burden. Further work may be 
necessary in order to assess those patients most likely to benefit from the 
programme. 
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5.2 Interpretation 
Knee pain is common in men and women aged over 45 years, and inflicts a 
sizeable physical, psychosocial and economic burden. The provision of a 
simple home exercise programme as outlined in this thesis could help to 
alleviate some of the pain and disability associated with knee pain, although 
such improvements are likely to be modest. It is unlikely that the cost of 
delivering the exercise programme would be ameliorated by fewer health 
contacts or reduced medication costs, and given the high prevalence of knee 
pain, the cost of delivering this programme could be substantial. 
5.3 Recommendations for the future 
This study aimed to demonstrate that subjects with knee pain could benefit 
from exercise therapy regardless of a clinical diagnosis of OA. Evidence was 
provided to suggest that patients most likely to benefit from the intervention. 
were those with moderate levels of knee pain, poor muscle strength and who 
were not overweight. Further work to identify possible predictors of response 
that could be used by general practitioners in prescribing exercise therapy 
would help to improve the efficacy of the treatment. Secondly, the importance 
of continued treatment participation is consistently reported. An improved 
understanding of how to encourage greater individual responsibility for the 
nlanagenlent of chronic pain would be useful. 
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Frequency of resource use data from the trial suggested that drug therapy was 
important in the medical management of knee pain. By contrast physiotherapy 
or advice to lose weight were rarely documented. The current study was not 
designed as a fonnal audit of current practice. Nevertheless, the recent 
publication of updated guidelines for the medical management of knee OA 
Pendleton, Arden, et al. (2000) means that such an audit would now be 
infonnative. In addition, more research into alternative treatments such as the 
use of health food products, aromatherapy and osteopathy would be helpful in 
elucidating the personal cost of knee pain more accurately. 
Finally, every effort was made to adhere to the published guidelines for 
conducting economic evaluations alongside clinical trials. Nevertheless, 
controversy continues over the most appropriate methods to be used for the 
collection, analysis and dissemination of the results of economic analyses 
(Johnston et al. 1999, pg 38). Until these issues are resolved, the 
comparability of study findings and generalisability of results will continue to 
be problematic. 
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Appendices 
Appendix 1: Consent forms 
DEPARTMENT OF HEALTH, KNEE PAIN INTERVENTION STUDY 
CONSENT FORM 
A community-based, randomised intervention study examining the effects of 
exercise on knee pain and its associated disability. 
(1) CLINICAL AND RADIOGRAPHIC ASSESSMENT 
I voluntarily agree to participate in the above study. I understand that I will: 
1. Be examined by a trained therapist with respect to knee and other joint diseases, 
and answer additional questionnaires relating to my health. 
2. Be investigated for muscle strength using an especially constructed chair. 
3. Go for knee X-rays to the City Hospital, Nottingham. 
I also give consent for my medical records to be examined as necessary. 
I understand that I may withdraw from this study at any time, without prejudicing my 
future medical care or treatment. 
I confirm that I have read and understood the information sheet provided for this study 
and have had the opportunity to ask questions therefrom. 
Name: 
Date: 
Investigator: 
Date: 
DEPARTMENT OF HEALTH, KNEE PAIN INTERVENTION STUDY 
CONSENT FORM 
A community-based, randomised intervention study examining the effects of exercise on 
knee pain and its associated disability. 
(2) TREATMENT STUDY 
I voluntarily agree to participate in the above study. I understand that I will be randomly 
allocated to receive one or more of the following treatment regimes: 
• Specific leg muscle exercises. 
• Regular telephone contact from the Rheumatology Unit. 
• A health food product containing Calcium; which is thought to be beneficial for 
osteoarthritis. 
• General advice concerning knee pain and its management. 
I realise that the treatment study will continue for 2 years and that I will be assessed at 6 
months, 12 months, 18 months and 24 months in the same way as before. 
I understand that I may withdraw from this study at any time without prejudicing my 
future medical care or treatment. 
I confirm that I have read and understood the information sheet provided for this 
study and have had the opportunity to ask any questions arising therefrom. 
'arne: Date: 
Investigator: Date: 
APPENDICES 
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ARTHRITIS IN THE COMMUNITY 
This questionnaire has been prepared by the Rheumatology Unit, City Hospital Nottingham 
and the Department of Public Health Medicine and Epidemiology, Queens Medical Centre. 
We want to find out more about the extent of knee pain in the community, in order to find 
ways of improving the management and care of osteoarthritis. It is therefore of great 
importance that you help us by filling in this questionnaire. Even if you do not have knee 
pain, please fill it in, as we are still very interested in your responses. We think you will find 
the questionnaire interesting and it should only take about 15-20 minutes to complete. 
Most of the questions require a tick in a box, for the others, clear instructions are given. 
Much thought has gone into the design of this questionnaire, we are aware a few questions 
may seem similar - this is intentional and necessary for our research, please fill in all of them 
to the best of your ability. 
Please return it in the pre-paid envelope (no stamp required) as soon as possible to the 
Department of Public Health Medicine and Epidemiology, Queens Medical Centre, 
Nottingham. 
Your answers are strictly confidential. 
Please do not pass this questionnaire onto anyone else. 
If you have any questions about this work please ring : 
Anna Follows, Study Administrator on 0115 9691169 extension 45557. 
or 
Alex Sutton, Research Assistant on 0115 9249924 extension 42004. 
Thank you for your assistance with this important area of research. 
A mall number of you may, at a later date, be invited to participate in a further stud } 
(which would involve an examination and X-Rays of your knees). Even if . ou would 
110t be lvilling to help us further please return this questionnaire. 
Funded by the Departm.ent of Health 
II SECTION I : ABOUT YOUR ELF II 
1. What is your surname? 
(Please also include your maiden name, if applicable, in brackets) 
2. What are your fIrst names? 
3. What is your date of birth? 
DD day 00 month DD year 
4. What sex are you? (Tick one box onl 'J 
o male 
D female 
5. What is your marital tatus? 
o married 
D single 
o divorced 
D widowed 
D eparated 
6. What is your height? 
DDft ODin 
7. What is your weight? 
DDt DOtb 
or 
r 
DDDcm 
DOD 0 
8. Has your weight changed a lot over your adult life? - (other than when pregnant, 
if relevant). (Tick one box only) 
JOno 
20 gradual increase 
30 gradual decrease 
40 changeable 
9. What is your ethnic origin? (Tick one box only) 
10 White 
20 Afro Caribbean 
30 SE Asia 
40 Middle Eastern 
50 Indian, Pakistani or Bangladeshi 
60 Mixed, please specify . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
70 Other, please specify .................................... . 
II SECTION 2 : II 
10. Please give details of your current or last j ob. 
What was the job title? 
· . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. .. . .. .. .. .. . .. .. .. .. .. .. .. .. . .. . ........ . 
Please give approximate date during which you did thi job. 
DD month DO year to DD month DD year 
or (tick) 0 till emplo 'ed in the job 
Please give detail of your job including hat the organi ation you wor -ed for make 
or do 
· . . . . . . . . . . . . . . .. . . . . .. . . . .. .. .. . .. .. . .. .. .. .. .. .. . .. .. . .. .. .. .. .. .. .. .. .. . . . . . ... 
· . . . . . . . . . . . . . .. .. . . . .. . . . .. . . . . . . . . .. . . .. .. . . .. . .. .. .. .. . .. . . . . . . . . ... 
11. Please give details of the longe t job that ' u han h Id in y ur life. 
What was the job title? 
· . . . . . . . . . . . . . . . .. . . . . . . . . . . .. .. . . .. .. .. .. . . . .. . . .. .. .. .. . .. .. .. .. . . . .. .. .. 
Please give approximate date during which you did thi jo . 
DD month 00 year to DO month DO year 
Please give detail of your job including what the organi ation you \ . r ed for make 
or do. 
.. . . . . .. . . . . . . . . . . . . . . . . . . . . . . .. .. . .. .. .. .. .. .. .. . .. .. .. .. . .. .. . .. .. . .. .. .. . . . .. 
. . . . . . . . .. . . . . . . . . . ............................................................... .. . 
12. Plea e give details of your p us or parto r ' curr ot or It ' b includin the 
job title . 
. . .. . . . . . . . . . . . . . .. . . . . . . . . . . .. .. . .. .. .. . .. .. . .. . .. .. .. .. .. . .. . .. . . . . . . . . . . 
3 
11 SECTION 3: ABOUT YOUR SMOKING HABITS II 
13. Have you ever smoked regularly i.e. at least once a day for at least 3 months. 
(Tick one box) 
Dyes 
Dno 
If yes, are you a - (Tick one box) 
D current smoker 
D ex-smoker 
Approximately how many did you or do you smoke? 
D/day 
How long ago did you start smoking? 
DDmonths or DDyears 
If an ex-smoker, how long ago did you stop? 
DDweeks or DDmonths 
4 
or DDyears 
II SECTION 4: II 
14. Do you currently take pain killer bought over th c unter or pr cribed 
by your GP? (Tick one box) 
o never 
o occasionally 
D regularly 
If you do take pain killer pJe e tate which one 
· ... . ......... . .... . . . . . .......................................... . ........ ... . 
· . . . . . . . . . . . . . . . . . . . . . . .. . .. . . .. .. .. .. . .. .. .. .. . . . . . . .. . . . . . .. . . .. . . . .. . . 
15. Do you currently take any other medicati n pr crib by y ur P? 
(Tick one box) 
o yes 
D no 
If ye , please gi e the name ) below: 
· . . . . . . . . . . . . . . . . .. . . . . . . . . . . .. . .. . . . .. . . . . . . . . . .. . . . . . .. . . . . . .... 
· . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . .. . . .. .. .. . . . . .. . . . . . . . . 
· . . . . . . . . . . . . . . . .. . . .. . . . . . . . . . .. . . . . . . .. . . . . . . . . . . . . . . .. . . . . . . . 
· . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . .. .. . .. . . . . . . . .. . . . . . . . . . 
16. Do you take any herbalist or health food h p r m di ~ ~ r y ur j in ? 
(Tick one box) 
If ye , please give the name( ) below: 
· .......................................... . .................. . 
· . . . . . . . . . . . . . . . . .. . . . . .. . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . ... 
= = = ~ - - - = = = = = = = = = = = = = = = = i l l
SECTION 5: ABOUT ANY PAIN YOU MAY SUFFER 
17. ABOUT BACK PAIN: 
(a) Have you ever had back pain on most days for at least a month? (Tick one box) 
Dyes 
Dno 
If so, have you experienced any back pain during the last year? (Tick one box) 
Dyes 
Dno 
(b) Have you had back pain on most days in the last month? (Tick one box) 
Dyes 
Dno 
(c) Have you had back pain within the last year that occurred on most days for at 
least a month? (Tick one box) 
(d) 
Dyes 
Dno 
If 0 , at what age did you first notice this type of back pain? 
.... .... . . years old. 
Have you ever injured your back? (Tick one box) 
Dye., if ye at what age did this occur ? . .... years old, or date . .... .. . 
Dno 
If yes , did thi injury r quire medicallho pital treatment? D yes D no 
What \ as the ausc f thi injury? .. . .................... . 
18. ABOUT HIP PAl 
(a) Have you ever had pain in or around a hip on mo t da Cor at Ie t a month? 
(Tick one box) 
D yes 
D no 
If 0, have you experienced any hip pain during the last year? (Tick one box) 
D yes 
D no 
(b) Have you had hip pain on mo t da 
D yes 
D no 
(c) Have you had hip pain within the la t year that occurred n m da ' for a least 
a month? (Tick one box) 
If 0, at what age did you fir t notice thi type of hip pain . 
. . . . . . . . . . year old. 
(d) Have you ever offered from clickin hip? (Tick one boo ) 
Dye, if ye at what age did thi occur? .. . . . year old, or d teo .. . ... . 
D no 
If ye ,did thi injury require medicallho pi tal treatment? 0 e D no 
What was the cau e of the injury? ....................... . 
7 
19. ABOUT KNEE PAIN: 
(a) Have you ever had pain in or around a knee on most days for at least a month? 
(Tick one box) 
Dyes 
Dno 
If so, have you experienced any knee pain during the last year? (Tick one box) 
Dyes 
Dno 
(b) Have you had knee pain on most days of the last month? (Tick one box) 
(c) 
Dyes 
Dno 
Have you had pain within the last year in or around the knee that occurred on 
most days for at least a month? (Tick one box) 
Dyes 
Dno 
If so, at what age did you first notice this type of knee pain? 
........ .. years old. 
(d) Have you ever injured either of your knees? (Tick one box) 
D ye , if yes at what age did this occur? ..... years old, or date ..... .. . 
Dno 
If Y , did thi injury require medicallhospital treatment? Dyes D no 
What wa .. the cau of thi injury? ....................... . 
8 
20. 
II SECTION 6 : 
Have you been diagno ed by your D tor hal'in n) 
(Please tick any that apply) 
I 0 Heart Di ease 
20 Stroke 
30 Lung Di ease 
40 Cancer 
5D Diabete 
6D Rheumatoid Arthriti 
70 0 teoarthriti 
21. In general, would you ay your health' (tick one bo ) 
10 Excellent 
20 Very good 
30 Good 
4D Fair 
sO Poor 
II 
th f 11 in? 
22. Compared to one year ago, how would you rat 
(tick one box) 
ur n'r 1 h Ith.!!....l.? 
I D Much better now than one year a 
20 Somewhat better now than on ye r 
30 About the arne 
o omewhat wor e now than on ye r 
50 Much wor 'e now than one year ago 
o 
o 
SECTION 7: HEALTH AND DAILY ACTIVITIES 
23. The following questions are about activities you might do during a typical day. 
Does your health limit you in these activities? If so, how much? 
(Please tick one box on each line) 
Yes, 
limited 
a lot 
Vigorous activities, such as running, D 
lifting heavy objects, participating 
in strenuous sports 
Moderate activities, such as moving a 
table, pushing a vacuum cleaner, 
bowling or playing golf 
Lifting or carrying groceries 
Climbing several flights of stairs 
Climbing one flight of stairs 
Bending, kneeling or stooping 
Walking more than a mile 
W lking half a mile 
Walking 100 yard 
Bathing and dr . tng ur If 
D 
D 
D 
D 
D 
D 
D 
D 
D 
Yes, 
limited 
a little 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
No, not 
limited 
at all 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
24. 
25. 
During the pa t 4 wee " , ha\ e .:ou h d 
work or other regular dail) activiti 
(Please tick yes or no for each que lion ) 
Cut down on the amount of time you 
other activitie 
=-==== =...=..=;.;;:.:;:. than you would Ii "e 
nt n 
Were limited in the kind of wor ' or other ti Itie 
Had difficulty perfonnjng the wor ' or oth r iti 
(e.g. it took e tra effort) 
Cut down on the amount of lime you 
other activitie 
~ = = = = ~ ~ ~ than you would Ii . 
Didn't do work or other tivitie 
] 1 
nt on 
u u J 
r D 
D 
ith our 
lth? 
D 
D. 
Do 
o 0 
o 
o 
o 
lit 
26. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbours or groups? (Please tick one) 
27. 
28. 
10 Not at all 
20 Slightly 
30 Moderately 
40 Quite a bit 
50 Extremely 
How much bodily pain have you had during the past 4 weeks? (Please tick one) 
10 None 
20 Very mild 
30 Mild 
40 Moderate 
50 Severe 
60 Very severe 
During the past 4 weeks, how much did pain interfere with your normal work 
(including work both outside the home and housework)? (Please tick one) 
10 Not at all 
20 A little bit 
JO Mod rately 
40 Quit a bit 
50 °tr n1ely 
II SECTIO 8: II 
29. The e questions are about how you fe I and h thin h b n ith u 
during the past month. (For each qu tion. pi i di t th 
that comes do e t to the way you have b n e lin 
(Please tick one box on each line) 
How much time during the All 10 t m 
past month: of the o the f the 
time time the tim tim 
Did you feel full of life? D D D D 
Have you been a very nervou D D D D 
per on? 
Have you felt 0 down in D D D D 
the dump that nothing could 
cheer you up? 
Have you felt calm and peaceful? D D D D 
Did you have a lot of energy? D D D D 
Have you felt downhearted and D D D D 
low? 
Did you feel worn out? D D 0 D 
Have you been a happy per on? D D 0 0 
Did you feel tired? D D 0 D 
D D 0 D 
little 
of the 
time 
D 
0 
D 
D 
D 
D 
D 
0 
0 
0 
~ ~ 'one 
of th 
time 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
SECTION 9: ABOUT YOUR HEALTH IN GENERAL 
J! 30. Please choose the answer that best describes how true or false each of the 
~ ~ following statements is for you. (Please tick one box on each line) 
Definitely Mostly Not Mostly Definitely 
true true sure false false 
I-
I seem to get ill more D D D D D 
[ easily than other people 
I am as healthy as D D D D D 
[ anybody I know 
I expect my health D D D D D 
[ to get worse 
My health is D D D D D 
[ excellent 
We would like to ask you more about your health at the moment. For each question 
[ place a tick in the box that closest describes your health state. 
31. Please indicate your level of mobility. 
10 I have no problem in walking 
r 20 
~ ~
I have some problems in walking about 
30 I am confined to bed 
~ 2 . . Please indicate your level of self-care. 
10 I have no problems with self-care 
o I have orne problems washing or dre ing my elf 
o I am unable to wa h or dre my elf 
l4 
33. Please indicate your abilit), to p rform your u u th°ti , 
1 D I have no problem with performing m u u 1 
(eg, work, tudy, hou ework. family or lei ure iti 
2 D I have some problem with performing my u ill I cli 'hie 
30 I am unable to perform m) u ual cli itie 
34. Please indicate your level of paino 
35. 
36. 
10 I have no pain or di comfort 
20 I have moderate pain or di comfort 
3D I have extreme pain or di comfort 
Please indicate your level of anxiet or depr 
10 I am not anxiou or depre ed 
20 I am moderately anxiou or depre ed 
3D I am extremely anxiou or depre ed 
n , 
Compared with my gen ral level of h alth 0\' r th 
state today i 
10 Better 
20 Much the arne 
30 Wor e 
2 m nth • my h alth 
37. To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked by 100 
and the worst state you can imagine is marked by O. 
We would like you to indicate on this scale how good 
or bad is your own health today, in your opinion. 
Please do this by drawing a line from the box below 
to which ever point on the scale indicates how good or 
bad your current health state is. 
Your own 
health state today 
16 
Best 
imaginable 
health state 
100 
4 0 
-t-
T 
3 0 
2 0 
1 0 
I 
o 
Worst 
imaginable 
health tate 
II SECTION 10: 
We are interested in certain key p c 0 di t. 
information to the best of your abilit .. 
tr. 
38. Please indicate your total milk inta e, includin mil . 'n drin . and 
on breakfast cereal etc. at different ag 
(PLease tick appropriate box) 
one Up to Y2 • ore than 
pt/wee Y2 pt/ ee 
A a teenager D D D 
20-44 yrs old D D 0 
45 yr to pre ent D 0 D 
39. Have you ever followed any of the di 
Low Fat D Ye D 0 
Vegetarian D Ye D 0 
Vegan o Ye 0 0 
Other ................ 
(Please specify) 
40. Have you ever taken any vitamin 
over a period of appro imatel 
If ye 
If ye 
If e 
D, iron, calcium fi h oil ,evenin primr 
ppr pri t b . 
Le th re o n't 
I pt/d th I P 
d il) 
0 0 0 D 
0 0 0 0 
D 0 0 0 
• (ti one box or a 1z) 
ge : from ........ to ....... ear 
from ........ to .... .. . 
ge : from ........ t •.. . .. . ear 
ge : rom ........ to....... ear 
ii, 
Ono (If )e , Plea eli t hrand, dail do nd 
amelbrand Daily D 
.. . .. ..... ..... .. .... fr m ........ t · ...... . 
2 ....... . . ... . . ..... . fr m ....... . 
3 ... ........ .... . . .. . fr m ....... . · ...... . 
4 ..... . .. ...... . .... . r m ......•. t · ...... . 
17 
o 
o 
o 
.,,1 
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SECTION 11: OCCUPATIONAL PHYSICAL ACTIVITY 
We are interested in the decade of your life, between the ages of 40 and 50 years. If you 
are not yet 50 please consider the time period starting when you were 40 to the present. 
The questions below ask about your habitual physical activity in the past i.e. please only 
answer for the time period defined. 
41. Were you in full time employment? 
(Please tick) 
o yes, please name occupation 
Ono 
................................. 
If yes please answer the questions below before moving on to SECTION 12. 
If no, please go on to SECTION 12 now (page no.20). 
Questions 42-51 ask about the physical nature of your main occupation at that time 
i.e. in your forties. 
Please put a ring around the responses which best described you then. 
42. In your 40's, at work did you sit ... 
never / seldom / sometimes / often / always 
43. In your 40's, at work did you stand ... 
n ver / eldom / sometimes / often / always 
44. In your 40's, at work did you walk ... 
n r / eldom / ometimes / often / always 
45. In your 40' at work did y u lift heavy I d 
never / eldom / ometime / often / ery often 
46. In your 40' after work did you feel tir d ... 
very often / often / ometirne / Idom / ne er 
47. In your 40's, at work through ph} icaJ e ertion did u u to at ... 
very often / often / ometime I eIdom / ne er 
48. In your 40' do you think in comp . D ith th r ==.....:.:.:..:::c:.....::a::. 
phy ically ... 
much heavier / heavier / as heavy / light r / much ighter 
49. In your 40' h w many minut did ou -at - r d y t nd r m ~ ? ? ... 
- . ..... . . . ... minute. 
so. In your 40' how many minut did y u c)cI p r d ) t n rk? ... 
. . ... . ..... . - minute . 
51. In your 40' what w ur appr xim ht? 
DDt DDlb or DOD 
19 
SECTION 12 : LEISURE TIME PHYSICAL ACTIVITY 
While still thinking about the same time in your life as previous section (i.e. in your forties) 
please answer the following questions on leisure activities. 
52. Did you play any sports (e.g. golf, tennis, cricket etc), or participate in any 
physical activities (e.g. ballroom dancing, aerobics, hiking etc) ? ••• 
Dyes 
Dno 
If yes 
which sport did you play most frequently? 
how many hours a week? hours 
how many months a year? months 
If you played a second sport: 
h· h .. ? W IC sport IS It. . ...................................... . 
how many hours a week? hours 
how many months a year? months 
Did you play any other sports? - please list .......... , ............... . 
& • ,. ••• ,. ................. " ........................ . ........................ .. 
, ~ ~ .. . .. , . . . . . .. . .. . . .. . . . " .. . . . . . . . . . . . . .. . .. . . . .. . . . .. .. . .. .. . . .. .. .. .. . . . 
For questions 53-61 please put a ring around the responses which best described you then. 
53. Do you think in comparison with others your own age at that time, your physical 
activity during leisure time was ... 
much m r / mor / the arne / Ies / much Ie s 
54. During your leisure time did your activities cause you to sweat ... 
very often / often / sometimes / seldom / never 
55. During your leisure time did you play sport ... 
never / seldom / sometimes / often / very often 
56. During your leisure time did you watch television ... 
never / seldom / sometimes / often / very often 
57. During your leisure time did you walk ... 
never / seldom / sometimes / often / very often 
58. During your leisure time did you cycle ... 
never / seldom / sometimes / often / very often 
59. During your leisure time did you do DIY activities (e.g. home improvement, 
painting, etc)? ... 
never / seldom / sometimes / often / very often 
60. During your leisure time did you work in the garden ... 
never / seldom / sometimes / often / very often 
61. How many hours per day did you sleep on average? 
hours. 
21 
APPENDICES 
-
Appendix 3: Assessment questionnaire 
271 
REF NO DDDDD.D 
Department of Health Knee Pain Study 
I ASSESSMENT: I 
1 ' l ~ ~ 1 8 : :•••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
] [ ) ~ ~ ~ 1 8 : :.......................................................... . 
1 ' l 1 8 : X ~ ~ ~ S S 1 8 : S S ~ 1 8 : 1 ' l ~ ~............................... . 
C = ; ~ « = ) l l J ~ ~ ••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
X-RAY RE.C18:IV18:][) ................................. . 
If found please phone Louise Cooke on tel: (0115) 9691169 ext 45557. 
REF ~ o n = J D D D D D
PATIENT SERVICE l'SE Q L E S T I O ~ ~ A I R E E
II PERSONAL DETAILS 
We would like you to complete the following questions ahout ~ · o u r s e l f . .
l. What is your current employment situation'? 
(please tick appropriate box) 
Full time employed 
Part time employed 
Retired 
Unemployed 
Not employed 
2. Has your employment situation changed in tht: la"l ! 2 1l1()f1th<' 
(please tick appropriate box) 
o No (If ticked, please go stmight to (j·1 i 
o Yes 
3. Was the change due to knee pain? 
(please tick appropriate box) 
o No (If ticked, please go straight to Q4) 
o Yes 
If Yes, please state how your employment situation has been changed 
(please tick appropriate box) 
10 Stopped working 
20 Reduced hours worked 
30 Increased hours worked 
40 Gone back to work 
50 Other (please explain) 
4. Have you taken any time off work in the last 6 months because of your knee pain? 
(please tick appropriate box) 
o No (if no please go straight to Q6) 
o Yes (if yes please answer Q5(a) and 5(b) before moving on to Q6) 
\ (a) Approximately how much time have you taken off work? 
............... hours/days/weeks (delete as appropriate) 
5. (b) Was this time off \Nork paid or unpaid! Il,/elise [itt. "P!'rll!'riu!,' h"x I: 
10 Unpaid 
20 Paid at full rate 
Paid at reduced rate {please npluin I 
40 Do not know 
6. Are covered by private health insurance.' 1{,leu\/, lick ,if'{'/"f,rili!, h,)l., 
D 
o 
No 
Yes (please explain hriej7y.i 
.................................... 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
7. Are you exempt from prescription charges'.' '/,It'(/\I' ti,) ti!,!,!I!!''':d" h'\, 
o No 
o Yes 
We would like you to complete the following questions about your use of health services 
in the last six months. (For some services we ask about your use of them in the last 
year). 
8. In the last 6 months have you seen your G.P in the surgery or at home? (Please tick 
appropriate box) 
D No (if no please go to QIO) 
D Yes 
9. Were any of the times you were seen by the GP due partly or fully to your knee pain? 
D No 
D Yes 
D Don't know 
10. In the last 6 months have you at£ended a h o ~ p i t a l l outpatient clinic for consultation: 
D No (if 110 please go straigizt to Q 12) 
DYes (if yes please list the hospitals you J w ~ · t ! ! ilUt'ndl!d as atl outpaTient) 
.................................................................................................... 
..................................................................................................... 
...................................................................................................... 
11. Were any of the times you attended as an outpatient due panly or fully to your knee 
pain? 
o No 
o Yes 
o Don't know 
II INPATIENT CARE ·11 
12. In the last 12 months have you been admitted to hospital for planned or emergency 
care? 
o No (if no please go straight to Q14) 
o Yes if yes please list the hospitals you were admitted to: 
.............................................................................. 
.............................................................................. 
.............................................................................. 
13. Were any of the times you were admitted to hospital due partly or fully to your 
knee pain? 
o No 
o Yes 
o Don't know 
! MEDICATION ;! 
We would like you to complete the following questions about your medication taken in 
the last six months. 
14. In the last 6 months because of your knee pain have you been prescribed or purchased 
any tablets, medicine or creams or gels for your knee pain',) (please tick the 
appropriate box) 
D 
D 
Name of 
Medication 
No (if flO please ga straight to Q /5) 
Yes (if yes please complete the falloH'in It chart bt'/ore !1lm'ing on to Q / 5) 
Prescribed by GP ! If not on What was the 
or hospital? (if yes prescription how JppfC'xirnate cost 
please indicate many times did you l)f each purchase? 
which) purchase it? 
I i , 
i 
! I , 
I i 
I 
I 
I 
I 
I i I 
I 
I 
I 
I 
i 
! , 
I 
I 
i 
i 
I 
I 
I 
I 
I 
II 
I 
I 
II EQUIPMENT AND OTHER EXPENDITURES II 
We would like you to complete the following questions about any equipment bought to 
help your knee pain. 
15. Do you have any equipment or items that you have obtained especially because of 
your knee pain? (please tick appropriate box) 
o No (if no please go straight to Q16) 
DYes (if yes please complete the following chart before moving to Q16) 
Please complete one row for each item or equipment. 
Type of Did you If provided Was this item If known, 
Equipment! purchase it? by someone purchased in what was the 
item YeslNo else, who was the last 12 approximate 
this? months? cost? 
YeslNo 
, 
I' 
Ir Ii I 
" I 
" 
" 
, 
" , 
" ! ~ ~ --- -- .-.---
" 
I , 
i 
I I 
I 
---- ----"------------- -- -
-'. - .. .. 
--
. - - - . - ~ ~ . ---- - - ~ - . - - - - - - - - -
16. In the last 12 months have you incurred any other funher costs Occause of your knee 
pain? (please tick appropriate box) 
D No 
D Yes (if yes please complete lhe following charf) 
I I, 
Type of additional expenditure I What was the a p p r o x i m ~ t [ e e extra !j , I !I I 
cost?iplease specify if onc-off Ii Ii 
cost or regular amount) 
:1 
il 
!! 
, Ii I , 
I 
I 
II 
i II 
I I' .1 I II ! 
II 
JI 
We would like to ask you about any operations or injuries you have had 
to your legs (including your knees, hips and back) which have lead you 
to hospitalisation. 
Please list below the name of the operations or injuries you have had to 
your legs (or a brief description of what you had done in hospital), which 
hospital you attended and approximate dates. 
operation / injury hospital attended date 
1. . ......................................... . 
2. . ......................................... . 
3. . ......................................... . 
4. . ......................................... . 
5. . ......................................... . 
II ABOUT YOUR HEALTH /lV GElvERAL ]1 
We would like to ask you more about your health at the moment. for each 
question please place a tick in the box that closest describes your health state. 
1. Please indicate your level of mobility. 
o I have no problem in walking 
o I have some problems in walking about 
D I am confined to bed 
2. Please indicate your level of self-care. 
o I have no problem with self-care 
D I have some problem \.vith washing or d r ~ s s i n g g myself 
D I am unable to wash or dress myself 
3. Please indicate your ability to perform your usual acth·itics. 
D I have no problems with perfonning my usual acti\'ities 
(e.g. \vork, study. housework. family or leisure actiyitit:s) 
o I have some problem with pcrfonning my llsual activities 
D I am unable to perfom1 my usu:ll actiyitics 
4. Please indicate your leHI of pain. 
o I have no pain or discomfort 
o I have moderate pain or discomfort 
o I have extreme pain or discomfort 
5. Please indicate your lenl of anxiet)· Of depression. 
o I am not anxious or depressed 
o I am moderately anxious or ckpress..:d 
o I am extremely anxious or depressed 
6. Compared with my gencrallcvel of hcalth ovef the past 12 months, my 
health state today is ... 
o Better 
o Much the same 
o Worse 
7. To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked by 100 
and the worst state you can imagine is marked by O. 
We would like you to indicate on this scale how good 
or bad is your own health today, in your opinion. 
Please do this by drawing a line from the box below to 
which ever point on the scale indicates how good or 
bad your current health state is. 
Your own health 
state today 
Best 
imaginable 
health state 
100 
o 
Worst 
imaginable 
health state 
SF-36 
ilSECTION 1: 
1. In general, would you say your health is: (lick one box) 
D Excellent 
D Very good 
D Good 
D Fair 
D Poor 
2. Compared to one year ago, how would you rate your general 
health.n!UY? (tick one box) 
D 
o 
o 
D 
D 
Much better now than one year ago 
Somewhat better now than one year aao 
- 0 
About the same 
Somewhat worse now than one year ago 
Much worse now than one year ago 
~ ~ ~ ~
3. The following questions are about activities you might do during a 
typical day. Does your health limit you in these activities? If so, 
how much? (please tick one box on each line) 
Vigerous activities, such as running, 
lifting heavy objects, participating 
in strenuous sports 
Moderate activities, such as moving 
a table, pushing a vacuum cleaner, 
bowling or playing golf 
Lifting or carrying groceries 
Climbing several flights of stairs 
Climbing one flight of stairs 
Bending, kneeling or stooping 
Walking more than a mile 
Walking half a mile 
Walking 1 DO yards 
Bathing and dressing yourself 
Yes, 
limited 
a lot 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
Yes, 
limited 
a little 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
No, not 
limited 
at all 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
4. During the past 4 weeks, have you had any of the following 
problems with your work or other regular daily activities ~ ~
result of your pbysical bealth? (please tick yes or no for each 
question) 
Cut down on the amount of time spent 
on work or other activities 
Accomplished less than you would like 
Were limited in the kind ofv.'ork or 
other activities 
Had difficulty performing the work or 
other activities (e.g. it took extra effort) 
Yes No 
~ ~ 0 ' , , ' ' ~ ~
, : o 
i_' n 
5. During the past 4 weeks, have you had any of the following 
problems with your work or other regular dail)' activities nJL 
result of any emotional problems (such as feeling depressed or 
anxious)? (please tick yes or no for each question) 
Cut down on the amount of time you spent on 
work or other acti vities 
Accomplished less than you would like 
Didn't do work or other activities as ~ m l i l l \ ' '
",. 
as usual 
'{es No 
1_: [J 
o 
, , 
C--J n 
,"'" 
6. During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities 
with family, friends, neighbours or groups? (Please tick one) 
0 Not at all 
0 Slightly 
0 Moderately 
0 Quite a bit 
0 Extremely 
7. How much bodily pain have you had during the past 4 weeks? 
(please tick one) 
0 None 
0 Very mild 
0 Mild 
0 Moderate 
0 Severe 
0 Very severe 
8. During the past 4 weeks, how much did pain interfere with your 
normal work (including work both outside the home and 
housework)? (please tick one) 
0 Not at all 
0 A little bit 
0 Moderately 
0 Quite a bit 
0 Extremely 
II .... SECTION 3 ABOUT YOUR FEELI1VGS : ~ ~
9. These questions are about how you feel and how things have been 
with you during the past month. (For each question, please indicate 
the one answer that comes closest to the way you have been feeling) 
(please tick one box on each line) 
How much time during 
the past month: 
Did you feel full of life? 
Have you been a very 
nervous person? 
Have you felt so down in 
the dumps that nothing 
could cheer you up? 
Have you feIt calm and 
peaceful? 
Did you have a lot of 
energy? 
All 
of the 
time 
D 
D 
D 
D 
D 
Have you felt downhearted D 
and low? 
Did you feel worn out? D 
Have you been a happy D 
person? 
Did you feel tired? D 
Has your health limited yotl[ D 
social activities (like visiting 
friends or close relatives)? 
\fost 
of the 
time 
o 
! I 
D 
D 
D 
o 
0 
D 
D 
:\ good 
bit of 
time 
D 
1-' 
I I 
-' -' 
n 
n LJ 
D 
D 
o 
n 
D 
o 
Some 
of the 
time 
'-I i . 
L--J 
r: 
i I 
-' -
, I 
i I 
L-J 
LJ 
n 
~ ~
i! 
~ ~
A little 
of the 
time 
I 
. , 
'-' 
~ ~, 
I 
-! -! 
II i_I 
i ! 
LJ 
n , , 
L-.; 
~ ~
I 
'------' 
----, 
! 
'_. _i 
.-. 
None 
of the 
time 
o 
D 
D 
D 
o 
D 
o 
0 
0 
o 
10. Please choose the answer that best describes how true or false each 
of the following statements is for you. (Please tick one box on each 
line) 
I seem to get ill more 
easily than other people 
I am as healthy as 
anybody I know 
I expect my health to 
get worse 
My health is excellent 
Definitely 
true 
D 
D 
D 
D 
Mostly 
true 
D 
D 
D 
D 
Not Mostly Definitely 
sure false false 
D D D 
D D D 
D D D 
D D D 
1. 
2. 
3. 
HAD INDEX 
II· ABOUT YOIJR GE:NERA.L FEELINGS: II 
For each item please tick one box 
I feel tense or "wound u p ~ : :
D Most of the time 
D A lot of the time 
D Time to time, occasionally 
0 Not at all 
I still enjoy the things I used to enjoy: 
D Definitely as much 
D Not quite as much 
D Only a little 
o Hardly at all 
I get a sort of frightened feeling as if 
something awful is about to happen: 
D Very definitely and quite badly 
D Yes, but not too badly 
D A little, but it doesn't worry me 
D Not at all 
-f. 
5. 
6. 
I can Jaugb and see the funny side of 
things: 
0 As much as I always could 
r---l ~ o t t quite so much now r I 
L--.r 
I ~ r r
LJ Definitely not so much now 
if \:ot at all L1 
\Vorrying thoughts go through my 
mind: 
i i .4. great deal of the time 
l I r\ lot of the time 
-I -I From time to time but not tOO often L.J 
o Only occasionally 
I feel cheerful: 
0 ~ o t t at 311 
Ii L.J ~ o t t often 
0 Sometimes 
II 
r 1 \lost of the time 
~ ~
I can sit and feel relaxed: 11. I feel restless as if I have to be on the 
move: 
0 Definitely D Very much indeed 
0 Usually D Quite a lot 
0 Not often D Not very much 
0 Not at all D Not at all 
I feel as if I am slowed down 12. I look forward with enjoyment to things: 
0 Nearly all the time D As much as I ever did 
0 Very often D Rather less than I used to 
0 Sometimes D Definitely less than I used to 
0 Not at all D Hardly at all 
I get a sort of frightened feeling "like 13. I get sudden feelings of panic: 
butterflies" in the stomach: 
0 Not at all D Very often indeed 
0 Occasionally D Quite often 
0 Quite often D Not very often 
0 Very often D Not at all 
I have lost interest in my appearance: 14. I can enjoy a good book or radio or TV 
programme: 
0 Definitely D Often 
0 I don't take so much care as I should D Sometimes 
0 I may not take quite as much care D Not often 
0 I take just as much care as ever D Very seldom 
,-_._-._---- l4iO 
WOMAC OSTEOARTHRITIS INDEX 
II SECTION 1 : PAIN II 
The following questions concern the amount of pain you ha,'e expcriencl>d in 
your knees over the last week. (Please lick one hox j(Jr each item), 
How much pain do you have? 
None ~ v 1 i l d d \loderate Se\'ere Extreme 
1. Walking on a flat surface D 0 ,---, n 0 : I '--' 
None :vlild \loderate S ~ n ~ r e e Extreme 
2. Going up or down stairs D II ' ; 1"'1 0 I I I . LJ i-...J 
?\one \lild \1oderate Se\'cre Extreme 
3. At night while in bed 0 1"'1 0 i I 0 :_1 '----I 
None Mild \10dcrate Severe Extreme 
4. Sitting or Lying D n n 1"1 0 1_, 
None \1ild Moderate Sen!re Extreme 
5. Standing Upright D n n CJ 0 i-...J L...; 
The following two questions arc similar to those abo\'c but for these }'OU indicate 
your response by putting an "X" on the horizontal line. 
If you your "X" at the left hand of the line you arc indic3ting that you ha'H no 
pain. ' 
If you put your "X" at the right hand end of the line you are indicating that your 
pain is extreme. 
6. Walking on a flat surface 
NO PAIN t-) ----------------------ff E'\TRE\1E PAIN 
7. Going up or down stairs 
NO PAIN t - ~ ~ --------------------1 L'\TRE\tE PAl\: 
II SECTION 2: STIFFNESS II 
The following questions concern the amount of stiffness (not pain) you have 
experienced in your knees over the last week. Stiffness is a sensation of 
restriction or slowness in the ease with which you move your joints. (Please tick 
one box for each item) 
8. How severe is your stiffness after first wakening in the morning? 
None 
D 
Mild 
D 
Moderate 
D 
Severe Extreme 
D D 
9. How severe is your stiffness after sitting, lying or resting later in the day? 
None Mild Moderate Severe Extreme 
D D D D D 
II SECTION 3: PHYSICAL FUNCTION II 
The following questions concern your physical function. By this we mean your 
ability to move around and look after yourself. For each of the following 
activities, please indicate the degree of difficulty you have experienced over the 
last week due to problems with your knees. (Please tick one box for each item). 
What degree of difficulty do you have with: 
None Mild Moderate Severe Extreme 
10. Descending stairs D D D D D 
None Mild Moderate Severe Extreme 
11. Ascending stairs D D D D D 
None Mild Moderate Severe Extreme 
12. Rising from sitting D D D D D 
None Mild Moderate Severe Extreme 
13. Standing D D D D D 
None Mild Moderate Severe Extreme 
14. Bending to floor D D D D D 
None Mild Moderate Severe Extreme 
15. Walking on the flat D D D D D 
None Mild Moderate Severe Extreme 
16. Getting in/out of car D D D D D 
None 
17. Going shopping D 
None 
18. Putting on socks/stockings D 
None 
19. Rising from bed D 
None 
20. Taking off socks/stockings D 
None 
21. Lying in bed o 
None 
22. Getting in/out of bath D 
None 
23. Sitting D 
None 
24. Getting on/off toilet o 
None 
25. Heavy domestic duties o 
None 
26. Light domestic duties o 
Mild 
D 
ivfild 
D 
Mild 
o 
Mild 
D 
~ v 1 i l d d
o 
Mild 
\;lild 
o 
!\.1ild 
o 
?vIild 
o 
Mild 
D 
Moderate 
n 
Moderate 
o 
\ I o d e r a t ~ ~
\loderatc 
~ 1 0 d e r a t e e
n 
'-' 
\'1oderatc 
[J 
\-foderate 
,., 
, ' 
L.....J 
\1oderate 
o 
\foderate 
.\-foderate 
Severe Extreme 
,., 
I i 
Sewre 
Severe 
Severe 
I ~ i i
,_! 
D 
Extreme 
o 
Extreme 
U 
Extreme 
o 
Se\'ere Extreme 
'_i 0 
Severe Extreme 
D 0 
Severe Extreme 
n n 
Severe Extreme 
o o 
Severe Extreme 
o o 
Severe Extreme 
r i_' o 
*NOW we would like you to think again about each a f o n , : m t : n t i o n ~ d d symptoms which 
you have just rated. 
Then select one pain item (section I), one stiffness item (section 2) and one physical 
function item (section 3) which arc most important to you i.e, which you most h o ~ ~
could be improved. 
Indicate your selections by circling the appropriatt: item numbers, 
Remember to select only: 
one pain item 
and one stiffness item 
and one physical function item 
RIGIIT 
J > l e a ~ e e shaLle on the <..1iagraIll an.'- areas ,"vhere you l10rrnaiiy sutTer pain. Place a sIl."lall :-,:" , .... hen: the pain is In ... ~ s t t sevel·e. 
\ J. 4 7 1 ~ ~
. 
I 
~ ~
""-.: / : ~ ~ / 
\:/ 
I 
FRONT 
LEFT 
Fibromyalgia Pain 
(Axial & two diagonally 
opposite quadrants. 
e.g. R arm & L leg) 
1 = yes O=no 
D 
J; L 
, 
~ i / /
LEFT 
BACK 
RIGHT 
- - -- ------- _ -- - _. ____ ~ ~ . ___ ~ _ _ .. ~ ~ ._ -...c .... ,- --_. _____ ------.. .  
REF NO DDDDO.O 
PHYSICAL EXA1\1INA TION 
HEIGHT O.ODm 
STANDING 
1. 
2. 
EXTENSION OF BACK (pain) 
O=nonnal l=abnonnal 
location of pain 
FLEXION OF BACK (pain) 
O=normal I =abnomlal 
location of pain 
3. HYPERMOBILITY SCREEN 
0= no rrnal I=abnonnal 
\\'EIGHT 
a) Thumbs (bring thumb back parallel to / touching forearm) 
b) Little Fingers (extend little finger >90°) 
c) Elbows (extend elbow >10°) 
d) Knees (extend knee> 10°) 
e) Touch Floor (with both hands flat. legs straight) 
maximum score=9 hypcrmobilc=6 or more 
DDOkg 
Right 
o 
o 
o 
o 
D 
o 
D 
TOTAL 0 
Left 
o 
o 
o 
o 
4. FIBROMY ALGIA SCREEN 
TENDER POINTS (tick if painful) 
Jl 
0" 
+ 
score 0-18 fibromyalgia= 11 or more 
(approximate force of 4kg) TOTAL DD 
ON THE COUCH 
LYING FLAT 
Right Left 
I. INTERNAL ROT A TION OF HIPS (pain or restriction of movement) 
O=normal l=abnormal D D 
location of pain R .............................. . 
L .............................. . 
1 EXTERNAL ROTATION OF HIPS (pain or restriction of movement) 
O=normal \=abnormal D D 
location of pain R .............................. . 
L ............................. .. 
SITTING UP R L 
1. EFFUSION 0 0 
O=no or doubtful effusion 
1 =positive effusion 2=tense effusion 
2. TEMPERATURE 0 0 
O=norrnal l=warrn 
3. BONY SWELLING 0 0 
O=absent 1 =present 
4. CREPITUS 0 0 
O=absent 1 =present 
5. POPLITEAL CYST 
O=absent l=present 0 0 
6. JOINT LINE TENDERNESS 
O=no tenderness 2=subject winces (a) Patellofemoral 0 0 
1 =tender 3=subject withdraws (b) Medial 0 0 
(c) Lateral 0 0 
7. PERIARTICULAR TENDERNESS 
O=no tenderness 2=subject winces (a) Inferomedial 0 0 
1 =tender 3=subject withdraws (b) Superomedial 0 0 
(c) Inferolateral 0 0 
(d) Superolateral 0 0 
8. RANGE OF MOVEMENT (passive / in degrees) 
full extension 000 000 
full flexion 000 000 
9. HEBERDENS NODES ON HANDS 0 0 
0-4 for each hand 
10. THUMB IPJ NODES 0 0 
O=absent 1 =present 
11. THUMB BASE (squaring, crepitus, pain) 0 0 
O=normal l=abnormal 
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KNEE PAIN AND OSTEOARTHRITIS 
Knee osteoarthritis is often a cause of knee pain and stiffness. It is a condition 
which becomes increasingly common among people over t h ~ ~ age of 45 years. 
Osteoarthritis (OA) is a form of joint disease, which can make every day activities 
increasingly difficult to do. 
In a normal knee joint the ends of our bone are covered by a thin layer of smooth 
gristle called cartilage. This acts as a shock absorber for the joint and it's smooth 
surface allows freedom of movement. The bone end and cartilage are surrounded 
by a membrane (synovial membrane) which produces a small amount of thick fluid 
(synovial fluid) to help oil these surfaces. These structures are enclosed in a 
protective capsule. The knee joint is stabilised by four ligaments (two inside and 
two outside the joint) which help prevent dislocation and the thigh muscles 
(quadriceps). (see diagram 1) 
diagram 1 
THIGH MUSCLE---.... 
P A T E l - L A - - ~ ~
(KNEE CAP) 
~ - - SYNOVIAL 
SYNOVIAL ----H+-iI MEMBRANE 
FUJI 0 
F : : : : : : = = _ ~ Y - - ; : = - - J'OI WT CARTI L-AC E 
T E N D O N - - ~ ~
THE NORMAL KNEE JOINT 
Wh h kn e OA their cartilage becomes thinner and it's surface en someone as e . d f th 
d Th b underneath becomes thicker and grows out at the SI e 0 e roughene. e· one . Th' I 
. . t if 't trym' g to reduce the amount of pOSSIble movement. e s ~ o V 1 a a
Jom as 1 was .' d extra fluid fonns, making the 
membrane usually becomes a httle inflammed an 
joint swell slightly. The c a p ~ u l e e and ligaments may thicken and get stretched. In 
severe cases there may be qIDte a lot of damage to the cartil . th b 
. age, exposmg e one 
underneath. DepOSIts of c ~ s t a l s s may form in the remaining cartilage and synovial 
membrane and float around m the fluid. (see diagram 2) 
diagram 2 
W E ~ K N f S S S ------I-TJ 
OF' TH'C.H MU5C\..E 
R O U ~ H E N E . D D - - + - - ~ ~
8 A C ~ ~ OF PATE 
nE-----iHICKEN£O 
MEMBAANE. ICAPs\JL-E 
~ ~ : = ~ = = ~ ~ ~____ - - - D A H ~ £ D D~ ~ CARilL.AC:;E 
~ - - - - BONY CR00.ITH 
TISH\ 
OSTEOARTHRITIC JOINT 
Although osteoarthritis often causes no trouble, in some cases damage caused to 
the joint may result in pain and difficulty with movement. Osteoarthritis tends to 
develop very slowly over a period of months or years. Symptoms are usually 
variable, you may get good and bad days. In a very few cases constant pain 
develops even during rest at night. 
There is no actual known cure for osteoarthritis and treatment is thus aimed at 
relieving or reducing the symptoms of pain and stiffness. 
SELF HELP IN CONTROLLING KNEE PAIN 
1. Keeping your weight at a sensible level: If you are overweight, losing weight 
will reduce the stress on your joints, particularly your knees which have to 
support your whole body. 
2. Exercise: Resting for long periods may cause the joints to stiffen badly, while 
too much exercise may cause a great deal of pain. The general advice is to do a 
little exercise often and strike a balance between too much activity and too 
much rest. Exercise can help maintain the full range of movement in the knee. 
It also helps to keep the muscles surrounding your knee strong to protect and 
stabilise the joint. Swimming and walking (in sensible shoes!) are particularly 
good exercises for the knees. 
3. Foot wear: Shoes with shock absorbing air cushioned soles help reduce jolting 
of the knee joint when walking. Footwear such as trainers are kind to the knees. 
4. Pain-killing Tablets: Paracetamol can often help, it may be helpful to take this 
regularly at full dose, but never exceed the doses advised on the label. If these 
do not work for you go and see your doctor who may be able to prescribe you 
some alternative pain-killing tablets, unfortunately though their effectiveness is 
not absolutely guaranteed, they may work in some people but not others. 
5. Herbal Remedies: There are a number of remedies on sale in health food 
shops which claim to be beneficial for arthritis. There is little evidence to 
suggest wether they do help or not, however there is no harm in trying them if 
you feel they may work for you. 
6. Copper Bracelets: Again despite popular belief copper bracelets have no 
beneficial effects on osteoarthritis, although some peoples faith in them seenlS 
to help them. 
7. Local Heat Applications: Although it does not have a long tenn effect local 
warmth often relieves pain and stiffness in osteoarthritic joints. Heat lamps are 
available commercially but a similar effect can be achieved more cheaply with 
hot water bottles wrapped in a towel (be careful, it is easy to bum yourself with 
either). Local heat should not however be used in cases where the joint is red 
or inflammed, or applied for longer than 20 to 30 minutes at a time. 
8. Local Cold Applications: Some people may fmd local cold applications 
helpful (as an alternative to local heat) in relieving painful or swollen joints. 
Make an ice pack by wrapping a packet of frozen peas in a damp towel. The 
cold application should be applied at a comfortable level of coldness and for no 
longer than 10 to 15 minutes at a time. 
9. Relaxation: If you do happen to be in pain try to concentrate on something that 
will take your mind from it. For example listen to some music or the television, 
or perhaps read a book. 
~ . ' '... lIS""· 
--
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t 
1\ ABOUT THE STUDY II 
The following questions concern your experience with our study. Please answer all 
of the following questions as fully as possible. 
1. Could you summarise your main reasons for agreeing to take part in this study? 
2. Have you benefited from your participation in this study? 
DYes 
o No 
Please explain: 
3. Have you incurred any injuries or adverse reactions as a result of your participation in 
this study? 
DYes 
o No 
If yes, please explain: 
4. Have you incurred any costs as a result of your participation in this study? 
DYes 
D No 
If yes, please explain: 
t.'· .' ,-
5. In the last 12 months have you been to a private hospital for any of the following, as 
a result of you knee pain? (Do NOT include G.P referrals) 
Treatment Type Number of Sessions I Tests 
Consultations: 
X-rays: 
Blood Tests: 
! 
Other tests: 
(Please specify) 
I 
I 
I 
I 
Arthroscopy: 
Knee Replacement: 
Other Treatment: 
(Please specify) 
6 In the last 12 months have you attended any of the following as a result of your knee 
pain? 
Treatment Type Number of Sessions 
Private Physiotherapy: 
Osteopath / Chiropractor: 
Homeopathy / Aromatherapy: 
Toning Tables: 
Other (please specify): 
7. In the last 12 months have social services provided any of the following as a result of 
your knee pain? 
• Home aids (e.g. installation of shower, rails or ramps) 
Please specify: ______________ _ 
• Meals on wheels 
• Home help 
• Other (please specify): __________ _ 
Did you make a contribution towards the cost of any of the above? 
D Yes D No 
If yes, which ones? ________________ _ 
How much did you contribute? ____________ _ 
Yes No 
DD 
DD 
DD 
8. Do you, or any member of your household, claim any of the following as a result of 
your knee pain? 
Disability living allowance 
Mobility allowance 
Attendance allowance 
Carers allowance 
Incapacity benefit 
Other (please specify) _____________ _ 
Yes No 
DD 
DO 
DD 
DD 
DD 
9. Since the start of this study, has your level of physical activity changed? (This DOES 
NOT include any exercises you may have been given as part of this study). 
o Yes, I am more active now than I was at the start of the study. 
o I am neither more nor less active than I was at the start of the study. 
o No, I am less active than I was at the start of the study. 
Was this change influenced in any way by your participation in the study? 
DYes 
o No 
D Unsure 
10. Since the start of this study have you lost weight? 
DYes 
D No 
D Unsure 
If yes, was this change influenced in any way by your participation in this study? 
DYes 
D No 
D Unsure 
11. Have you use any of the following products during the period of the study? 
D creams / gels (not supplied by your doctor). 
D calcium supplements. 
D vitamin supplements. 
D cod liver oil. 
D copper bracelets. 
D other (Please specify ________________ ), 
Instructions: 
We are interested both in how much help you feel you need, and how much help you get, 
in performing your usual daily activities. For each of the following activities, could you say 
whether or not you need any help, and whether you do in fact receive assistance either 
from family or friends? 
Firstly, it would help us to know if you live alone, with family or in warden aided 
accommodation? 
o alone D partner D family D warden aided 
Example: Vou need help to do your shopping and you receive that help from your 
neighbour. Vour knee problems playa large part in causing this difficulty. 
Your response would be as seen below. 
Activity Need Help? Get Help? Source of Paid? Knee 
help? related? 
Yes / No Yes / No Live-in = 1 Yes/No Yes / No 
Live-out = 2 
Example Ves Ves 2 No Yes (See above) 
Shopping 
Cooking 
Light domestic 
duties 
Heavy domestic 
duties 
Having a bath 
Having a shower 
Dressing e.g. 
putting on socks 
and stockings. 
Rising from bed 
I-
Walking 
""-
Getting in/out of 
a car i 
.... 
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KNEE PAIN 
INTERVENTION STUDY 
EXERCISE DIARY 
NAME: .............................................................. . 
STARTING DATE: .......................................... . 
FINISHING DATE: ... ....................................... . 
"l!.T", 
~ 4 , / ~ 1 ) \ & t ~ ~ ~ ~ Funded by the Department of Health o.ol:' 
.,t. " 
I( E ~ ~ Y 
ABOUT THE EXERCISES 
Exercise is very important for everyone. For someone with 
knee pain however, it is particularly important. When joints are 
painful and therefore not used as much, the muscles around 
them tend to get weaker and this may cause further pain and 
damage. These exercises are designed to strengthen the 
muscles around the knee, particularly the thigh (quadriceps) 
muscles. We think you will find the exercises fun to do and 
should only take you about 20 minutes each day . You will find 
a diary at the back of this booklet in which to record your 
efforts. 
General Advice: 
• Exercise in a wann room in clothes which are not too tight. 
• Build the exercises into your daily routine and do them at a 
time of day when you are least likely to be disturbed. If you 
like you can split up the exercises and do a few at various 
times throughout the day. 
• Whilst exercising, rest your hands on your thighs so that you 
can feel the muscles working. 
• If you do not manage to exercise on a particular day do not 
do double the next day. 
• Increasing muscle strength is a slow process so do not 
become discouraged if you can not see an improvement 
immediately. Do not stop exercising. 
1 
• It is better to do a few strong exercises than lots of weak 
ones. There is no need to get breathless, take your time and 
rest in between each exercise. 
• Do not do more than the maximum recommended amount 
for each exercise. As you feel comfortable with the exercises 
build them up. 
Pain: 
• As with any new exercise, there may be some fatigue or 
muscle ache. This is only a sign that the muscle has been 
working and is nothing to worry about. If the exercises are 
proving too difficult, cut down slightly and try to gradually 
build them up again. 
• Try to do the exercises-when you knees are not too painful. 
Take painkillers if necessary and do the exercise once they 
have started to work. 
• If you experience a lot of pain whilst doing the exercises, 
stop for the day and cut back on the number of exercises you 
were doing. 
If you have any questions or concerns, please phone your 
therapist ................................................. for advice. 
Tel: (0115) 9691169 ext.45557 
2 
THE EXERCISES 
The exercises are arranged in five sections: 
Section A ::::::> Flexibility Exercises 
Section B ::::::> Unresisted Exercises 
Section C ::::::> Resisted Exercises 
Section D ::::::> Functional Exercises 
Section E ::::::> Aerobic Exercises 
There are several exercises in each section. It is expected that you 
will work through the sections one at a time, doing at least two of the 
exercises each day. Please remember though that the more you do 
the more likely you are to feel some benefit from these exercises. 
When you find each exercise becoming easy, move on to one you 
find harder to do. 
Do not progress through the exercises in section D and E until 
you have been told to do so by your therapist. 
Exercise equipment: 
As you progress to Section C of the exercise program your therapist 
will give you a large elastic band to make your muscles work harder. 
These come in various thicknesses, so you can progress from easy 
thin ones to tougher thick ones (doubling the thin ones makes the . 
exercises harder). 
• Keep it as wide as possible so that it doesn't dig into the leg when 
exerCIsIng. You could try some padding around your leg for 
comfort (e.g. socks padded with cotton wool or cloth). 
Untie all knots after exercising - this will help it to last longer. 
Storing the band in a plastic bag with a little talcum powder will 
make untying the band easier. 
3 
II II 
These exercises are designed to increase the range of movement 
in the knee and ankle before you begin the strengthening 
program. 
Repeat the exercises in section A five times. Gradually build 
up to a maximum of twenty for each leg. 
At Sitting on the floor (or bed) 
4 
Sit with your back supported 
and both your legs straight out 
in front and your toes pointing 
to the ceiling. Each ankle is 
then extended and flexed by 
pointing the toes and then 
flattening the foot. 
BASIC 
A2 Lying on the bed (or floor) 
~ ~
__ 1) 
Lie on your back and bend 
your knees. Then in tum 
straighten each leg as far as 
possible and hold in this 
position for five seconds 
BASIC 
A3 Standing up (or lying on your side or front on the 
floor or bed) 
5 
Use a wall for balance and 
stand on one leg. Bend the 
other knee and bring your foot 
towards your bottom. Support 
your foot in your hand. If you . 
find this difficult to do the 
exercise lying on your side or 
front. 
DIFFICULT 
SECTION B: UNRESISTED EXERCISE 
,.';::.' "':'::':'::::,':': .'.;,.';':.':-:-:'>' 
These are gentle strengthening exercises to start building up the 
muscles around the knee. 
Hold the positions for five seconds. Repeat each exercise five 
times for each leg. Gradually build up to twenty. 
Bl Sitting in a chair 
6 
Sit upright in a high chair e.g. 
dining chair. Support your 
back by holding on to the seat 
with your hands. Now 
straighten one leg out in front 
of you. 
BASIC 
B2 Sitting on the floor (no back support) 
Start with both your legs out in 
front of you, toes pointed 
towards the ceiling, with a 
rolled up towel beneath one 
knee to make it slightly bent. 
Try to push that knee back into 
the floor so that the thigh 
muscle tightens. Hold this 
position for five seconds. 
BASIC 
B3 Sitting on the floor (back supported) 
Start with both legs out in 
front of you, toes pointing to 
the ceiling and back supported 
by a wall. Place a finn 
support beneath your knees. 
This should be very finn and 
almost too big to get your· 
hands around (e.g. a thick 
L' F T towel rolled around a milk 
bottle). Straighten this leg 
with the back of the knee still 
in contact with the roll; the foot should leave the floor. 
MORE DIFFICULT 
7 
These exercises are designed to give the thigh muscles more 
work to do by having them stretch out large elastic bands. 
Hold the positions for five seconds. Repeat each exercise five 
times for each leg. Gradually build up to twenty. 
Cl Sitting on the floor (back supported) 
Sit on the floor with your 
back supported by a wall. 
Bend both your knees. Tie 
the exercise band loosely 
around one ankle. Twist it 
into a figure of eight and put 
the new loop over the instep 
of the other foot. Now try and 
straighten the latter leg 
C2 Sitting on the floor (back supported) 
8 
Sit on the floor with your 
knee supported as for exercise 
B3. Place a pillow over the 
ankle of one leg. Straighten 
this leg with the back of the 
knee still in contact with the 
roll. This is harder than B3 
because of the pillow. 
C3 Sitting in a chair 
Sit upright in a high chair, 
your knees should be bent at 
right angles. Tie a strong 
elastic band around the ankle 
of one leg and the back chair 
leg. The band should be tied 
tight enough so that there is no 
slack, but not so tight that it is 
uncomfortable. Now try to 
push against the band with 
your leg as hard as you can as 
though you are trying to straighten it. Support your back by 
holding on to the seat with your hands. Use padding around 
your ankle. 
C4 Sitting in a chair 
Sit upright in a high chair. 
With your feet together tie the 
elastic band around your 
ankles (the band should be 
tight enough so that there is no . 
slack in it, but not so tight that 
it is uncomfortable, use 
padding around your ankle if 
necessary). Straighten one leg 
out as far as you can, keeping 
the other leg still. Support 
your back by holding on to the seat with your hands. 
9 
I 
These are exercises designed to help directly with the tasks of 
every day life. They should become easier as your strength 
develops. 
PLEASE DO NOT DO THE EXERCISES IN SECTION D 
AND E UNTIL YOU HAVE BEEN TOLD TO DO SO BY 
YOUR THERAPIST. 
Take your time when doing these exercises, there is no need to 
get breathless. Take a rest in between each exercise if 
necessary. 
The exercises in Section D should be repeated five times for 
each leg. Gradually build up to twenty. 
10 
Dl Rising from sitting 
D2 Standing 
1 1 
Sit in a chair with your arms 
folded across your chest. Now 
try to get up from the chair 
without using your arms to 
push yourself up. Try to do 
this exercise in a high chair to 
start with but as it becomes 
easier to do try to sit in a lower 
chair. 
Stand with your back leaning 
against a wall and feet slightly 
apart (approximately 12 inches 
from the wall). Slide your 
back down the wall, (only 
slightly to start with), so that 
you are in a squatting position 
and hold for five seconds. As 
you find this exercise easier to 
do try to get a little further 
down. 
These exercises are also designed to help directly with the tasks 
of every day life. They should become easier as your strength 
develops. 
PLEASE DO NOT DO THE EXERCISES IN SECTION D 
AND E UNTIL YOU HAVE BEEN TOLD TO DO SO BY 
YOUR THERAPIST. 
Take your time when doing these exercises, there is no need to 
get breathless. Take a rest in between each exercise if 
necessary. 
These exercises should be repeated five times for each leg. 
Gradually build up to twenty. 
El Up and down a step 
Use the lowest step of your 
stairs, step up onto the step 
with your right foot and 
follow with your left. Then 
step back down. Do this five· 
times and repeat, this time 
leading with your left leg. 
Take a rest in between if 
necessary. Gradually build up 
to twenty times for each leg. 
You can use the banister for 
balance, but do not use it to pull yourself up. 
EASY 
12 
. ~ ~
E2 Stepping down 
E3 Walking 
13 
Stand on the lowest step facing 
as though you are going down. 
With one leg step down but 
just before your foot hits the 
floor (about an inch from the 
ground). Hold this position 
for five seconds. 
DIFFICULT - start carefully 
Plan yourself a walk around 
where you live. The walk 
should be about a mile in 
length. Take a walk using this 
route three times each week. 
Time yourself each time, and 
record the minutes in the back 
of this diary. Try to walk a 
little faster as the weeks go by. 
NOTES: 
Please use the space below to record any comments or difficulties 
you have had with the exercise programme. 
14 
EXERCISE DIARY 
The following pages consist of your exercise diary. Please try 
to fill it in as accurately as possible. It is very important to us to 
get a picture of how much exercise you have done - so please 
fill out the diary honestly even if you have not been able to do 
any of the exercises. 
• Please complete the exercise diary every day when you have 
finished exercising. 
• Write down which exercises you have done and how many of 
each. 
• If you do any additional exercise (e.g. walking, swimming 
etc.) please make a note of it in space marked "additional 
exercise" for the relevant day. 
• If you miss a session or stop for any reason, please make a 
note of the reason in your diary and recommence as soon as 
possible. Do not worry about it, just start off gently again. 
• Remember even if you go on holiday you can still continue 
with your exercise program. 
• Your completed diaries will be collected by your therapist 
once they are full. If you run out of diary space, please 
continue to exercise and use the back page to record your 
exercises until your therapist_ visits you again. 
ENJOY THE EXERCISE PROGRAM 
15 
MONDAY TUESDAY WEDNESDAY T ~ ~
Date: 
Additional Exercise 
Date: 
Additional Exercise 
Date: 
Additional Exercise 
Date: 
Additional Exercise 
Date: 
~ - - -
Additional Exercise 
Date: 
Additional Exercise 
16 
THURSDAY FRIDAY SATURDAY SUNDAY 
, 
I 
17 
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Appendix 7: Strength of exercise bands under laboratory 
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Graph showing band strengths under laboratory conditions. 
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Appendix 8: Assessment of adherence 
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RATING OF TREATMENT ADHERENCE - DIARIES 
1. Number of Days Exercising: 
6 5 4 3 2 1 
D D D D D D 
Nearly Miss Miss Started Missed Little 
every 1-2 days 2-3 days keen - 2-3 times or 
day for per week per week tailed in 1st 8 nothing. 
6 months. over 6 over 6 off. and few 
months. months. after. 
2. Number of exercises done. 
1 2 
D D 
0-2 3-5 
3. Number of repetitions. 
1 2 3 
D D D 
<10 10 >10 
Choose one from sections 1 - 3. Add together the scores and deduct 2 points. 
This will allow a score of 1 - 9 ( 9 being the best degree of compliance and 1 the 
worst). 
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Appendix 9: Telephone support checklist 
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TELEPHONE INTERVENTION MONITORING FORM 
NAME ................. . 
1st Topic Introduced 0 
Date: ................. . 
Initials: ............. . 
1. State of the Knees 
2. Medication! Alternative Therapies/Problems 
3. GP Visits 
4. Sleep patterns 
~ ~
5. Social/Getting out and about 
6. Mood - How are you feeling 
Ref No I I I I I I D 
Start. ...... . 
Time 
Finish ....... . 
Mins. DO 
D 
D 
D 
D 
D 
D 
7. Level of support required (in daily functions) D 
8. General Health 
9. Any other pain 
10. Initiated topic from respondent 
If found, please return to Anna Follows ext: 45557 . 
... 
D 
D 
D 
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Appendix 10: Case note abstraction forms 
• GP abstraction form 
• GP prescribed medicines abstraction form 
• Hospital abstraction form 
• Summary forms for GP, GP prescribed medicines and hospital costs 
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Case Note Abstraction - G.P. Notes 
ame: Assessed: / / 
- - -
ef: o of 8: I / 
- - -
-
PERIOD 
From: To: 
-
I.B. Don't record nurse visits (contact time or drugs given). If blood taken for tests - record as investigation, but 
nder one of the doctor's visits . 
... 
Oate(s): 
Knee Pain: 
1 = yes 
2= % yes 
3= GI 
4= no 
5= unsure 
Seen By: 
1=G.P. 
3 = Phone 
What was Investigation Investigation 
provided? 
Number. ...... Number ....... 
Drugs 
Number ...... 
I Treatment 
Number ...... 
I 
I X-ray I 
I Number: ...... 
! 
I Home visit 
YES/NO 
I 
I 
Night visit 
YES/NO 
Comments 
l 
Osteoarthritis? D 
HoSpital treatments? 
KRGP _ABS FORt-.t 23 O-liO 1 
Drugs 
Number ...... 
Treatment 
Number ...... 
X-ray 
Number: ...... 
Home visit 
YES/NO 
Night visit 
YES/NO 
YES/NO 
Total: 
-
1 = 
2= 
... 
3= 
4= 
5= 
1 = 
3= 
Investigation Investigation Investigation Investigations 
Number ...... Number ....... Number ....... Number ........ 
Drugs Drugs Drugs Drugs Number ...... Number ...... Number ...... Number ........ 
Treatment Treatment Treatment 
Number ...... Number ...... Number ...... Treat's 
Number ........ 
X-ray X-ray X-ray 
Number: ...... Number: ...... Number: ...... 
X-Ray 
Number: ........ 
Home visit Home visit Home visit Home v's YES/NO YES/NO YES/NO Number ....... 
Night visit Night visit Night visit 
YES/NO YES/NO YES/NO Night v's 
Number ....... 
Rheumatoid Arthritis? D 
Continued YES / NO (Please circle) 
I; 
, 
! 
: 
! ~ ~
G.P Prescribed Medicines 
Name: Assessed: I I 
- --
Ref: D ofB: I I 
PERIOD 
---
From: To: 
-----
-----
* = repeat prescription 
Drug Type Dose Amount Number BNF Knee pain Priee Total Price II 
of Code (from notes) per 
prese's prese'n 
issued 1 =yes,2=% yes 3=no,4=unsure 
I 
TOTAL DRUGS COST: £._--- KNEE PRESCRIPTIONS: 
TOTAL PRESCRIPTION: RELATED PRESCRIPTIONS: ___ _ 
Continued YES 1:\0 (Please circle) 
Case Note Abstraction - Hospital Notes 
Name: Ref: D of B: I I 
PERIOD 
---
From: To: 
------ ------
-
,... 
Date: Total: 
Provider: 1 = 
1=City,2=QMC 2 = II 
" 3a=Private Hospital i' 
(paid by practice) 3a= Ii 
3b= Private Hospital 3b= I 'I 
(paid by self) 4 = 
4=NHS out of region 
Speciality: 
--------Reason: 1= 
1 = knee pain 2= 
2 = arthritis general 
(locomotor) 3= I 
3 = G.\. 4= I 
4 = not related 
Service Type: 1= 
1=inpatient 2= 
2=daycase 3a= 3a=outpatient(new) 
3b=outpatient(FU) 3b= 
4=A& E 4= 
Length of Stay: 
(Inpatients only) 
Days in leu: J: 
If knee pain (1): 
Seen By: 1= I 2= 
Consultant (1) 3= 
Registrar (2) 4= 
SHO (3) Nurse (4) 5= Other - specify (5) 
X-Ray: I I 
(Each knee = 1) 
Blood tests: i 
I 
Injections to I, 
jOint: 
Drugs: 
Physio/Hydro 
lOT 
Other: 
jSRecify) 
Operations: 
(Specify) 
Comments 
T 
-
---
C O N T I ~ l - E D D YES / ;-';0 
SUMMARY OF GP ABSTRACTION FORM 
Period: 
------
1st Assessed: I 
I 
Name: Ref: 
---------------------
DoB: I I 
-- --
KNEE 0/0 KNEE G.I TOTAL 
GP: 
Phone: 
Investigations 
Drugs 
Treatments 
X-rays 
Home visits 
Night visits 
Osteoarthritis (1): D 
DNA: 
----
Comments: 
KRlGP _summary_form 26 0401 
Rheumatoid Arthritis (2): D 
Hospital: YES I NO 
Entry complete: 
(I nitial) 
~ ~
~ ~
PERIOD 
-----
Name: _________ _ Ref: 
KNEE PAIN DRUGS (Those quoted by patient and G.P notes) 
NSAIDs RUBSI ANALGESICS GIDRUGS OTHER 
GELS 
10.1.1 10.3.2 4.7.1 or 4.7.2 1.3.1, 1.3.5 or 1.3.4 e.g. steroids 10.1.2 
Normal SR <£5.50 >£5.50 anti-depressants 4.3.1 < 60mg Quinine (If quoted by patient) 
£ £ £ £ £ £ £ 
.. 
.... 
.. 
RELATED DRUGS (Any of above drugs not previously mentioned by patient) 
NSAIDs RUBSI 
GELS 
10.1.1 10.3.2 
Normal SR 
£ £ £ 
.-
Over the Counter Drugs 
NSAIDS = 
RUBS/GELS = 
OTHER = 
ANALGESICS GIDRUGS 
4.7.1 or 4.7.2 1.3.1, 1.3.5 or 1.3.4 
<£5.50 >£5.50 
£ £ £ 
ANALGESICS = 
HEALTH FOODS = 
TOTAL DRUGS COST £_--- KNEE PRESCRIPTIONS: 
OTHER 
e.g. steroids 10.1.2 
antJ-depressants 4.3.1 < 60mg 
Quinine (If quoted by patient) 
£ 
. 
TOTAL PRESCRIPTIONS: ___ _ RELATED PRESCRIPTIONS: 
KRJdrug ummary _ form124111/97 
SUMMARY OF HOSPITAL ABSTRACTION FORM 
Period: 
-----
Name: 
---------------------
Ref: 
----
Knee 0/0 Knee GI Total 
Inpatient: 
Length of stay 
Days in ICU 
Day case: 
Outpatient - new ~ . .
~ ~ . ~ ~
Outpatient - FU 
A&E 
~ ~ -
Dep't 1 __________ _ Oep't 2 _______ _ Oep't 3 
Knee only (Code 1) 
. ., 
Consultant Knee Total 
i 
Registrar City 
SHO QMC 
Nurse Practitioner Private (practice) 
Other Private (self) 
X-Ray NHS Other 
.-
Blood Tests 
Injections Operation 1: 
Drugs 
Physio/OT Operation 2: 
Other 
(Specify) 
Comments: 
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Thomas, K and Miller, P. on behalf of the Osteoarthritis Research Group 
(1999) The cost-effectiveness of a home-based exercise programme in 
relieving the pain and disability of knee osteoarthritis. Journal of 
Epidemiology and Community Health 53, S 12. 
Objective: To assess the cost-effectiveness of a home-based exercise 
programme in relieving the pain and disability of knee osteoarthritis. 
Design: A two-year, single-blind, randomised factorial trial. Treatment arms 
included: exercise therapy, telephone social support, a placebo health food 
product and no intervention. Economic data were collected prospectively 
alongside the trial. Analysis was conducted on an intent-to-treat basis. 
Setting: Community-based trial using two GP Practices in the Nottingham 
area. 
Subjects: 500 women, 286 men aged 45 years and over. Initial recruitment 
via postal survey (n = 9,296). 
Primary outcome: Self-reported knee pain at 24 months (assessed using 
WOMAC). 
Results: Exercise therapy resulted in a significant reduction in knee pain, 
knee stiffness and knee related physical disability at 24 months (p=<O. 001, 
0.01 and <0.001 respectively). Effect sizes were modest, but improvements 
were incremental to normal care. The number needed to treat (NNT) in order 
to achieve a ~ ~ 500/0 reduction in pain at 24 months for a single individual was 
between 8 and 13. The cost per person of the two-year exercise programme 
was £ 112.48. Analysis of GP records revealed no change in the use of either 
arthritis related services or total medical costs during the first 12 months of the 
trial. The cost of achieving a clinically significant outcome in a single 
individual (based on NNT figures) was £1,012. 
Conclusion: Home-based exercise therapy could be a very cost-effective 
treatment option for the management of knee pain in the community. Further 
research is required in order to assess its impact on medical costs in the longer 
term. 
